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1. INTRODUCTION 
Avian influenza (AI) affects the respiratory, digestive and/or nervous system of many 
bird species. AI viruses are influenza A viruses belonging to the Orthomyxovirus 
family, and they are classified according to their pathogenicity and the antigenicity of 
the surface proteins haemagglutinin (HA) and neuraminidase (NA) of which 16 and 9 
variants, respectively, are known to date (FOUCHIER et al. 2005). Viruses containing 
subtypes H5 and H7 are highly pathogenic in poultry and cause outbreaks of highly 
pathogenic AI (HPAI), with mortality rates reaching 100 % (WEBSTER et al. 1992). 
HA-specific antibodies are protective as a result of their ability to prevent virus 
attachment and penetration of the host cell. HA is a homotrimer, each monomer is 
synthesised as a single polypeptide (HA0) that is cleaved by host proteases into HA1 
and HA2. HA1 contains receptor-binding pocket surrounded by antigenic binding 
sites (BAIGENT and MCCAULEY 2003; KREIJTZ et al. 2007; NAYAK et al. 2009; 
SHOJI et al. 2008; TONEGAWA et al. 2003). H5 and H7 subtypes emerge at 
irregular intervals and cause severe economic losses in poultry (HAMPSON and 
MACKENZIE 2006), furthermore, it was demonstrated that H5N1 subtype could 
directly cross the species barrier to replicate in humans and cause severe disease 
(HAMPSON and MACKENZIE 2006; KODIHALLI et al. 2000). Vaccination can be a 
powerful tool to support eradication programs if used in conjunction with other control 
methods. Adjuvanted killed vaccines can provide a strong humoral immune response 
and they provide an effective protection against homologous low pathogenic AI 
(LPAI) and HPAI challenges. One of the concerns in the use of the commercially 
available vaccines (consisting of inactivated AI virus) to control HPAI in poultry farms 
is the possibility that while these vaccines may protect from disease, they do not 
hinder infection. Thus asymptomatic virus circulation may continue, resulting in 
spread of infection to non-immunized birds, e.g. in other (neighbouring) farms 
(KODIHALLI. et al. 2000). Inactivated influenza vaccines will lead to development of 
antibodies not only to the protective epitopes on the HA and NA, but also to the 
internal proteins which make the differentiation between infected and vaccinated 
animals (DIVA) difficult (SUAREZ and SCHULTZ-CHERRY 2000). On the other 
hand, inactivated hetrologous vaccines are manufactured in a similar way to 
inactivated homologous ones. The use of hetrologous neuraminidase DIVA strategy 
is an acceptable approach but availability of diagnostics is an issue. Several 
recombinant fowl pox (FP) viruses expressing the H5 antigen have been developed 
 14 
and one has been licensed in Mexico (SWAYNE and SUAREZ 2000). Other vectors 
have been used to successfully deliver the H5 or H7 antigens, such as constructs 
using infectious laryngotracheitis virus (ILT). Recombinant vectored vaccines also 
enable DIVA. However, their use is restricted to countries in which they are legally 
available. In addition, the use of these vaccines is also restricted to species in which 
the vector virus will replicate (SWAYNE et al. 2000). Peptide vaccination could be an 
alternative to commercially available vaccines. Subunit vaccines based on conserved 
antigens provide broader protection. Moreover, HA protein derived recombinant 
peptides would not elicit an immune response against internal viral proteins which 
facilitate DIVA. The HA1 antigenic domain of HA has been shown to induce an 
immune response equal to that of the full-size protein (TONEGAWA et al. 2003). 
Unfortunately, there is no effective and specific treatment of HPAI in poultry. The 
precise diagnosis of AI and effective vaccination, which has been shown to induce 
immune responses, can help control the spread of the disease. Hence, the on-site 
and rapid detection of AIV and surveillance of AI in flocks is significant for the 
economics of poultry production and human health (BECK et al. 2003).  Flocks are 
usually tested as a group, rather than testing all the individual birds. Often ten to thirty birds 
are randomly selected from suspect flock and the birds are tested with a type-specific 
influenza detection test. Serological methods are usually used for detection of type-
specific antibodies produced against nucleoprotein antigen (NP) and subtype 
antibodies against HA and NA. Agar gel immunodiffusion test (AGID) is used to 
detect circulating antibodies to type A influenza group-specific antigens, namely the 
NP and Matrix (M), regardless of subtype. It is preferred for its simple and fast 
realization and for the possibility of studying large numbers of samples. AGID test 
may not be suitable as a universal assay for some other species of birds; serum 
samples from water fowl do not contain good precipitin antibodies (CATTOLI et al. 
2006; SUAREZ and SCHULTZ-CHERRY. 2000). The HI test is more sensitive and 
rapid than the AGID test. However, it is allowed the titration of antibodies and it is one 
of the best technique to measure the level of protection in vaccinated chickens as 
well as to check the efficacy of vaccine (MEULEMANS et al. 1987). However, it is 
complicated due to the existence of 16 HA subtypes of AIV and it is laborious. 
The indirect Elisa (I-Elisa) using crude or purified viral antigen on the solid-phase to 
detect viral specific antibodies has been developed for detection of chicken and 
turkey antibodies to AIV (ABRAHAM et al. 1988; ADAIR et al. 1989). Several different 
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types of Elisa have been developed for chicken (ZHOU et al. 1998). The Elisa rely 
upon the detection of antibodies against NP (BECK et al. 2003).  Recently,  detection 
of NP, N3 and N7 antibodies to AI virus by indirect ELISA using yeast-expressed 
antigens revealed that these indirect Elisas are rapid, sensitive, specific and can be 
used as promising tests during serological surveillance (UPADHYAY et al. 2009). 
Furthermore, the recombinant protein-based serological tests may have higher 
sensitivity and specificity as the target antigen is immuno-dominant and devoid of any 
non-specific moities present in whole cell preparations (ERRINGTON et al. 1995; 
MOHAN et al. 2006). The yeast P. pastoris has the potential of rapid growth to very 
high cell densities in inexpensive media as strong promoters are available 
(ROMANOS et al. 1992). It can produce high-level of foreign proteins either 
intracellular or extracellular. In addition, it has the capability of performing many 
eukaryotic post-translational modifications, such as glycosylation, disulfide bond 
formation and proteolytic processing (CEREGHINO et al. 2002; DALY and HEARN. 
2005).  
Aim of the work: 
1. Expression of truncated sequences of influenza A subtype H5N1 in P. pastoris  
2. Studying the possibilities to be used for immunization of chickens against H5 
influenza virus 
3. Development of recombinant Elisa for detection of influenza A subtypes H5 
antibodies in chickens and ducks. 
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2. REVIEW OF LITERATURE 
2.1 Avian influenza virus 
AI, an infectious disease of birds that is caused by influenza virus type A strains, was 
identified first in Italy in 1878 (LIGON 2005). The causative agent was eventually 
isolated from chickens in 1902 (A / Chicken / Brescia / 1902, H7N7). Similar 
outbreaks were observed in Europe and then worldwide, with subsequent isolation of 
several fowl plague viruses (H7 subtypes). By contrast, the first human influenza 
virus was not isolated until 1933 (LAMB and TAKEDA 2001). Influenza virus was 
named in the 1960s because of their ability to bind to mucus and to distinguish them 
from another family of enveloped negative-strand RNA viruses (paramyxoviridae). 
However, influenza viruses belong to Orthomyxoviridae, a Greek word (orthos, 
“standard, correct” and myxo, “mucus”). Orthomyxoviruses appear as roughly 
spherical or filamentous particles 80–120 nm in diameter or cross-section. The 
Orthomyxoviridae are composed of about 1 % RNA, 70 % protein, 20 % lipid, and 5 
% to 8 % carbohydrate (LAMB and TAKEDA 2001). At present the Orthomyxoviridae 
family consists of five genera: influenzavirus A, influenzavirus B, influenzavirus C, 
ogotovirus, tick-borne viruses that occasionally infect mammals, and isavirus, the 
virus responsible for infectious salmon anaemia. These viruses are enveloped RNA 
with single-stranded genomes of negative sense (i.e. the virus RNA is 
complementary to the messenger RNA (ALEXANDER 2006, 2007). Influenza viruses 
are polymorphic particles with a host-derived lipid bilayer envelope covered by about 
500 projecting glycoprotein spikes with HA and NA activities (PEREZ et al. 2005). 
The viral genome of influenza A viruses consists of eight segments (Figure 1). To be 
infectious, a single virus particle must contain each of the eight unique RNA 
segments. Influenza A viral RNA segments encode 11 proteins as follow: polymerase 
B1 protein (PB1), polymerase B2 protein (PB2), polymerase A protein (PA), HA, NP, 
NA, matrix protein (M1), M2, non-structural 1 protein (NS1), NS2 and polymerase B1-
F2 protein (PB1-F2) (SWAYNE 2006a; WEBSTER et al. 1992). Influenza viruses are 
classified into types A, B, and C on the basis of the antigenic nature of M1 and NP 
proteins (CHEN and DENG 2009; SUAREZ and SCHULTZ-CHERRY 2000). Type B 
and C viruses generally only infect humans, but type A viruses infect humans, pigs, 
horses, mink, marine mammals and a wide variety of domesticated and wild birds 
(OLSEN et al. 2006; TAMURA et al. 2005). Type A viruses are further subdivided into 
subtypes based on the antigenic differences in the HA and NA molecules. At present, 
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there are 16 HA (H1–H16) and NA (N1–N9) subtypes (FOUCHIER et al. 2005). Each 
virus has one H and one N subtypes. All H and N subtypes of influenza A viruses in 
the majority of possible combinations have been isolated from avian species 
(ALEXANDER 2000; TAMURA et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1): Schematic  diagram of influenza A virus (SUBBARAO and JOSEPH 2007) 
 
 
2.2 Influenza virus proteins  
2.2.1 Polymerase subunits PB2, PB1, PA 
PB2 polymerase is encoded by RNA segment 1, the slowest-migrating RNA species 
by gel electrophoresis. It is a member of the protein complex providing viral RNA-
dependent RNA polymerase activity. It is known to function during initiation of viral 
mRNA transcription as this protein recognizes and binds the 5' cap structures of host 
cell mRNAs to use as viral mRNA transcription primers. Endonucleolytic cleavage of 
these cap structures from host mRNAs is also at least in part a function of PB2. The 
role of PB2 in the other virus-directed RNA synthetic processes (WEBSTER et al. 
1992). PB1 polymerase is encoded by RNA segment 2. It functions in the RNA 
 18 
polymerase complex as the protein responsible for elongation of the primed nascent 
viral mRNA and also as elongation protein for template RNA and vRNA synthesis. 
PB1 proteins localizes in the nucleus of infected cells. Moreover, PA polymerase is 
encoded by RNA segment 3. It also localizes in the infected cell nucleus and is a 
member of the RNA-dependent RNA polymerase complex along with PB1 and PB2, 
but its role in viral RNA synthesis is unknown. There is evidence for possible roles as 
a protein kinase or as a helix-unwinding protein (WEBSTER et al. 1992). 
2.2.2 Nucleoprotein  
NP is the major structural protein that interacts with the RNA segments to form 
ribonucleoprotein (RNP). NP is one of the type specific antigens and also the major 
target of cross reaction cytotoxic T lymphocytes generated against all influenza virus 
subtypes in mice and humans (LATHAM and GALARZA 2001). NP functions in both 
viral assembly and RNA synthesis (BROWN 2000). 
2.2.3. Haemagglutinin 
The HA was originally named because of the ability of the virus to agglutinate 
erythrocytes (LAMB and CHOPPIN 1983). The HA protein is an integral membrane 
protein and the major surface antigen of the influenza virus. It is responsible for 
binding to host cell receptors and for fusion between the virion envelope and the host 
cell. It undergoes three kinds of post translational processing; proteolytic cleavage, 
glycosylation, and fatty acid acylation. Newly synthesized HA is cleaved to remove 
the amino-terminal hydrophobic sequence of 14 to 18 amino acids (aa), which are the 
signal sequence for transport to the cell membrane. Carbohydrate side chains are 
added, whose number and position vary with the virus strain. The HA (HA0) is 
cleaved into two disulfide-linked chains, HA1 and HA2 (MITNAUL et al. 2000; 
SKEHEL and WILEY 2000). This cleavage is accomplished by host-produced trypsin-
like proteases (KIDO et al. 1992) and is required for infectivity because virus-cell 
fusion is mediated by the free amino terminus of HA2 (LEWIS 2006; STEVENS et al. 
2006). The fully processed HA consists of HA1 (typically) of about 324 aa plus 
variable carbohydrate, and HA2 (typically) of about 222 aa plus variable carbohydrate 
and 3 palmitate residues. The three-dimensional structure of a complete HA trimer 
has been determined. Each HA molecule consists of a globular head on a stalk. The 
head is made up exclusively of HA1 and contains the receptor-binding cavity as well 
as most of the antigenic sites of the molecule. The stalk consists of all of HA2 and 
part of HA1. The carboxy-terminal region of HA2 contains the hydrophobic 
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transmembrane sequence and a terminal cytoplasmic anchor sequence where 
palmitate is attached (WEBSTER et al. 1992). The HA mediates attachment to and 
entry of virus into host cells by binding to sialic acid receptors at the cell surface. HA 
is also the main viral target of protective humoral immunity by neutralizing antibody 
(DE JONG and HIEN 2006; STEVENS et al. 2006) and the T - cell mediated immune 
responses (HORVATH et al. 1998). The binding affinity of HA to the sialic acid 
residues partly accounts for the host specificity of the various influenza A virus 
subtypes. The epitopes involved in receptor-binding show great variability due to 
mutations in the RNA causing amino acid substitutions at several sites on the HA1 
molecule (BROWN 2000; HORVATH et al. 1998). Influenza viruses from different 
hosts can differ with respect to specificity and affinities for the 2-3 or 2-6 linkage of N-
acetyl neuraminyl-galactose (SA 2,3 Gal; SA 2,6 Gal). These binding specificities 
correspond to the types of sialic acid linkages within these hosts and therefore avian 
strains preferentially bind SA 2,3 Gal, whereas human strains preferentially bind SA 
2,6 Gal (WOOD et al. 1993). Owing to error-prone viral RNA polymerase activity, 
influenza virus HA is subject to a very high rate of mutation. Selection for amino acid 
substitution is driven at least in part by immune pressure, as the HA is the major 
target of the host immune response. Several recent reports demonstrated that HA 
and HA1 fragment containing the majority of antigenic determinants are responsible 
for generation of virus-neutralizing antibodies and vaccines based on conserved 
antigens provide broader protection (KREIJTZ et al. 2007; SHOJI et al. 2008; 
TONEGAWA et al. 2003).  
2.2.4 Neuraminidase 
NA is also a type II integral membrane glycoprotein (MITNAUL et al. 2000) and a 
second major surface antigen of the virion. NA cleaves terminal sialic acid from 
glycoprotein or glycolipids. Thus, it is thought to be important in the final stages of 
release of new virus particles from infected cells, prevent the new virus particles 
agglutinating, thus increasing the number of free virus particle and hence spread of 
the virus from original site of infection (DE JONG and HIEN 2006). NA is glycosylated 
and possesses an amino-terminal hydrophobic sequence which functions both as 
signal for transport to the cell membrane and as transmembrane domain; it is not 
cleaved away. The distribution of NA has not been conclusively resolved; 
immunogold-labeling experiments suggest that the NA tetramers are not evenly 
distributed over the virion envelope, as is HA, but aggregate into patches or caps 
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(BROWN 2000). The complete three-dimensional structure of an NA tetramer, bound 
to antibody, has been determined. Like HA, NA is highly mutable with variant 
selection partly in response to host immune pressure. Nine subtypes of NA have 
been identified in nature; they are not serologically cross-reactive. Different variants 
of several subtypes are known (BROWN 2000; WEBSTER et al. 1992). Many studies 
have documented that influenza virus particles with low NA enzymatic activity cannot 
be efficiently released from infected cells, resulting in the accumulation of large 
aggregates of progeny virions on the cell surface (LIU et al. 1995; MITNAUL et al. 
2000). Inhibition of this important function represents the most effective antiviral 
treatment strategy to date (LEWIS 2006). The substrate binding site is in the middle 
of the head of tetramer, which is attached by a stalk to the membrane. Substrate 
analogues have recently been introduced for therapy of influenza virus infection. Anti-
drugs currently being used to treat infected patients are oseltamivir (Tamiflu). 
2.2.5 Non-structural proteins 
NS1 mRNA is collinear with the viral RNA. The NS1 protein forms a dimmer that 
inhibits the export of poly-A containing mRNA molecules from nucleus and is 
expressed in large amounts in influenza virus infected cells but it has not been 
detected in virions, hence the designation NS for non-structural. NS1 is a 
phosphoprotein, and the protein is found in infected cells associated with polysomes 
and also in the nuclease and nucleolus. The NS1 protein is required for virulence in 
mice (LIPATOV et al. 2005). When NS1 is absent or altered, the virulence of 
influenza A viruses is highly attenuated. NS1 protein functions as a type I interferon 
(IFN) antagonist raise the question whether this protein can also increase viral 
pathogenicity in vivo (LIPATOV et al. 2005). The NS1 protein of influenza A virus 
associates with p53 and inhibits p53-mediated transcriptional activity and apoptosis 
(WANG et al. 2010). The NS2 was originally misnamed but is not thought to exist in 
virions and to form an association with the M1 protein. NS2 is a small molecule. NS2 
functions in the nucleocytoplasmic export of RNP for assemble into virions and have 
been shown to posses a nuclear export signal. A new name has been proposed 
nuclear export protein (NEP) (ALEXANDER 2007). 
2.2.6 Matrix protein 
Segment 7 encodes two proteins, M1 and M2. The proteins encoded by these 
mRNAs share their initial 9 amino acids and also have a stretch of 14 amino acids in 
overlapping reading frames.  The M1 protein is a highly conserved 252-amino acid 
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protein. It is the most abundant protein in the viral particle, lining the inner layer of the 
viral membrane and contacting the RNP core. M1 has been shown to have several 
functions including regulation of the nuclear export of viral RNP (vRNPs), both 
permitting the transport of vRNP particles into the nucleus upon infection and 
preventing newly exported vRNP particles from re-entering the nucleus (MARTIN and 
HELENIUS 1991). M1 may also be involved in the inhibition of viral transcription in 
the late stages of infection and regulation of the switch from replication to viral 
assembly (PEREZ and DONIS 1998; WAKEFIELD and BROWNLEE 1989; 
ZVONARJEV and GHENDON 1980).  M1 binds RNA (SHA and LUO 1997; YE et al. 
1999; YE et al. 1989), vRNPs (YE et al. 1999) and lipids (GREGORIADES and 
FRANGIONE 1981) dimerizes with other M1 molecules (HARRIS et al., 2001); and 
interacts with both the HA and NA proteins (ALI et al. 2000; ENAMI and ENAMI 
1996). It is also involved in export to the cytoplasmic membrane, virus assembly, and 
budding (GOMEZ-PUERTAS et al. 2000; LATHAM and GALARZA 2001). It has been 
reported repeatedly that the virulence and growth of influenza viruses are influenced 
by changes in the internal proteins. M1 protein is a multifunctional protein which 
contributes to the control of virulence, growth, (ENAMI et al. 1993; SMEENK and 
BROWN 1994; YASUDA et al. 1994) and host specificity of influenza viruses 
(MURPHY et al. 1989). M2 is an integral membrane protein and a large number of 
M2 molecules are expressed at the plasma membrane of the influenza virus infected 
cell surface, with a ratio of approximately two M2 molecule per HA (ZEBEDEE and 
LAMB 1988). The 97-amino acid M2 protein is a homotetrameric integral membrane 
protein exhibits ion channel activity and is composed of 24 extracellular amino acids, 
and 54 cytoplasmic residues (BAUER et al. 1999; HOLSINGER and LAMB 1991; 
SUGRUE and HAY 1991; WANG et al. 1994). Disulfide bonds link the protein 
through cysteines located in the extracellular region (HOLSINGER and LAMB 1991). 
Amantadine and remantadine inhibit virus replication by blocking the ion channel 
formed by the M2 Protein. Certain mutations in the M gene lead to viruses that are 
resistant to antiviral drugs (positions 26, 27, 30, 31, and 34) within the 
transmembrane domain of M2 has been implicated in loss of sensitivity of M2 
blockers (HAY et al. 1979; PINTO et al. 1992). 
2.2.7 PB1-F2 protein 
PB1-F2 is encoded by an open reading frame within an alternative reading frame of 
PB1 (CHEN et al. 2001). This 87-residue protein seems to participate in the induction 
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of apoptosis and also functions to kill host immune cells responding to influenza virus 
infections. This protein was shown to be non-essential for virus replication in vitro 
(SIDORENKO and REICHL 2004). 
2.3 Virus replication 
Influenza virus particles attach to sialic acid containing cellular receptors via the viral 
HA glycoprotein. Virions penetrate into the cell by a clathrin-dependent receptor-
mediated endocytosis. Although several other entry pathways for influenza virus are 
also reported (SIECZKARSKI and WHITTAKER 2002) the endocytic pathway seems 
to be the most common. vRNPs are released from the endosome when the 
endosomal pH is decreased to  5.0,  which activates viral M2 ion channels and allows 
protons to enter the interior of the virus particle. As a result, the viral M1 proteins 
undergo conformational changes, followed by the disruption of M1- vRNP interactions 
and acid-catalysed conformational rearrangements of HA proteins. As a 
consequence, viral and endosomal membranes fuse and individual vRNPs are 
released into the cellular cytoplasm. The import into the nucleus, through nuclear 
pore complexes, is mediated by a nuclear localization signal (NLS), carried by NP. 
Since M1 proteins inhibit this import of vRNPs, its detachment from vRNP plays a 
crucial role at this step. Virus particles unable to fuse with the membrane, e.g., virions 
with defective M2 ion channels, are degraded by lysosomes. Three types of viral 
RNAs are synthesized in the cellular nucleus: viral mRNAs of positive polarity 
(vmRNA), viral genomic RNAs (vRNA) of negative polarity, and complementary 
RNAs (cRNA) of positive polarity. Influenza virus vmRNAs contain a cap structure at 
the 5´ end and a poly (A) tail at the 3´ end, which are taken from cellular precursor 
mRNAs. Their synthesis is governed by the viral polymerase complex and comprises 
several steps. Splicing of M and NS mRNAs, also occurs in the nucleus. It is 
regulated by NS1 proteins. Newly synthesized viral mRNAs are efficiently exported 
from the nucleus into the cytoplasm via nuclear pores. Genome replication involves 
the synthesis of full-length vRNA (–) and cRNA (+) strands. While transcription is 
carried out by PB1 and PB2 proteins, genome replication requires PB1 and PA 
subunits of the polymerase complex (CASSETTI et al. 2001). Experiments show that 
NP proteins bind to elongating strands. It is also known that NP proteins promote the 
initiation of unprimed transcription and block the synthesis of viral mRNAs. The 
cRNAs serve as templates for vRNA synthesis, while newly replicated vRNAs are 
used for the production of further vmRNAs and cRNAs as well as for the assembly of 
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vRNP complexes. The proteins PB1, PB2, PA, NP, NS1, NS2, and M1 are produced 
in the cellular cytoplasm. When influenza virus particles internalize into the cell, the 
rate of cellular protein production slows down. The hypothesis that the translation 
machinery of infected cells efficiently processes only mRNAs possessing the viral 
untranslated region was recently challenged (CASSETTI et al. 2001). However, there 
are three possible mechanisms for the inhibition of cellular protein synthesis (PARK 
and KATZE 1995). One of them involves the degradation of cellular precursor 
mRNAs in the nucleus. Another possibility is the inhibition of the translation of cellular 
mRNAs at initiation and elongation steps. Finally, cellular protein production can be 
suppressed by retarding the transport of cellular mRNAs to the cytoplasm. While 
cellular protein synthesis is at least partially inhibited, viral proteins are synthesized at 
a maximum rate by ribosomes organized in polysome complexes. Newly synthesized 
polymerases as well as nucleocapsid, M, and NS are then transported to the nucleus, 
where they participate in M and NS mRNAs splicing, transcription, and genome 
replication. Additionally, they are consumed for the production of new vRNP 
complexes. M2, HA, and NA protein synthesis is carried out by ribosomes bound to 
the membranes of the endoplasmic reticulum (ER). Newly synthesized envelope 
proteins are inserted into the ER, glycosylated, and transported to the Golgi 
apparatus. Finally, they are delivered to the membrane of the host cell to be 
assembled with vRNP complexes. Formation of vRNP complexes takes place in the 
nucleus. It results from the binding of newly synthesized PB1, PB2, PA, NP, and NS2 
proteins to vRNAs. M1 proteins attach to vRNPs, forming M1-vRNP complexes, and 
catalyze the transport of vRNPs to the cytoplasm. Nuclear export of vRNPs is also 
directed by NS2 proteins and nuclear export signals (NES) carried by NP proteins 
(PORTELA and DIGARD 2002). As stated above, M1 proteins also inhibit the import 
of vRNP complexes. Therefore, newly synthesized vRNPs associated with M1 
protein are unable to penetrate into the nucleus again. The vRNP-M1 protein 
complexes interact with the cytoplasmic tails of M2, HA, and NA proteins, that leads 
to the formation of a bud at the assembly site, e.g., the apical membrane of polarized 
epithelial cells. This bud separates from the cellular membrane and a virion is 
released to the extracellular medium. Most of the cellular membrane proteins are 
excluded from virus particles by NA proteins (LUO et al. 1993). 
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2.4 Antigenic shift and drift 
Two surface glycoproteins HA and NA, undergo gradual, continuous minor antigenic 
changes due to point mutations in the HA and NA genes, referred to antigenic drift. 
This phenomenon occurs in all influenza A viruses due to the lack of a proof reading 
system for the RNA polymerases. Due to the segmented nature of the viral genome, 
the exchange of RNA segments, called genetic reassortment, between two 
genetically different AI viruses infecting the same host cell may potentially result in 
the generation of a novel strain and / or subtype, which can lead to major antigenic 
changes in the HA or NA genes. This is referred antigenic shift. The emergence of 
resultant virus strains enhanced human infectivity and may lead to influenza 
pandemics (BOUVIER and PALESE 2008; SHOHAM 2006; TAMURA et al. 2005; 
WEBSTER et al. 1992). Animals, particularly the importance of pigs and poultry have 
a great role in the emergence of the new influenza viruses (MANUGUERRA and 
HANNOUN 1997). On the other hand, ducks are the "Trojan horses" of H5N1 
influenza (KIM et al. 2009). It is generally accepted that wild duck species can spread 
HP H5N1 viruses, but there is insufficient evidence to show that ducks maintain these 
viruses and transfer them from one generation to the next. 
2.5 Avian influenza pathogenicity 
Influenza A viruses are divided into two groups on the basis of their ability to cause 
disease in chickens which are HPAI and LPAI (PANTIN-JACKWOOD and SWAYNE 
2009). HPAI viruses have been restricted to subtypes H5 and H7, although not all 
viruses of these subtypes cause HPAI. All other viruses (LPAI) cause mild symptoms, 
which nevertheless, may be exacerbated by other infections or environmental 
conditions resulting in a much more serious disease. A crucial role in AI pathogenicity 
is played by HA. This is because HA0 requires post-translational cleavage by host 
proteases before the protein is functional and the virus particles are infectious. It has 
been demonstrated that the HA0 precursor proteins of AIV of low virulence for poultry 
are limited to cleavage by host proteases such as trypsin and trypsin-like enzymes. 
Thus AIV remains restricted to replication at sites in the host where such enzymes 
are found, i.e. the respiratory and intestinal tracts. In contrast virulent viruses appear 
to be cleavable by (a) ubiquitous protease(s). The remains to be fully identified but 
appears to be one or more proprotein-processing subtilisin-related endoproteases of 
which furin is the leading candidate (STIENEKE-GROBER et al. 1992). This enables 
these viruses to replicate throughout the animal, damaging vital organs and tissues 
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which brings about disease and death in the infected bird. Comparisons of the 
amino-acid sequences at the HA0 cleavage site of AIV of high and low pathogenicity 
revealed that while viruses of low virulence have a single basic amino acid (arginine) 
at the site, all HPAI viruses possessed multiple basic amino acids (arginine and 
lysine) adjacent to the cleavage site either as a result of apparent insertion or 
apparent substitution (CHEN et al. 1998a; SENNE et al. 1996; VEY et al. 1992; 
WOOD et al. 1993). The potential for LPAI virus appearing in meat of infected 
chickens is negligible, while the potential for having HPAI virus in meat from infected 
chickens is high, but proper usage of vaccines can prevent HPAI virus from being 
present in meat (SWAYNE and BECK 2005). Most HPAI viruses appear to have 
arisen as result of spontaneous duplication of purine triplets, which results in the 
insertion of basic amino acids at the HA0 cleavage site, and this occurs because of a 
transcription fault by the polymerase complex. However, this is clearly not the only 
mechanism by which HPAI viruses arise. Some appear to result from nucleotide 
substitution rather than insertion, whereas others have insertions without repeating 
nucleotides. H7N3 HPAI viruses show distinct and unusual cleavage site amino acid 
sequences (PASICK et al. 2005). The factors that bring about mutation from LPAI to 
HPAI are not known. In some instances, mutation seems to have taken place 
immediately after introduction to poultry from wild birds at the primary site, whereas in 
others, the LPAI virus has circulated in poultry, sometimes for months before 
mutating. The HPAI viruses do not show high virulence for all species of birds, and 
the clinical severity seen in any host appears to vary with both bird species and virus 
strain (ALEXANDER et al. 1978; ALEXANDER et al. 1986). In particular, ducks rarely 
show clinical signs as a result of HPAI infections, although there are reports that 
some of the Asian H5N1 viruses have caused disease (STURM-RAMIREZ et al. 
2005). Ostriches (Struthio camelus) also appear to have an unusual clinical response 
to HPAI infection. The clinical condition caused by HPAI is very similar to that caused 
by LPAI viruses (CAPUA and ALEXANDER 2006). Despite the application of control 
measures in most countries, infections of HPAI H5N1 continue to occur, and in 2008, 
outbreaks in poultry were reported in Benin, Egypt, Germany, Iran, India, Thailand, 
Turkey, Ukraine, and Vietnam, whereas infections of wild birds were reported in 
China, Hong Kong, and the United Kingdom. The  peak virus titres excreted and the 
time required for virus titres to reach a minimal chicken infectious dose may be the 
critical phenotypes influencing the transmissibility of highly pathogenicity AI viruses in 
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chickens (SUZUKI et al. 2010).  Moreover, H6N2 viruses can infect both chickens 
and ducks, but based on the number of birds shedding virus and on histopathology, 
these viruses appear to be more adapted to chickens. Virus shedding, which could 
go unnoticed in the absence of clinical signs in commercial chickens, can lead to 
transmission of the virus among poultry (JACKWOOD et al. 2010). The OIE adopted 
the following criteria for the classification of an AIV as HP: (1) any influenza virus that 
is lethal for six, seven or eight of eight 4– to 8-week-old susceptible chickens within 
10 days following intravenous inoculation with 0.2 ml of a 1/10 dilution of a bacteria-
free infective allantoic fluid; any virus that has an intravenous pathogenicity index 
(IVPI) greater than 1.2; (2) the amino acid sequence of the connecting peptide of the 
HA must be determined. If the sequence is similar to that observed for other highly 
pathogenic AI isolates, the isolate being tested will be considered to be highly 
pathogenic. 
2.6 Clinical signs 
Following an incubation period of usually a few days (rarely up to 21 days), 
depending upon the characteristics of the isolate, the dose of inoculum, the species, 
and age of the bird, the clinical presentation of AI in birds is variable and symptoms 
are fairly unspecific (ELBERS et al. 2005). The symptoms following infection with 
LPAI may be as discrete as ruffled feathers, transient reductions in egg production or 
weight loss combined with a slight respiratory disease (BARR et al. 1986; CAPUA 
and MUTINELLI 2001). Some LP strains such as certain Asian H9N2 lineages, 
adapted to efficient replication in poultry, may cause more prominent signs and also 
significant mortality (BANO et al. 2003). Both 1918 and 2009 H1N1 influenza viruses 
behave as LPAI in gallinaceous poultry (BABIUK et al. 2010). LPAI (H4, H6 and H9) 
can infect and be shed by chickens and turkeys. However, detection is difficult 
because these viruses don’t cause clinical disease or mortality, but only induce mild 
microscopic lesions and exhibit poor seroconversion (MORALES et al. 2009).  
In HPAI, the illness in chickens and turkeys is characterized by a sudden onset of 
severe symptoms and a mortality that can approach 100 % within 48 hours 
(SWAYNE and SUAREZ 2000). Spread within an affected flock depends on the form 
of rearing: in herds which are litter-reared and where direct contact and mixing of 
animals is possible, spread of the infection is faster than in caged holdings but would 
still require several days for complete contagion (CAPUA et al. 2000). Often, only a 
section of a stable is affected. Many birds die without premonitory signs so that 
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sometimes poisoning is suspected in the beginning (NAKATANI et al. 2005). It is 
worth noting, that a particular HPAI virus isolate may provoke severe disease in one 
avian species but not in another: in live poultry markets in Hong Kong prior to a 
complete depopulation in 1997, 20 % of the chickens but only 2.5 % of ducks and 
geese harboured H5N1 HPAIV while all other galliforme, passerine and psittacine 
species tested virus-negative and only the chickens actually showed clinical disease 
(SHORTRIDGE 1982). Individual birds affected by HPAI often reveal little more than 
severe apathy and immobility (KWON et al. 2005). Oedema, visible at feather-free 
parts of the head, cyanosis of comb, wattles and legs, greenish diarrhoea and 
laboured breathing may be inconsistently present. In layers, soft-shelled eggs are 
seen initially, but any laying activities cease rapidly with progression of the disease 
(ELBERS et al. 2005). Nervous symptoms including tremor, unusual postures 
(torticollis), and problems with co-ordination (ataxia) dominate the picture in less 
vulnerable species such as ducks, geese, and ratites  (KWON et al. 2005) 
2.7 Gross lesions  
The appearance of gross lesions is variable depending on the virus strain, the length 
of from infection to death, and the age and species of poultry affected (KOBAYASHI 
et al. 1996; SWAYNE et al. 1997). In general, clinical signs, lesions and death have 
been seen with domestic poultry of the order galliformes, family phasianidae, but not 
for birds of the orders anseriformes or charadriiformes when infected with HPAI 
viruses. In most cases peracute infections with death (days one to two of infection), 
poultry have lacked visible gross lesions (HOOPER et al. 1995). However, some 
strains, such as A / chicken / Hong Kong / 220 / 97 (H5NI) and A / chicken / Italy / 
330 / 97 (H5N2) have caused severe lung lesions of congestion, haemorrhage and 
edema in chicken, such that excised tissue exuded serous fluid and blood (SUAREZ 
et al. 1998). Edema of the brain has also been reported. During the acute stages of 
infection with death (days three to five post-infection) chickens have ruffled feathers, 
congestion and/or cyanosis of the comb and wattles and swollen heads, especially 
prominent from periorbital and intramandibular subcutaneous oedema (ACLAND et 
al. 1984; HOOPER et al. 1995; KOBAYASHI et al. 1996; SWAYNE et al. 1997). 
Some viruses produced hyperaemia and edema of the eyelids, conjunctiva and 
trachea (BARR et al. 1986). In birds which die, generalized congestion and 
haemorrhage may occur (HOOPER 1989). Lesions are common in the combs and 
wattles, especially in adult chicken, and include petechial-to-ecchymotic 
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haemorrhages, swelling from oedema and eventually depressed dark red-to-blue 
areas of ischemic necrosis as the result of vascular infarction. Subcutaneous 
haemorrhages and oedema may be present around the hock, on the shanks and feet 
and occasionally on feathered skin all over the body. Some HPAI viruses, such as A / 
Queretaro  / 14588-19 / 95 (H5N2), commonly caused thickening of the skin over the 
distal legs with gelatinous oedema (SWAYNE et al. 1997). Petechial – to- ecchymotic 
haemorrhages may be present in multiple visceral organs or on the serosal surface, 
such as the epicardium of the heart, serosa of small intestine ,abdomintal fat, serosa 
of sternum, caecal tonsils, Meckel's  diverticulum, Peyer's lymphoid patches of the 
small intestine, proventriculus around the glandular ducts or between glands, under 
the cuticle of the skeletal muscles primary lymphoid organs such as cloacal bursa 
and thymuses are severely atrophic, while the spleen may be normal in size or 
enlarged. Occasionally, spleens have white foci of necrosis and the pancreas may 
have red to light orange to brown mottling (HOOPER 1989). Ruptured ova with yolk 
peritonitis have been reported in layers and broilers turkey breeders. 
2.8 Vaccination 
Vaccination has proven to be a powerful tool for control of H5N1 HPAI outbreaks. 
Vaccination increases the bird resistance to field virus transmission (CAPUA and 
MARANGON 2007a; VAN DER GOOT et al. 2005; ELLIS et al. 2004). Vaccination 
and companion DIVA testing are highly recommended by OIE for control and 
prevention of HPAI (CAPUA and MARANGON 2007a). Wild birds and waterfowl play 
a potential role as reservoirs in AIV circulation and evolution (NORMILE 2005; 
OLSEN et al. 2006). However, the global distribution and persistence of LPAI viruses 
in wild bird populations is not fully clear (WEBBY and WEBSTER 2003). Influenza 
viruses can have numerous antigenic subtypes and rapidly evolve due to constant 
gene mutation and reassortment. These factors contribute to the fact that AI is a 
disease difficult to be eradicated in some circumstances. An ideal AI vaccine would 
provoke an immune response that protects against disease and prevents infection 
(SWAYNE and KAPCZYNSKI 2008). Current commercially available vaccines will not 
prevent infection completely, but experimental and field studies have shown that 
properly used vaccines can accomplish multiple goals: (1) protect against clinical 
signs and death, (2) reduce shedding of field virus if vaccinated poultry become 
infected, (3) prevent contact transmission of field virus, (4) protect against challenges 
by low to high doses of field virus, (5) protect against a changing virus, and (6) 
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increase a bird's resistance to AI virus infection (SWAYNE 2006b). If possible, 
selection of strains for inclusion in poultry AI vaccines should be based on an 
analysis of the field challenge virus in comparison with the licensed vaccine strains, 
which may require some flexibility in registration processes to allow for new products 
and re-formulation of existing vaccines to facilitate timely adjustments of vaccine 
formulation. Unlike human influenza A vaccines where antigenic drift of the field virus 
requires changing vaccine strains every few years, antigenic drift of poultry influenza 
viruses has not required a similar frequent need to change the vaccine strain 
(SWAYNE and KAPCZYNSKI 2008). In one study, an H5 vaccine strain provided 
broad protection against diverse H5 HPAI viruses collected during 38 years and 
differing as much as 12 % in amino acid sequence of the HA gene. The closer the HA 
gene sequence similarity between vaccine and field viruses, however, the greater the 
reduction in challenge virus replication and shedding from the respiratory tract 
(SWAYNE and KAPCZYNSKI 2008). The use of a poorly matched vaccine can result 
in clinical disease and increased virus shedding when vaccinated poultry are 
naturally infected (SWAYNE 2006b). The duration of effective immunity will vary 
based on the number of doses given, age of bird at time of vaccination, antigen 
quantity in each dose of vaccine, and avian species. Using traditional whole virus 
inactivated oil-emulsion vaccines in chickens, peak HI titres are observed 4-6 weeks 
post vaccination (BRUGH et al. 1979), with the same work indicating a much lower 
seroconversion rate in turkeys. Additional studies in turkeys indicate two doses of 
inactivated vaccine are necessary to reduce virus shedding and replication to levels 
needed to reduce viral spread (KARUNAKARAN et al. 1987). The immunogenicity of 
vaccines is correlated to antigen mass, its formulation and the age of vaccination (DI 
TRANI et al. 2003). The different levels of immune responses are due to antigenic 
quality and contents as well as the adjuvant composition (CRISTALLI AND CAPUA 
2007).  
2.8.1 Inactivated whole virus vaccine 
As early as 1971, inactivated oil emulsion vaccines were used to immunize chickens 
and turkeys against AI virus infection (ALLAN et al. 1971). Up to now, inactivated 
vaccines in chickens and turkeys against AI have been reported, subtypes H1 
(ABRAHAM et al. 1988; SWAYNE et al. 2001), H5 (CRAWFORD et al. 1998; 
SWAYNE 2006a; SWAYNE et al. 2001), H6 (CARDONA et al 2006), H7  
(CHERBONNEL et al. 2003; FATUNMBI et al. 1992; PHILIPPA et al. 2005) and H9 
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(PAN et al. 2009; SWAYNE 2006a). Inactivated vaccines are major vaccine type 
used in the poultry industry. They produce strong humoral immune response but they 
do not produce a strong mucosal immune response. In addition, Adjuvanted killed 
vaccines can provide a strong humoral immune response and they provide an 
effective protection against LPAI and HPAI challenges. The main disadvantage of 
inactivated full virus vaccines is that vaccinated birds will develop antibody not only to 
protective epitopes on the HA and NA proteins, but also to the internal influenza 
proteins as M1 and NP. Vaccinated birds could not be distinguished from naturally 
infected birds using the commonly used serological assays as Elisa and AGID 
(MARANGON et al. 2007; SUAREZ and SCHULTZ-CHERRY 2000). On the other 
hand, inactivated heterologous vaccines are manufactured in a similar way to 
inactivated homologous ones. The use of heterologous NA DIVA strategy is an 
acceptable approach but availability of diagnostics is an issue. Reverse genetics 
have been applied to develop improved vaccines against AI (LIU et al. 2003; 
NEUMANN et al. 2003; TIAN et al. 2005; WEBSTER et al. 2006). Conventionally 
prepared reassortant H5N1 vaccines developed by reverse genetics are currently 
being used in China and other Asiatic countries (SWAYNE. 2009; TIAN et al. 2005).  
In addition, H7 and H9 subtype vaccines developed by reverse genetics have been 
used experimentally (CHEN 2004; JOSEPH et al. 2008). These vaccines have similar 
performance to conventional inactivated vaccines. However the efficacy under field 
conditions is questionable. This technology does not solve the problem related to the 
egg-based production as production of vaccines in egg is cumbersome, lengthy, and 
costly (SWAYNE 2009; WANG et al. 2006). 
2.8.2 Live recombinant vector-based vaccine 
Recombinant vectored vaccines have been developed for poultry using viral vectors 
such as FP virus  (SWAYNE et al. 2000): vaccinia virus (CHAMBERS et al. 1988; DE 
et al. 1988; YEWDELL et al. 1985), retrovirus (ALTSTEIN et al. 2006; BROWN et al. 
1992; HUNT et al. 1988), adenovirus (GAO et al. 2006; Hoelscher et al. 2006; 
SARUKHAN et al. 2001), ND virus  (DINAPOLI et al. 2010; DINAPOLI et al. 2007; 
GE et al. 2007; KIM and SAMAL 2010; NAKAYA et al. 2001; NAYAK et al. 2009; 
PARK et al. 2006; ROMER-OBERDORFER et al. 2008; SCHROER et al. 2009; 
STEEL et al. 2008; VEITS et al. 2008; VEITS et al. 2006), ILT herpes virus 
(LUSCHOW et al. 2001; PAVLOVA et al. 2009a; PAVLOVA et al. 2009b). Several 
recombinant FP viruses expressing the H5 antigen have been developed (BOYLE et 
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al. 2000; BUBLOT et al. 2007; HGHIHGHI et al. 2010; KYRIAKIS et al. 2009; 
MINGXIAO et al. 2006; QIAO et al. 2009; STEENSELS et al. 2009; SWAYNE 2009; 
SWAYNE and SUAREZ 2000). These vaccines have been reported to be effective in 
reducing virus shedding and providing clinical protection. However, these vaccines 
are likely to be used only in birds that are susceptible to infection with the vector virus 
(CAPUA and MARANGON 2007b). Some studies with these vaccines appear to have 
shown evidence of a period of growth inhibition in chickens (MINGXIAO et al. 2006). 
Recently, recombinant ND virus vectors expressing HA of H5 or H7 HPAI virus, 
developed using reverse genetics, have been licensed for use in China and Mexico 
(SWAYNE 2009). However, maternal antibodies and active humoral immunity to ND 
virus vector will interfere with and reduce the protective efficacy. Additionally, 
biosafety and biosecurity of such live vaccines should be assessed (SWAYNE 2009).  
2.8.3 DNA- based vaccine 
DNA vaccines have been shown to elicit robust immune responses in various animal 
species, from mice to nonhuman primates (BARRY and JOHNSTON 1997; LUCKAY 
et al. 2007). In human trials, these vaccines elicit cellular and humoral immune 
responses against various infectious agents, including influenza, SARS, SIV and HIV. 
In addition to their ability to elicit antibody responses, they also stimulate antigen-
specific and sustained T cell responses (BARRY and JOHNSTON 1997; GARES et 
al. 2006; GURUNATHAN et al. 2000; RAVIPRAKASH and PORTER 2006). DNA 
vaccines have been used in chickens to generate antisera to specific influenza 
viruses and confer protection against the LP H5N2 strain (KODIHALLI et al. 1997; 
LEE et al. 2003, 2006). Trials to generate DNA vaccines were done in chickens and 
mice (BOT et al. 1996; CHERBONNEL et al. 2003; FYNAN et al. 1993; Olsen 2000; 
PENG et al. 2003; ROBINSON et al. 1997). On the other hand, A single 
immunization with HA DNA vaccine by electroporation induces early protection 
against H5N1 AIV challenge in mice (ZHENG et al. 2009). Multivalent HA DNA 
vaccination protects against highly pathogenic H5N1 AI infection in chickens and 
mice (RAO et al. 2008). DNA vaccines against AI in poultry have not been as 
efficacious and consistent as conventional inactivated vaccines. 
2.8.4 RNA- based vaccines 
To avoid the potential risk of DNA sequence integration into the host genome with 
DNA vaccination, RNA has been proposed as the expression vector (VIGNUZZI et al. 
2001). The mRNA construct encoding the foreign gene delivered intramuscular or 
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liposome-entrapped mRNA injection. However, antigen expression sufficient to 
stimulate an adequate immune response is a major problem facing such type of 
vaccines.  
2.8.5 Live vaccine 
The use of live influenza vaccines in poultry has never been seriously considered for 
several reasons. First, there is the possibility of bird-to-bird or farm-to-farm 
transmission. This may establish AI virus as an endemic infection. Second, the use of 
live vaccine may cause vaccine-induced respiratory disease in commercial poultry. 
Third, presumably the most important, there is a potential for recombination with 
newly introduced AI virus strains to create recombinant AI viruses, which are more 
pathogenic or has the capability of spreading to different hosts. However, with the 
advancement in the biotechnology, it may be possible to consider new vaccine 
approaches using genetically engineered live virus. For example, several 
experiments showed the possibility of attenuating influenza virus by introducing 
changes in the PB2 gene, exchanging the promoter region of the NA gene with a 
different promoter, and generating influenza viruses that have truncated NS1 genes 
(MURPHY et al. 1997; MUSTER et al. 1991). The study with TK / OR / 71- del, which 
has truncated NS1 protein, showed attenuation in pathogenicity and a decreased 
ability to replicate in chickens. The influence of the multi-basic cleavage site (MBS) of 
the H5 HA on the attenuation, immunogenicity and efficacy of a live attenuated 
influenza A H5N1 cold-adapted vaccine virus was studied in mice and results showed 
that restoring the MBS in the H5 HA of the vaccine virus improved its immunogenicity 
and efficacy, likely as a consequence of increased virus replication, indicating that 
removal of the MBS had a deleterious effect on the immunogenicity and efficacy of 
the H5N1 vaccine in mice  (SUGUITAN et al. 2009). 
2.9 The immune response to influenza infection 
To develop vaccines, it is important to understand the immune response against AI 
virus. The main protective humoral response against AI virus infection is the 
production of virus-neutralizing antibodies induced by the HA protein and to some 
extent by the NA protein. In chickens and turkeys, the primary antibody response is 
initiated by the development of IgM antibody, which can be measured as early as 5 
days post-infection. Subsequently, IgY (the mammalian counterpart of IgG) is 
produced. The mucosal antibody response against AI virus is not clear, but IgA, 
which is critical for local immunity in respiratory and intestinal tract will likely be 
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produced after the IgM response similar to what happens after other viral infection in 
chickens (SUAREZ and SCHULTZ-CHERRY 2000). Local mucosal immunity in avian 
species is dependent on lymphoid tissue of the head and tracheo-bronchial region. 
Secretory antibodies against AI virus in the upper respiratory tract are thought to be 
important for AIV immunity, especially in preventing virus spread since the initial 
infection usually begins in this area. The protective role of IgA has been shown 
against several respiratory viruses including ND virus and IB virus (JAYAWARDANE 
and SPRADBROW 1995; RAJ and JONES 1996). However, similar studies have not 
been conducted with the mucosal immune response in poultry against AI infection. 
Neutralizing antibodies, produced against the two surface proteins, HA and NA are 
the major determinants for a protective immune response. The presence of high titres 
of humoral antibodies to the HA protein correlates well with protection from clinical 
disease and with low levels of virus recovery from the trachea of infected birds. For 
HPAI virus, subtype-specific antibodies prevent viremia, which limits spread from the 
respiratory or intestinal tract to other susceptible organs such as the kidney and 
brain. The primary role of the HA protein for inducing protection is further highlighted 
by the protection of birds with subunit vaccines that contain only the HA protein or the 
gene that encodes the HA protein. For this reason, vaccination for influenza is 
targeted primarily toward the HA subtype in poultry. Another surface protein, NA, also 
elicits neutralizing antibody, and NA specific vaccines can provide some protection 
against an HPAI challenge in chickens (KAWAOKA and WEBSTER 1988). Although, 
antibody to the NA protein is thought to be less important than the antibody to the HA 
protein, the level of reduction in virus shedding after vaccination of mice with NA 
protein alone was much lower than vaccination with the HA protein. However, greater 
protection was achieved to mice that were vaccinated with a DNA vaccine that 
included both the HA and NA genes rather than HA gene alone (CHEN et al. 1998b). 
Although antibody to the NA protein is valuable for protection, typical killed whole 
virus vaccines do not induce a good antibody response to the NA protein because 
much less NA is present in the virion as compared to the HA protein. Detectable 
antibody responses are also observed against M1, M2, and NP proteins (CHEN et al. 
1998b; SLEPUSHKIN et al. 1995). In the mouse model, antibodies to the M2 protein 
provided some level of protection in terms of preventing virus shedding 
(SLEPUSHKIN et al. 1995). Although the host usually produces high antibody levels 
to the M1 and NP proteins, these proteins are not accessible on the surface of the 
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virion and anti-M1 or NP antibody in the body cannot bind and neutralize the virus. 
The approach using those influenza genes as a vaccine have attracted the attention 
of many researches because they are more conserved in amino acid sequence as 
compared to the HA and NA proteins, and could potentially be a target protein to 
develop universal or heterosubtypic influenza vaccines (NEIRYNCK et al. 1999). 
However, vaccines lacking the HA or NA and based solely on conserved internal 
proteins have not been shown to be protective in poultry. Cellular immunity plays a 
role in the clearance of the influenza virus (MCMICHAEL et al. 1983). However, 
reports concerning a role for cell-mediated immunity in protection against AI virus are 
limited. T cells are the most important cells that mediate the cellular immune 
response and the T cell subpopulations with diverse functions have been identified in 
chickens. Infection of BALB/c mice with the H5N9 virus A / Turkey / Ontario / 7732 / 
66 resulted in the induction of class-2 MHC-restricted CTL, which recognized an 
epitope on the H5HA (HIOE and HINSHAW 1989). Similar results were observed 
with immunization of mice with purified A/Hong Kong / 156/97 H5 recombinant 
proteins generated in insect cells which induced an H5 –specific CTL response that is 
primarily class 2-restricted (KATZ et al. 2000). Experiments with a CTL peptide, 
which consists of an 18 amino acid peptide encompassing the CTL epitope, indicated 
that a class 2-retricted CTL response, in the absence of HI antibody, was not 
sufficient to protect mice from death as a result of infection with a highly lethal 
H5N1virus. Although cellular immunity conferred by H9N2 virus provided some level 
of protection as measured by mortality rate against subsequent HPAI H5N1infection, 
all the H9N2 immunized chickens died after challenge with H5N1 influenza virus, but 
with a longer mean death time and the birds continued to shed virus in their faeces. 
The cross-protective immunity is based on the presence of large number of killer T 
cells specific for influenza (SEO et al. 2002). Clearly, much more research should be 
done in analyzing the immune response to AI virus. Further understanding may lead 
to more rational design of vaccines to enhance the protective immune response. 
2.10 Host response 
The ability to cause disease and the ability of the host to respond to influenza varies 
greatly by species. For example, viruses that are highly pathogenic for chicken show 
either no disease or only mild disease signs in several different types of ducks 
(PHILPOTT et al. 1989b). Differences in pathogenicity between species have also 
been observed using experiential studies with LPAI and HPAI viruses in galliforms 
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(LAUDERT et al. 1993). For example in a study of two LPAI isolates in chickens and 
turkeys, the virus  was  asymptomatic in chicken but caused disease with 25 % 
mortality in turkeys (LAUDERT et al. 1993). Generally, the differences in disease do 
not appear to be the result of viruses either being able to infect or not infect a 
particular species, since evidence of infection occurred with most experimental 
inoculations of virus. The pathogenesis of AI in different species can also be very 
different, primarily when comparing ducks to chickens and turkeys. Replication of AI 
in ducks is believed to be primarily enteric, although respiratory disease has been 
reported in commercially raised and experientially infected ducks (ALEXANDER et al. 
1978). Even when generally characterizing the disease and replication patterns of 
influenza in ducks caution needs to be used since there are many different species of 
wild and domestic ducks that may have different response to influenza infection. 
Differences are also apparent when comparing the immune responses, primarily 
antibody titres, of different species to AIV infections. Several comparative studies of 
responsiveness in different species of birds using a variety of antigens suggest that 
antibody was greater for chicken >> pheasant >> turkey > quail > duck. A similar 
immunologic response was observed for both vaccination using killed influenza virus 
or experimental infection with AIV (BRUGH et al., 1979; HOMME and EASTERDAY 
1970). Ducks have been reported to develop poor antibody responses and lack HI 
antibody responses to natural and experimental AI infections (KIDA et al. 1980). The 
inability of ducks to produce haemagglutinating antibody is probably related to other 
deficiencies of duck antibody, including precipitation, complement activation, and 
opsonization. The HA protein has the two main functions of being the virus receptor 
binding site and containing the fusion domain necessary for the viral RNA to be 
released into the host cell. The HA protein is glycosylated integral membrane protein 
that forms a homotrimer on the surface of the virus. At least five antigenic sites have 
been determined for human influenza viruses, with each site being capable of 
producing neutralizing antibody (WILEY et al. 1981). Similar observations have also 
been made for H5 AIV (PHILPOTT et al. 1989b). HA titre in poultry strongly 
correlates with protection from challenge with virulent viruses of the same HA 
subtype. The NA protein is an enzymatically active protein that is thought to be 
important in cleaving sialic acid allowing the virus to be released from the cell 
surface. Antibody responses are also made to the internal virus proteins, especially 
the NP and M1 proteins. Both proteins are important antigens when used in 
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diagnostic tests because both have high sequence conservation that allows the 
detection of antibody from birds infected by any type A influenza virus. In poultry, the 
primary methods of detection of type specific antibody are the AGID test and Elisa 
(MEULEMANS et al. 1987; SNYDER et al. 1985). The mucosal immune response 
probably also has a role in protection from the HPAI infection because the initial 
exposure to the virus is through a mucosal surface. However, little direct work has 
been done with the mucosal immune response in chickens and turkeys.  
2.11 Diagnostic tests  
2.11.1 Virus isolation and Identification 
Basically, there are two approaches for diagnosis of AI: (1) isolation of the virus 
followed by subtyping using classical methods and (2) molecular characterisation by 
nucleic acid sequencing. Conventionally, AI virus is isolated by inoculation of swab 
fluid or tissue homogenates into 9- to 11-day-old embryonated chicken eggs, usually 
by the chorioallantoic sac route (WOOLCOCK et al. 2001). Depending on the 
pathotype, the embryos may or may not die within a five-day observation period and 
usually there are no characteristic lesions to be seen in either the embryo or the 
allantoic membrane (MUTINELLI et al. 2003). Eggs inoculated with HPAIV-containing 
material usually die within 48 hours. The presence of a haemagglutinating agent can 
be detected in harvested allantoic fluid. HA is an insensitive technique requiring at 
least 106.0 particles per ml. If only a low virus concentration is present in the 
inoculum, up to two further passages in embryonated eggs may be necessary for 
some LPAIV strains, in order to produce enough viruses to be detected by HA. In the 
case of HPAIV, a second passage using diluted inoculum may be advantageous for 
the optimal production of haemagglutination. Haemagglutinating isolates are 
antigenically characterised by HI tests using (mono-) specific antisera against the 16 
H subtypes and, for control, against the different types of avian paramyxoviruses 
which also display haemagglutinating activities. The NA subtype can be subsequently 
determined by neuraminidase inhibition (NI) assays, again requiring subtype-specific 
sera (AYMARD et al. 2003). In case isolates of the H5 or H7 lineages are 
encountered, their intravenous pathogenicity index (IVPI) needs to be determined to 
distinguish between LP and HP biotypes (ALLAN et al. 1971). This is achieved by 
intra-venous inoculation of ten 6-week old chickens with the egg-grown virus isolate. 
The chickens are observed over a period of ten days for clinical symptoms. Results 
are integrated into an index which indicates a HPAI virus when values greater than 
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1.2 are obtained. Alternatively, a HPAI isolate is encountered when at least seven out 
of ten (75 %) inoculated chickens die within the observation period. The described 
classical procedures can lead to a diagnosis of HPAI within five days but may 
demand more than a fortnight to rule out the presence of AIV. In addition, high quality 
diagnostic tools (SPF eggs, H- and N-subtype specific antisera) and skilled personnel 
are a prerequisite. Currently, there are no cell culture applications for the isolation of 
AIV that can achieve the sensitivity of embryonated hen eggs (SEO et al. 2001).  
2.11.2 Molecular diagnosis 
A more rapid approach, especially when exclusion of infection is demanded, employs 
molecular techniques, the presence of influenza A specific RNA is detected through 
the reverse transcription-polymerase chain reaction (RT-PCR) which targets 
fragments of the M gene, the most highly conserved genome segment of influenza 
viruses  (FOUCHIER et al. 2000), or the nucleocapsid gene (DYBKAER et al. 2004). 
When a positive result is obtained, RT-PCRs amplifying fragments of the HA gene of 
subtypes H5 and H7 are run to detect the presence of notifiable AIVs (DYBKAER et 
al. 2004). When positive again, a molecular diagnosis of the pathotype (LP versus 
HP) is feasible after sequencing a fragment of the HA gene spanning the 
endoproteolytic cleavage site. Isolates presenting with multiple basic amino acids are 
classified as HPAI. Feather pulp was the best sample to detect and isolate HPAIV 
from infected chicks from 24 hours after inoculation onwards. Kinetic studies on the 
persistence of virus in infected carcasses revealed that tissues like muscle could 
potentially transmit infectious viruses for 3 days post-mortem. While other tissues 
such as skin, feather pulp and brain retained their infectivity as long as 5-6 days post-
mortem at environmental temperature (22 - 23 °C). T hese results strongly favour 
feather as a useful sample for HPAIV diagnosis in infected chickens as well as in 
carcasses (BUSQUETS et al. 2010). PCRs and other DNA techniques have been 
designed for the detection of Asian lineage H5N1 strains (COLLINS et al. 2002; 
PAYUNGPORN et al. 2004). Non-H5/H7 subtypes can be identified by a canonical 
RT-PCR and subsequent sequence analysis of the HA2 subunit (PHIPPS et al. 
2004). There are also specific primers for each NA subtype. A full characterisation 
might be achievable within three days, especially when real time PCR techniques are 
used. An exclusion diagnosis is possible within a single working day. The 
disadvantages of molecular diagnostics are economic issues, although, if available, 
many samples can be analysed by less personnel in grossly shorter times in 
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comparison to virus isolation in eggs. However, it should not be kept secret that each 
PCR or hybridisation reaction, in contrast to virus isolation in eggs, harbours an 
intrinsic uncertainty related to the presence of specific mutations in a given isolate at 
the binding sites of primers and/or probes which might render the assay false 
negative. Thus, a combination of molecular (e.g. for screening purposes) and 
classical methods (e.g. for final characterisation of isolates and confirmation of 
diagnosis of an index case) may help to counterbalance the disadvantages of the two 
principles. Rapid assays have been designed for the detection of viral antigen in 
tissue impression smears and cryostat sections by use of IF or by antigen-capture 
enzyme-linked immunosorbent assay (AC-ELISA) and dip-stick lateral flow systems 
in swab fluids. So far, these techniques have been less sensitive than either virus 
isolation or PCR, and therefore might be difficult to approve for a legally binding 
diagnosis, especially of an index case (CATTOLI et al. 2004; DAVISON et al. 1998; 
SELLECK et al. 2003). The use of pen side tests in the veterinary field is still in its 
infancy and needs further development. 
2.11.3 Serological diagnosis 
Group-specific antibodies (influenza virus type A) against the NP can also be 
detected by AGID and by ELISA (JIN et al. 2004; MEULEMANS et al. 1987). Various 
forms of enzyme immunoassays have recently been developed and prove to be more 
sensitive and specific than AGID and HI. The AGID test requires large quantities of 
reagents and 24-48 hours for results to be obtained. Furthermore, the AGID test may 
not be suitable as a universal assay for some other species of birds; serum samples 
from water fowl do not contain good precipitating antibodies. The HI test is more 
sensitive and rapid than the AGID test, but it is complicated due to the existence of 
16 HA subtypes of AIV.  
 
 
 
 
 
 
 
 
 
 39 
3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Avian influenza virus 
A highly pathogenic influenza A subtype H5N1 (A / Thailand / 1 (Kan-1) / 2004) 
isolated from Thailand (PUTHAVATHANA et al. 2005) was obtained from Dr. 
Puthavathana, Department of Microbiology, Bangkok as a supernatant of infected 
MDCK-cells. The published sequence of this virus (Accession number: AY555150) 
was used for isolation of coding fragments of epitope based truncated sequences of 
HA. Also, this virus was used for preparation of inactivated H5N1 antigen to be used 
for vaccination and in serological tests.  
3.1.2. Bacteria 
XL10-Gold® ultracompetent cells (Stratagene, La Jolla, CA, USA) were used. These 
cells exhibit the Hte phenotype, which increases the transformation efficiency of 
ligated and large DNA molecules. The genotype of XL10-Gold ultracompetent® cells 
as follow: Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 Tn10 (Tetr) Amy Camr]. 
3.1.3 Pichia pastoris strains 
Two P. pastoris strains, supplied by Invitrogen Life Technologies (Invitrogen, 
Karlsruhe, Germany) were used. GS115 (his4) strain is an auxotrophic mutant 
deficient in histidine dehydrogenase, while SMD1168 H (his4, pep4) is additionally 
defective in the vacuole peptidase A (pep4).  
3.1.4 Expression vector 
For recombinant protein expression, pGAPZαC vector (Invitrogen GmbH, Karlsruhe, 
Germany) was modified and designated pAOX. Briefly, the AOX promoter was 
amplified from SMD1168H genomic DNA with appropriate primers and used to 
replace the GAP promoter. 5´ AOX1 promoter region induces expression in the 
presence of methanol. The plasmid contains on α-factor signal sequence 
(responsible for secretion of target protein), multiple cloning sites (MCS) (to insert 
gene of interest) and polyhistidine (6xHis-tag to facilitate purification and protein 
detection). Moreover, Zeocin® She ble resistance gene is incorporated into the 
cloning vector and used as a selectable marker for transformation (Figure 1). 
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Figure (2): Schematic diagram of pAOX vector (modified pGAPZαC vector, 
Invitrogen) 
3.1.5 Cells 
Chicken red blood cells (RBCs) suspension  
Blood was collected from wing vein of chickens in sterile tubes containing 3.8 % 
sodium citrate solution. Equal volume of PBS was added and the erythrocytes were 
centrifuged at 1000 rpm for 10 min. After 3 times wash cycles, 1 % RBCs in PBS was 
used for haemagglutination and HI tests.  
Vero cells  
The Vero cells CCL 81, derived from kidney epithelial cells of the African Green 
Monkey were used for influenza virus propagation, virus titration and in micro-
neutralization test (µNT). 
3.1.6 Animals 
Mice 
Eight BALB/c Mice were used to study the immunogenicity of different recombinant 
polypeptides (P1, P2 and rHA1). 
Chickens 
Twenty- four inbred commercial layer chickens were purchased from Lohman Animal 
Health (Cuxhaven, Germany). Chickens had a history of immunization against 
salmonellosis, infectious bronchitis (IB), Newcastle disease (ND), infectious bursal 
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disease (IBD), avian encephalomyelitis (AE), and ILT. History of vaccination program 
was shown in the following table: 
 
3.1.7 Positive  and negative serum samples 
Positive chicken sera 
One hundred and seventy nine serum samples were obtained from Egyptian broiler 
chickens,  previously vaccinated once with commercial inactivated H5N2 (A / chicken 
/ Mexico / 232 / 94 / CPA) vaccine at 7-day-old. These chickens were vaccinated also 
against IBD, ND, Marek´s disease (MD) and IBV.  Blood samples were collected from 
wing vein or by slaughtering at 4 weeks post vaccination and kept in a slope position 
at 37 oC for one hour then at 4 oC overnight. Sera were then separated by 
centrifugation at 3000 rpm for 10 minutes and stored at -20 oC till tested.  
Negative chicken sera 
25 serum samples obtained from influenza non-vaccinated broiler chickens and 
tested negative by AGID, HI (using H5N1 Thailand antigens) and Western blot were 
used as negative control in Elisa. These chickens were vaccinated against IBD, ND, 
MD and IBV. 
 
 
 
 
Age  Vaccination 
1-day Salmonellosis 
2 weeks IB 
3 weeks ND 
4 weeks IBD 
5 weeks IB 
6 weeks ND 
7 weeks Salmonellosis 
9 weeks ILT 
11 weeks AE 
13 weeks IB 
14 weeks ND 
15 weeks Salmonellosis 
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Duck sera 
Five serum samples were obtained from vaccinated Egyptian duck, aged 20 weeks. 
Ducks were vaccinated 3 times with commercial H5N2 vaccine. Also, three negative 
serum samples were obtained from non vaccinated duck as a negative control. 
Ducks have a history of vaccination against duck virus enteritis (DVE) and duck virus 
hepatitis (DVH). These serum samples were analyzed by rHA1-Elisa and HI test. 
3.1.8 Media for bacterial and yeast cultures 
3.1.8.1 Media for bacterial culture 
Low salt LB broth medium (LS-LB) 
 1 % (w/v)                     Peptone (from casein)                 
 0.5 % (w/v)                  Sodium chloride  
 0.5 % (w/v)                  Yeast extract 
Peptone, NaCl, and yeast extract were dissolved in dH2O; pH was adjusted with 
NaOH to 7.5. After autoclaving, the medium was left to cool and zeocin® was added 
at a concentration of 25 µg / ml. 
Low salt LB agar medium (LS-LB agar) 
1 % (w/v)                      Peptone (from casein) 
0.5 % (w/v)                   NaCl 
0.5 % (w/v)                   Yeast extract 
1.5 % (w/v)                   Agar- agar 
Peptone, NaCl, yeast extract and agar were dissolved in dH2O, after autoclaving, the 
medium was left to cool and zeocin® was added at a concentration of 25 µg / ml. 
3.1.8.2 Media for yeast 
Yeast peptone dextrose (YPD) 
1 % (w/v)                      Yeast extract            
2 % (w/v)                       Peptone (from casein) 
2 % (w/v)                        Dextrose (D-Glucose) 
Yeast extract and peptone were dissolved in 900 ml dH2O. After autoclaving 100 ml 
20 % (w/v) sterile glucose solution were added.  
Yeast peptone dextrose agar (YPD-agar) 
1 % (w/v)                      Yeast extract 
2 % (w/v)                       Peptone 
2 % (w/v)                       Dextrose (D-Glucose) 
2 % (w/v)                       Agar agar 
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Yeast extract, peptone and agar were dissolved in 900 ml dH2O. After autoclaving 
100 ml 20 % (w/v) glucose solution were added.   
Yeast peptone glycerol medium (YP-Gly) 
1 % (w/v)                      Yeast extract                           
2 % (w/v)                       Peptone 
1% (v/v)                         Glycerol  
Yeast extract and peptone were dissolved in dH2O. After autoclaving 2 % (v/v) 
glycerol were added just before use. 
Yeast peptone methanol, pH 8 (YP MeOH, pH8) 
1 % (w/v)                       Yeast extract 
2 % (w/v)                        Peptone 
60 mM                            Tris- HCl (pH 8.3) 
1% (v/v)                          Methanol 
Yeast extract and peptone were dissolved in dH2O. After autoclaving, sterile tris-Cl 
solution, pH 8.3 was added. Methanol was added just before use. 
Yeast peptone methanol, pH 6 (YP MeOH, pH 6) 
1 % (w/v)                         Yeast extract 
2 % (w/v)                         Peptone 
1.34 % (w/v)                    Yeast nitrogen base 
100 mM                            Potassium dihydrogen phosphate (KH2PO4, pH 6) 
1 % (v/v)                           Methanol 
Yeast extract, peptone and yeast nitrogen base were dissolved in dH2O. After 
autoclaving, sterile KH2PO4 (pH 6) was added. Methanol was added just before use. 
3.1.9 Buffers and solutions 
3.1.9.1 Buffers and solutions for E-coli transformation 
Tfb1 
300 mM                         Potassium acetate 
100 mM                         Rubidium chloride (RbCl) 
10 mM                           CaCl2 
50 mM                           MnCl2 
Dissolved in 300 ml dH2O and pH was adjusted with 10 % acetic acid to 5.8. 75 ml 
glycerine 99 % was added. The mixture was completed to 500 ml with dH2O and 
filtered with 0.2 µm bacteriological filter. This buffer was used for preparation of 
competent E-coli cells. 
 44 
Tfb2 
10 mM                            Potassium acetate 
75 mM                            RbCl 
10 mM                            CaCl2 
Dissolved in 50 ml dH2O and pH was adjusted with 1 M KOH to 6.5. 15 ml glycerine 
was added. The mixture was completed to 500 ml with dH2O and filtered with 0.2 µm 
bacteriological filter. This buffer was used for preparation of competent E-coli cells. 
3.1.9.2 Buffers and solutions for DNA and protein analysis 
Anode buffer 
25 mM                            Tris- Cl   
Dissolved in dH2O, pH was adjusted to 8.9 with HCl 
Block buffer for Western blot 
4 % (w/v)                        Skim milk in 1 x PBS 
5x Cathod buffer 
100 M                             Tris-Cl 
 0.5 M                             Tricine 
1.73 mM                         Sodium dodecyl sulfate (SDS) 
Gel drying solution 
30 %                                Ethanol (96 %) 
10 %                                Glycerine 
This solution was used for drying of the silver stained gel (SDS-PAGE) to be used as 
documentation. 
10x PBS 
1.37 M                            NaCl                                                       
27 mM                            Potassium chloride                                                   
80 mM                            Di-sodium hydrogenphosphate          
18 mM                            Potassium di-hydrogen phosphate      
Dissolved in dH2O and pH was adjusted to 7.4 with NaOH or HCl. 
 
50x TAE buffer 
  2 M                              Tris   
5.71 % (v/v)                   Acetic acid 
100 mM                         Ethylenediamintetraacetic acid (EDTA) 
Dissolved in dH2O and pH was adjusted to 8.5 with NaOH  
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TNE Buffer 
 10 mM                            Tris-Cl 
  100 mM                         NaCl 
  1mM                              Ethylenediamintetraacetic acid (EDTA) 
Dissolved in dH2O and pH was adjusted to 7.4 with NaOH or HCl 
Transfer buffer 
25 mM                            Tris 
192 mM                          Glycerine 
20 % (v/v)                       Methanol 
in dH2O 
 
2x Tricine sample buffer 
5 % (w/v)                        SDS 
12.5 % (v/v)                    1 M Tris-HCl pH, 6.8 
20 % (v/v)                       Glycerine 
0.08 % (w/v)                    Bromophenol blue 
in dH2O 
3.9.3 Buffers and solutions for polypeptide purification 
Elution buffer (1) 
 100 -300 mM                  Imidazole  
 300 mM                          NaCl 
 50 mM                            Tris- Cl             
Dissolved in dH2O and pH was adjusted to 7 with NaOH or HCl 
Elution buffer (2) 
 300 mM                          NaCl 
  50 mM                           Tris- Cl             
Dissolved in dH2O and pH was adjusted to 2-3 with HCl 
Elution buffer (3) 
150 mM                           NaCl 
 10 mM                            PBS 
  0.4 M                            methyl α- D- manopyranoside 
 Dissolved in dH2O and pH was adjusted to 7.4 with NaOH or HCl 
Wash buffer (1) 
 10 mM                             Imidazole  
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300 mM                             NaCl 
50 mM                             Tris- Cl             
Dissolved in dH2O and pH was adjusted to 7 with NaOH or HCl 
Wash buffer (2) 
300 mM                            NaCl 
50 mM                             Tris- Cl             
Dissolved in dH2O and pH was adjusted to 6.5 with NaOH or HCl 
Wash buffer (3) 
150 mM                            NaCl 
 10 mM                              PBS 
Dissolved in dH2O and pH was adjusted to 7.4 with NaOH or HCl 
3.1.9.4 Buffers and solutions for Elisa 
Block buffer 
  1x                                   PBS 
  3 %                                Bovine serum albumin (BSA) 
 0.05 %                            Tween20 
Coating buffer 
 200 mM                          Sodium bicarbonate 
Dissolved in dH2O and pH was adjusted to 7.4 with NaOH or HCl 
Substrate 
Tetramethylbenzidin (TMB) stock solution   
1 mg TMB (w/v) dissolved in 1 ml Dimethyle Sulfoxide solution (DMSO) and stored at 
– 20 until used. 
Sodium acetate citrate buffer 
               0.1 M                            Sodium acetate 
               500 ml                           dH2O 
pH was adjusted with 0.1 M citric acid monohydrate to 6 and stored at – 20 until used 
Working substrate 
1 ml                                TMB stock solution  
9 ml                                Sodium acetate citrate buffer 
2 µl                                  H2O2 
Wash buffer 
1X                                     PBS 
                0.05 %                               Tween20 
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In Millipore water 
3.1.10 Reagents for molecular biology 
Reagent Supplier 
Ethidium bromide 
dNTP-solution 
10x Denaturating buffer 
10 GS buffer 
Hi-Di-Formamide 
HPLC- water 
Magnesium chloride solution 
 
Magnesium sulfate solution 
Ni-NTA 
Pfu 10x Buffer 
Polyethylene glycol solution 4000 
6X Loading dye 
Lectin peroxidise concanavalin 
Tunicamycin 
Zeocin 
Sigma, Germany 
Fermentas, Leon-Rot, Germany 
New England Biolabs, UK           
New England Biolabs, UK           
Applied Biosystem 
Roth, Karlsruhe, Germany 
Invitrogen life Technology, Karlsruhe, 
Germany 
Fermentas, Leon-Rot, Germany 
Quiagen, Helden, Germany 
Fermentas, Leon-Rot, Germany 
Fermentas, Leon-Rot, Germany 
Fermentas, Leon-Rot, Germany 
Sigma, Germany 
Sigma, Munich, Germany 
Invitrogen life Technologies, Karlsruhe 
 
3.1.11 Enzymes 
Enzyme Supplier 
Restriction enzymes 
Endoglycosidase 
Pfu polymerase 
Plantium- Taq polymerase 
T4-Ligase 
Fermentas, Leon-Rot, Germany 
New England Biolabs, UK           
Fermentas, Leon-Rot, Germany 
Invitrogen life technologies 
Fermentas, Leon-Rot, Germany 
 
3.1.12 Protease Inhibitors  
Pepstatin                                                      Sigma Aldrich, Munich, Germany 
Phenylmethylsalfonylfluorid  (PMSF)           Roth, Karlsruhe, Germany 
3.1.13 Standards  
Gene Ruler 1 kb DNA Ladder                       Fermentas, Leon-Rot, Germany 
Gene Ruler 100 bp DN A – Ladder               Fermentas, Leon-Rot, Germany 
SDS- PAGE protein marker                          Serva, Heidelberg, Germany 
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3.1.14 Antibodies 
Antibody Supplier 
FITC monoclonal anti-chickens 
FITC monoclonal anti-maus 
Goat anti-bird IgG HRP 
Influenza anti-nucleoprotein 
Maus anti Histag 
Polyclonal rabbit anti-maus IgG HRP 
Rabbit anti-chicken IgY HRP conjugate      
Fermentas, Leon-Rot, Germany 
 Fermentas, Leon-Rot, Germany 
 Biomol, Hamburg, Germany 
 Gift from Prof. Dr. Christian Gassoy 
 Dianova, Hamburg, Germany 
  Dako, Hamburg, Germany 
  Millipore, Schwalbach, Germany 
3.1.15 Reagents for cell culture 
Reagent Supplier 
Crystal violet 
Dulbecco’s modified eagle media   
(DMEM + GlutaMAX TM-1) 
Dimethyle sulfoxide solution (DMSO) 
Fetal calf serum (heat inactivated) 
PBS 10x (-Ca2+, Mg2+) 
Penicillin 
Streptomycin 
Trypan blue solution (0.4 %) 
Trypsin 
Sigma, Germany 
Gibco Invitrogen Corporation  
 
Sigma, Germany 
Biochrom, Berlin, Germany 
Gibco Invitrogen Corporation 
Jenapharm, Jena, Germany 
Sanavita, Germany 
Gibco Invitrogen Corporation 
 Gibco Invitrogen Corporation 
3.1.16 Kits 
Kit Supplier 
Big dye terminator cycle sequencing kits 
Biorad protein assay 
Pichia easyCompTM Kit 
Wizzard SV® g el and PCR clean-up 
system 
Flock check commercial Elisa kits 
ZipTip® pipette tip 
Applied Biosystem, USA 
Biorad, Hercules, CA, USA 
Invitrogen life technologies, 
Promega, Mannheim, Germany 
 
Synbiotic, USA 
Millipore, Schwalbach, Germany 
 
3.1.17 Adjuvant 
Gerbu Adjuvant 10   
 
Gerbu Biotechnik GmbH, Gaiberg, 
Germany. 
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3.1.18 Fine chemicals 
 
Chemical Supplier 
Ammonium sulfate 
Aceton 
Acetic acid 
Acrylamide 
Agarose  
Agar agar 
Agarose 
APS 
Bromophenol 
BSA 
CaCl2 
Citric acid 
DEPC 
D-Glucose 
D-Sorbitol 
3,3´-Diaminobenzidin tetrachloride 
Disodium hydrogen phosphate 
EDTA 
Ethanol 
Formaldehyde 
Glycine 
Glycerol 
HCl 
Magnesium sulfate (MgSo4) 
MnCl2 
Peptone (from casein) 
Polyethylene glycol 1500 
Potassium acetate 
Potassium chloride 
Potasium dihydrogen phosphate 
Potassium sulfate 
Rubidium chloride 
Sigma ,Germany 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Applichem, Darmstadt 
Fluka, Swizerland 
Sigma, Germany 
Roth, Karlsruhe 
Roth, Karlsruhe 
Fluka, Swizerland 
Applichem, Darmstadt 
Applichem, Darmstadt 
Applichem, Darmstadt 
Applichem, Darmstadt 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
 
Roth, Karlsruhe 
Merck, Darmstadt 
Applichem, Darmstadt 
Roth, Karlsruhe 
Roth, Karlsruhe 
Applichem, Darmstadt 
Applichem, Darmstadt 
Roth, Karlsruhe 
Fluka 
 50 
SDS 
Silver nitrate 
Skim milk 
Sodium acetate 
Sodium carbonate 
Sodium chloride 
Sodium hydroxide 
Sodium thiosulfate – hydrate 
Sulfuric acid 
Sulfuric acid 0.5 M (Elisa stop sol.) 
Tetramethyl-ethylendiamine (TEMED) 
Tetramethylbenzidin (TMB) 
Trichloroacetic acid 
Tris base 
Tris-HCl 
Tween 20  
Urea 
Yeast extract 
Yeast nitrogen base 
Roth, Karlsruhe 
Vitalia GmbH, Sauerlach 
Applichem, Darmstadt 
Roth, Karlsruhe 
Applichem, Darmstadt 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Applichem, Darmstadt, Germany 
Serva, Heidelberg 
Roth, Karlsruhe 
Roth, Karlsruhe 
Applichem, Darmstadt 
Applichem, Darmstadt 
Roth, Karlsruhe 
Roth, Karlsruhe 
Fluka, Steiheim 
 
3.1.19 Instruments and measurements 
Instruments and measurements Supplier 
ABIPRISMTM 310 genetic analyzer Applied Biosystem, USA 
Autoclave Münchner Medizin Mechanik GmbH, 
Germany 
Balance 
- BP2100 S 
- BP 211 D 
 
  Sartorius, Göttingen, Germany 
 
Biostat C plus-C15-3 fermenter Sartorius BBI System GmbH, 
Melsungen,  Germany 
Block cycler 
- PTC 200 DNA Engine® thermal cycler  
 
Biorad, München, Germany 
Blotting apparatus (Mini Trans-Blot®) Biorad, München, Germany 
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Centrifuge 
- Eppindorf centrifuge 5417 R 
- Labor centrifuge 1K15 
- Rotina 46R 
- Vacuum centrifuge speed vac  
- Sorvall ® Ultraspeed centrifuge  
 
Eppindorf; Hamburg, Germany 
Sigma, Germany 
Hettich, Tuttlingen, Germany 
Savant 
Kendro, US 
Electrophoresis 
Agarose gel electrophoresis 
- Mini Sub® Cell GT 
- Wide Mini® Sub Cell GT 
- Electrophoresis chamber for 
polyacrylamide gel 
Power supply apparatus 
- Power Pac 300  
- Power Pac 3000 
 
 
 
 
 Biorad 
Gel documentation system  
MultimageTM Light Cabinet 
 
Alpha Innotech Corporation 
Heating block Eppendorf, Hamburg, Germany 
Ice machine  Scotsman, USA 
Incubators 
- Kelvitron®t  
- Incubator for yeast 
- Steri-Cult-HEPA filtered IR cell culture 
 
Heraeus, Hanau, Germany 
WTB Binder , Tuttlingen, Germany 
Forma Scientific 
Laminar Flow cabinet Heraeus Instruments  
Microwave (Panasonic Pro II 1400) Masushita electric industrial Co 
Microscopes 
- Fluorescent microscope DM IRB (inverse) 
- Fluorescent microscope DMRA 
- Fluorescent microscope DMRB 
- Inverse stereomicroscope DMIL 
 
 
 
Leica, Germany 
Refrigerators and freezers  
 -80 oC 
Liebherr, Ochsenhausen 
Thermo Scientific 
pH-Meter pH 540 GLP Wissenschaftlich- Technische 
 52 
Werkstätten, Germany 
Thermo mixer compact Eppendorf, Hamburg, Germany 
Photo spectrometer 
NanoDrop® 
SmartSpecTM 3000 
 
peQLab Biotechnologie Gmbh 
Biorad, München, Germany 
Vortexer (Vortex Genie 2) Scientific Industries 
Water bath  GFL, Burgwedel, Germany 
 
3.1.20 Consumption materials 
 
Materials Supplier 
Cell culture plate  (96, 24, 8 wells) 
Cover  slides  
Cryo tubes 
Disposable canula syringe 
Elisa plates (microlon high binding) 
Falcon tubes  
Filter tip gilson (10, 20, 200, 1000 µl) 
Micro tube 2 ml with cap 
Nitro-cellulose membrane 
Parafilm 
Petri dish 
Pipette tips 
 
Plastic pipette 
Reactions containers (50, 15,1.5) 
Rotilab® Spritzenfilter, 0.45 µm 
Rotilab® Spritzenfilter, 0.2 µm 
Rotilab® Micro titre plates (U- shape) 
 Rotilab® Micro titre plates (V- shape) 
Slides 76 X 26 
Tissue culture plastic flasks   
Vivaspin20                                                
Greiner Bio one, Frickenhausen 
Braunschweig, Germany 
Greiner Bio-One, Frickenhausen,  
Braunschweig, Germany 
Greiner Bio- One, Frickenhausen,  
Bedford, USA 
Greiner Bio-One, Frickenhausen 
Sarstedt, Nümbrecht  
Millipore, Schwalbach, Germany  
Pechiney plastic Packaging, Chicago 
Greiner Bio-One, Frickenhausen 
Greiner Bio one, Frickenhausen 
Sartedt 
VWR International, USA 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Roth, Karlsruhe 
Greiner Bio-One, Frickenhausen 
Sartorius-Stedim, Biotech GmbH, 
Göttingen, Germany 
 
 
 53 
3.2 Methods 
3.2.1 Expression of truncated sequences of influenza subtype H5 in P. pastoris 
3.2.1.1 Amplification of truncated sequences 
To identify regions within H5 protein that are highly conserved, protein alignments 
were performed using MacVectorTM 7.0. Four non-overlapping sequences of different 
functional domains of influenza A virus subtype H5 were chosen and designated P1, 
P2, P5 and rHA1 (the criteria of these epitopes are described in table 1, and 
appendix). RNA was extracted and cDNA of influenza A subtype H5N1 (A / Thailand / 
1 (Kan-1) / 2004) was synthesized. PCR was used to amplify 4 coding DNA 
fragments of epitope based truncated sequences of HA. Two primers for each coding 
sequence were used for a series of synthetic reactions. The primers were designed 
with specific restriction enzymes sites to create compatible ends (vector-PCR 
products). In the reverse primers, stop codons were not induced in order to fuse the 
coding sequence with 6xHis-tag (Table 1). PCR reaction was done in a 50 µl final 
volume containing 5 µl 10x polymerase buffer, 1.25 µl dNTP (10 mM), 1 µl of each 
primer (10 µM), 0.5 µl DNA polymerase (2.5 U / µl), 1 µl DNA template (200 ng / µl) 
and 10.25 µl deionised water. The block cycler (PTC 200 DNA Engine® Thermal 
Cycler) program was as follows: 95 oC, 3´; 5 X (95 oC, 3´; 55 oC, 20´´; 72 oC / 90´´; 
29X (95 oC, 30´´; 70 oC, 20´´; 72 oC, 90´´); 72 oC, 90´´ 
3.2.1.2 Agarose gel electrophoresis 
Agarose powder was added to 1X TAE Buffer to a final concentration of 0.8 % (w/v). 
The slurry was heated in a microwave oven until the agarose was dissolved. 5 µl 
ethidium bromide were added after cooling (70 oC) and the agarose solution was 
poured into the mold and the comb was properly positioned. After the gel was 
completely set, it was transferred into electrophoresis tank and covered with 1 X TAE 
Buffer, DNA samples were mixed with 6x DNA loading dye (5 vol. DNA solution plus1 
vol. DNA loading dye) and loaded into the slots of the gel. As a size standard, 50 bp, 
100 bp and 1Kb GeneRuler DNA LadderTM were used. The gel was run in TAE buffer 
under the voltage of 120 V for 30 minutes at RT. The gel was visualized by ultraviolet 
light and documented by MultilmageTM light cabinet with Chemilmager 4000 
computer program.  
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Table (1): Primers and peptide description 
 
aPeptide bPrimer sequence cPeptide description 
P1  Site E-sense: GTA CTC GAG AAG AGA 
GAG GCT GAA GCA GAT CTA GAT 
GGA GTG AAG CC 
Site E-as: CAT GCG GCC GCC TTC 
TCC ACT ATG TAG GAC C 
corresponds to the neutralizing 
epitope of site E of H3 (WILEY 
et al. 1981), conserved in H5, 
40 amino acids residues long, 
molecular mass is 7.5 kDa.  
 
P2  RBS-sense: GTA CTC GAG AAG AGA 
GAG GCT GAA GCA  AAT AAT ACC 
AAC CAA GAA GAT C 
RBS-as: CAT GCG GCC GCG TCC 
CCT TTC TTG ACA ATT TTG 
consists of the receptor binding 
site, site D and parts of site B, 
conserved in H5,  97 amino acid 
residues long, contains a 
glycosylation site, molecular 
mass is  13.9 kDa 
 
P5  Site A-sense: ´5 GTA CTC GAG 
AAG AGA GAG GCT GAA GCA TCA 
TTA GGG GTG AGC TCA GC 3´ 
Site A-as: 5´CAT GCG GCC GCG 
TAT GTA CTG TTC TTT TTG ATA 
AGC C 3´ 
conformational epitope in H5  
(PHILPOTT et al. 1989a),  not 
conserved in H5, 30 amino acid 
residues long, contains a 
glycosylation site, molecular 
mass is  6.5 kDa  
 
 rHA1 HA1-sense: 5´GTA CTC GAG  AAG 
AGA GAG GCT GAA GCA GAT CAG 
ATT TGC ATT GGT TAC C 3´ 
HA1-as: ´5GAT GCG GCC GCT CTT 
TGA GGG CTA TTT CTG AGC C´3 
contains the majority of those 
antigenic determinants of HA 
that are responsible for 
generation of virus-neutralizing 
antibodies, 320 amino acid 
residues long, contains 5 
glycolsyation sites, molecular 
mass is 39.6 kDa  
 
 
aP1, P2, P5 and rHA1 coding DNA fragments of epitope based truncated sequences 
of HA influenza A subtype H5N1 (A / Thailand / 1 (Kan-1) / 2004). 
bBold sequences indicate the sequence of restriction sites (Xho1 in sense primers 
and Not1 in antisense primers) , the sequence of alpha factor is underline.  
cMolecular mass calculated for his-tag polypeptide when alpha factor is completely 
processed (secreted in supernatant). 
3.2.1.3 DNA purification 
PCR product was purified using Wizard SV® Gel and PCR Clean-Up system 
according to manufacturer. The Wizard® SV Gel and PCR Clean-Up kit is based on 
the ability of DNA to bind to silica membranes in the presence of chaotropic salts. 
Briefly, one SV Minicolumn® was placed in a collection tube for each PCR reaction. 
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PCR product was placed to the SV Minicolumn® assembly and incubated for 1 
minute at room temperature, followed by centrifugation at 16,000 ×g (14,000 rpm) for 
1 minute. The liquid in the collection tube was discarded and 700 µl of membrane 
wash solution was added, previously diluted with 95 % ethanol, followed by 
centrifugation for 1 minute at 16,000 ×g (14,000 rpm). Again, the liquid in the 
collection tube was discarded and 500 µl of membrane wash solution was added 
followed by centrifugation for 5 minutes at 16,000 ×g. The column assembly was re-
centrifuged for 1 minute with the micro-centrifuge lid open after empting the collection 
tube. Carefully SV Minicolumn® was transferred to a clean 1.5 ml micro-centrifuge 
tube and 50 µl of nuclease-free water (supplied with the kit) were added directly to 
the centre of the column without touching the membrane with the pipette tip, 
incubated at room temperature for 1 minute and centrifuged for 1 minute at 16,000 
×g. The eluted DNA was stored at 4 °C or at -20 °C. 
3.2.1.4 Cloning of PCR product 
Both DNA product and pAOX plasmid were digested by Xho1 and Not1 restriction 
enzymes. The reaction composition was shown as follows: 5.5 µl O-buffer, 50 µl 
purified DNA, 1 µl Xho1 and 1 µl Not1 restriction enzymes. The reaction mixture was 
incubated 37 °C for 2 hrs.  DNA was purified again using Wizard SV® Gel and PCR 
Clean-Up system as described before.  
3.2.1.5 DNA ligation  
DNA concentration was determined using NanoDrop®. The method is based on the 
spectrophotometric measurement of the absorption. The principle of NanoDrop® 
depends on the measurement of the absorbance at A260. The ratio of absorbance at 
260 and 280 nm is used to assess the purity of DNA. A ratio of ~1.8 is generally 
accepted as “pure”. Digested P1, P2, P5 and rHA1 DNA with Xho1 and Not1 were 
mixed with digested pAOX vector at a ratio of 1:6 in a 10 µl of ligation reaction 
containing 1 µl T4-DNA ligase (2U), 1 µl 10x ligation buffer, and 1 µl 50 % (w/v) 
polyethylene glycol (PEG) 4000 (supplied with the enzyme). The mixture was 
incubated at room temperature for 2 hrs.  
3.2.1.6 Preparation of competent E-coli 
Firstly, a fresh plate of cells was prepared by streaking out cells from a frozen stock 
and growing at 37 oC. An individual colony was set in 5 ml low salt LB – medium (LS-
LB) without antibiotic. 1 ml of overnight culture was inoculated in a flask containing 
100 ml LS-LB medium. The flask was incubated at 37 oC with aeration until the 
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culture reached an OD595 of 0.200 - 0.300 (approximately 2 hrs). Culture was 
incubated on ice for 5 minutes then transferred to two 50 ml falcon tubes and 
centrifuged 2500 rpm for 10 minutes at 4 oC. Pellets were gently resuspended in 20 
ml Tfb I (for each tube) and centrifuged 3500 rpm for 10 minutes at 4 oC. The pellet 
was resuspended in 4 ml Tfb II and incubated on ice for 15 minutes. Competent cells 
were divided into convenient aliquots with equal amount of glycerine and frozen at – 
80 oC. 
3.2.1.7 Transformation of competent E-coli 
For amplification of plasmid construct, XL10-Gold® ultracompetent E- coli was used. 
Five microlitres of ligation mixture was mixed by stirring gently with pipette tip into 
competent E. coli cells which thawed on ice just before transformation. The mixture 
was placed on ice for 30 minutes and incubated at 42 oC for 30 seconds then rapidly 
placed on ice for 2 minutes. Three hundred microlitres of LB liquid medium was 
added before shaking at 37 oC for 1 hour. Transformed cells were spread on LB agar 
plate containing 25 µg / ml ZeocinTM (100 µl / plate). Plates were incubated overnight 
at 37 oC.  
3.2.1.8 Plasmid isolation from E-coli 
Plasmid isolation was done by Zyppy™ Plasmid Miniprep kit according to the 
manufacturer. Plasmid DNA isolated by this method suited for ligation, sequencing 
and restriction digestion. It is a modified alkaline lysis method. All buffers were 
supplied by the manufacturer. Briefly, selected colonies were picked up and 
inoculated into 5 ml LS- LB liquid medium pH, 7.5 and incubated overnight at 37 °C.  
600 µl of bacterial culture grown in LB medium were added to a 1.5 ml micro-
centrifuge tube. 100 µl of 7X lysis buffer (blue) were added and mixed by inverting 
the tube 4-6 times. 350 µl of cold neutralization buffer (yellow) were added and mixed 
thoroughly. The sample was inverted an additional 2-3 times to ensure complete 
neutralization, followed by centrifugation at 11,000 – 16,000 xg for 2-4 minutes. The 
supernatant (~900 µl) was transferred into the provided Zypy-Spin™ IIN column. The 
column was placed into a collection tube and centrifuged at 16,000 xg for 15 
seconds. The flow-through was discarded and 200 µl of Endo-wash buffer were 
added to the column followed by centrifugation at 16,000 xg for 15 seconds. 400 µl of 
Zyppy-Spin™ wash buffer were added to the column and centrifuged at 16,000 xg for 
30 seconds. The column was transferred into a clean 1.5 ml micro-centrifuge tube 
then 30 µl of Zyppy™ elution buffer were added directly to the column matrix and let 
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stand for one minute at room temperature, followed by centrifugation at 16,000 xg for 
15 seconds to elute the plasmid DNA. 
3.2.1.9 Analysis of plasmids 
The recombinant plasmids (designated pAOX H5-P1, pAOX H5-P2, pAOX H5-P5 
and pAOX H5-HA1) were analysed by restriction digestion and sequencing. pAOX 
H5-P1, pAOX H5-P2 and pAOX H5-HA1 plasmids were subjected to double digestion 
with Bgl II, whereas Bg1 II  and Xho1 were used for double digestion of pAOX H5-P5.  
3.2.1.10 Sequencing of the insert 
For this purpose, the plasmid was isolated from E- coli and its concentration was 
identified using NanoDrop®. PCR was performed using PGAPZ seq 1 primer (5´-
GTCCCTATTTCAATCAATTGAA-3´). The sequencing reaction consisted of 4 µl of 
dye-terminator reaction mix, 2 µl of 10 µM sequencing primer, 2 µl HPLC- H2O and 
200-500 ng (in 2 µl) of plasmid. The cycle sequencing reaction was performed by 
using the following thermal cycler program: 96 °C, 2´; 25 x (96 °C ,10´´; 55 °C , 5´´ ; 
60 °C, 4´); 60 °C, 4´. The PCR product was then pre cipitated by ethanol. 70 µl HPLC 
water and 10 µl 3 mM Na - acetate (pH 4.6-4.8) were added to 10 µl of the 
sequencing reaction in 1.5 ml ependorf. After addition of 250 µl 100 % ethanol, the 
sample was vortexed and centrifuged 14000 rpm / 35 min at 22 °C. Supernatant was 
discarded and 250 µl of 70 % ethanol was added followed by centrifugation 14000 
rpm / 35 min at 22 °C. Pellet was dried in speed va cuum for 10 min. The pellet was 
resuspended in 20 µl Hi- Di-Formamide. Sequencing the gene of interest was 
analyzed in an ABIPRISMTM 310 genetic analyzer. 
3.2.1.11 P. pastoris transformation 
P. pastoris competent cells were prepared according to Invitrogen manual and stored 
frozen until used. Native cells were prepared as follow:  50 ml YPD medium were 
inoculated with stationary culture (24 hrs) of native yeast cells grown in YPD medium 
to OD600= 0.02- 0.03. Cells were incubated for 18 – 20 hrs at 30 °C (250 rpm) until 
OD600 = 15-30. Aliquots were prepared (500 µl – 3-7x 108) cells) and stored at – 20 
°C until use. The shelf life is for several months.  Transformation was done according 
to EasyCompTM kits after some modifications described by Dr Kathrin Rall (Institute 
of Virology, Faculty of Medicine, Leipzig University, Germany). Briefly, after analysis 
of the insert, an amount of recombinant plasmid DNA was prepared. 5-10 µg (per 
transformation) were linearized by Bstx1, and dried in a vacuum centrifuge. One 
aliquot of competent cells (for one transformation) was thawed at room temperature 
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and added to tube containing dried DNA and mixed by pipetting. 200 µl of solution II 
(supplied with the kit) were added and mixed by vortexing. Cells were incubated at 30 
°C for I hr and vortexed every 15 minutes. Cells we re subjected to heat shock at 42 
°C for 15 minutes and 1 ml YPD medium was added. Af ter incubation at 30 °C for 1 
hr (vortex every 15 minutes), cells were centrifuged at 1500 xg for 5 minutes. Cells 
were washed with 500 ml solution III (supplied with the kit), and centrifuged at 1500 
xg for 5 minutes. The transformed cells were resuspended in 50 µl solution III. One 
aliquot of native cells (500 µl) of identical strain as competent cells was thawed, 
washed with 500 µl Solution III and centrifuged at 1500 xg for 5 minutes. Native cells 
were resuspended in 50 µl solution III and added to the transformed cells. After 
vortexing, the cell mixture was spread on YPD agar medium containing 100 µg 
ZeocinTM. Plates were incubated 2-4 days at 30 °C. 
3.2.1.12 Colony PCR 
Briefly, to perform colony PCR, primer seq2 (5´-GCAGCTCGCTCATTCCAATTCC-
3´) was used as promoter specific primer, however, specific sense primers for P1, 
P2, P5 and HA1 were used as antisense primers (Table 1). Swabs from selected 
clones were suspended in dH2O and heated 95 °C for 10 min, followed by 
centrifugation for 5 min at 4000 rpm. 10 µl of the supernatant was used to perform 
PCR. PCR reaction was done in a 20 µl final volume contains on 2 µl 10x polymerase 
buffer, 1 µl MgCl2, 0.5 µl dNTP (10 mM), 0.5 µl of each primer (10 µM), 0.25 µl DNA 
Taq polymerase (2.5 U / µl), 10 µl DNA template (200 ng / µl) and 5.25 µl deionised 
water.  The cycler program was 95 °C, 2´´, 30x (95 °C, 45´´; 56 °C, 45´´ ; 72 °C, 1´´), 
72 °C,10´´. PCR products were analysed by agarose g el electrophoresis. 
3.2.1.13 Small- scale expression  
Small scale expression was done to identify and confirm a recombinant pichia clones 
that express the correct protein and also to optimize the condition of expression. 
Primary culture was done from GS115 or SMD1168H Pichia cells in YP 2 % Gly 
using micro-titre plate 24 wells and incubated at 28 °C for 24 hrs at 250 rpm. An 
ensuing preparatory culture was initiated when OD600 = 0.8 - 1.0 and incubated at 28 
°C for 24 hrs at 250 rpm. Induction of expression w as done in YP 2 % MeOH either 
at pH 6 or 8 with OD600 = 30 - 70. Protein expression was analysed 12, 24, 48 and 72 
hrs after induction.  
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3.2.1.14 Mid-scale expression 
After confirming the desired protein in supernatant, the expression conditions were 
optimized. For production of large amounts of protein, expression was done in mid - 
scale using shaking flasks.  
3.2.1.15 Large scale expression 
Recombinant HA1 polypeptide was expressed in P. pastoris using BIOSTAT Cplus-
C15-3 fermenter to establish a high-density cell fermentation method. The culture 
temperature in pre-induced stage was optimised at 28 °C to adapt cell growth and 
recombinant protein expression in YP 2 % Gly at pH 6. Induction was done in the 
same media (at OD600 = 40) using 2 % methanol after adjusting pH to be 8.  
3.2.1.16 Protein extraction from yeast cells 
50 µl of yeast cells (nearly 109 cells) were resuspended in 1 ml cold distilled water 
followed by centrifugation 17900 xg for 1 min. Pellet was resuspended in 1 ml cold 
distilled water and 160 µl of a solution containing 1.85 M NaOH and 7.4 % mercapto-
ethanol were added. The tube was inverted and incubated on ice for 10 min. 160 µl 
50 % TCA were added and the tube was inverted and centrifuged 17900 xg for 5 
min. The pellet was washed with 1 ml cold acetone, centrifuged 17900 xg for 5 min 
and dried in speed vacuum for 2 min. For Western blot or SDS-PAGE, 80- 100 µl 2X 
tricine sample buffer was added and boiled for 5 min at 95 °C before loading the 
sample onto polyacrylamide gel. 
3.2.1.17 Purification of recombinant polypeptides  
All purification steps were performed at room temperature. The purification protocol 
was optimised for each polypeptide using nickel-nitrilotriacetic acid (Ni-NTA) or lectin 
affinity chromatography (lectin peroxidase concanavalin). Briefly, for nickel affinity 
chromatography, column was prepared according to the manufacture protocol using 
4 ml Ni-NTA agarose. The column was equilibrated by passing 10 ml equilibration 
buffer (wash buffer 1 or 2). Culture supernatant containing peptides of interest were 
passed through the column and washed with 10 ml washing buffer (wash buffer 1 or 
2). Elution was done by increasing the concentration of imidazole (elution buffer 1) or 
decreasing the pH (elution buffer 2). For lectin affinity chromatography, equilibration 
was done by wash buffer 3.  The unbound fraction was collected and the column was 
washed with 10 ml wash buffer 3. The bound fraction was eluted from the column 
with 0.4 M methyl α- D- manopyranoside in equilibration buffer (elution buffer 3). The 
fractions were dialyzed and concentrated by using vivaspin ultrafilter with a molecular 
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weight cut-off of 5,000 – 50.000 Da according to the size of polypeptide. 
Alternatively, purification was done under native or denaturing conditions using 4 M 
urea and 1 mM PMSF. 
3.2.1.18 SDS- PAGE 
P1, P2, P5 and rHA1 were separated by SDS-PAGE and stained by silver stain 
according to Nesterenko and co-workers (NESTERENKO et al. 1994). Proteins were 
separated by SDS-PAGE 10 % gels (Tables 2). Briefly, the SDS-PAGE apparatus 
was assembled then the separating gel was prepared and poured into the chamber 
up to the desired mark; the rest of the chamber was filled by adding distilled water. 
After polymerisation, the gel was dried by soaking with filter paper. The collecting gel 
was prepared and poured up on the separating gel. The selected comb was 
introduced to make the required numbers of slots. The gel is allowed to stand at room 
temperature until polymerisation. The gel was transferred into the electrophoresis 
chamber and running buffers (anode and cathode buffers) were added. Protein 
samples were mixed at a 1:1 ratio with 2x tricine sample buffer and heated 95 °C for 
5 minutes. 10-30 µl of the test sample along with the marker were loaded in 
respective slots with a special 100 µl syringe and a needle. Then the electrophoresis 
container was connected with a power source at 160- 180 V for 45 min -1 hr. After 
electrophoresis, the gel was either subjected to silver stain (Table 3) or Western blot. 
 
Table (2): Composition of polyacrylamide gel 
Solution Separating gel (10 %)  Stacking gel (4 %) 
Acrylamide (30 %) 
Tris  / Cl / SDS pH 8.45 
Dist. H2O 
Glycerine  
10 % APS 
TEMED 
1.63 ml 
1.67 ml 
1.17 ml 
0.53 ml 
16.67 µl 
3.4 µl 
0.27 ml 
0.52 ml 
1.3 ml 
- 
8.3 µl 
3.4 µl 
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Table (3): Silver staining of recombinant polypeptides 
Step Treatment  Time 
Fixation 
 
Rinsing 
Washing 
Rinsing 
Pre-treatment 
Pre-treatment 
 
Impregnation 
 
Rinsing 
Development 
 
Stopping 
Rinsing 
60 ml acetone (50 %), 1.5 ml TCA (50 % w/v) and 25 µl 
formaldehyde 37% 
dH2O 
dH2O 
dH2O 
60 ml acetone 50 % (v/v) 
100 µl sodium thiosulfate (10 % w/v) in 60 ml dH2O 
dH2O 
0.8 ml silver nitrate (2% w/v), 0.6 ml formaldhye 37 % in 
60 ml dH2O 
dH2O 
1.2 gm sodium carbonate, 25 µl formaldhyde and 25 µl  
sodium thiosulfate (10 %) in 60 ml H2O 
60 ml acidic acid 
dH2O 
5 min 
 
3X 5s 
5 min 
3X 5s 
5 min 
1 min 
3 X 5s 
 
8 min 
2X 5s 
 
10- 20s 
30s 
10s 
 
3.2.1.19 Western blot 
For western blot, proteins were transferred on nitrocellulose membrane (Roti®- 
PVDF) according to Towbin and co-workers (TOWBIN et al. 1979). The blotting was 
performed in transfer buffer at 160 mA for 1 hr followed by 3 times washing with 1X 
PBS, pH 7.4. The membrane was blocked by incubation in 1X PBS containing 4 % 
skim milk powder for 15 min at room temperature. For analysis of His-tag, the 
blocked membrane was incubated overnight with 1:200 mouse anti-His-tag. After 
washing with 1X PBS, the membrane was incubated with secondary antibody in a 
concentration of 1: 1000 (polyclonal rabbit anti-mouse IgG HRP conjugate) at room 
temperature for 2 hrs. The membrane was washed with 1X PBS and developed with 
1X PBS containing 5 mg of DAB and 10 µl H2O2 30 %.  
3.2.1.20 MALDI-TOF 
The ZipTip pipette tip is a 10 µl pipette tip with a bed of a chromatography media 
fixed at its end. It is intended for concentration and purifying peptide to be analyzed 
by MALDI-TOF. Sample preparation was done according to manufacturer, briefly; the 
pH of protein sample (10-20 µl) was adjusted to be less than 4 using 0.1 % TFA in 
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Milli Q®. The ZipTip pipette tip was equilibrated twice in 100 % ACN followed by twice 
in 0.1 % TFA. Protein was aspirated and dispensed 7-10 cycles. The ZipTip pipette 
tip was washed twice by aspirate and dispensing 0.1 % TFA. Elution was done by 
using varying concentrations of ACN (20 %, 30 %, 50 % and 70 %). The sample was 
dried by vacuum centrifuge and analyzed by MALDI-TOF in Institute of Biochemistry, 
Faculty of Medicine, Leipzig University. 
3.2.1.21 Glycosylation analysis 
3.2.1.21.1 Blot with concanavalin 
Glycosylated polypeptides (P2, P3 and rHA1) were separated by SDS – PAGE and 
transferred to nitrocellulose. The membrane was blocked by incubation in 1X PBS 
containing 2 % (v/v) Tween20 for 2 minutes. The blot was rinsed twice in 1X PBS 
followed by incubation with 10 µg / ml of lectin peroxidase (lectin from concanavalin) 
in PBS containing 0,05  % (v/v) Tween20, 1 mM CaCl2, 1 mM MnCl2, and 1 mM 
MgCl2 for 16 hrs at 20 °C.  The blot was rinsed in 1X PB S and developed using DAB 
as described in Western blot. 
3.2.1.21.2 Deglycosylation with endoglycosidase 
Deglycosylation was done using Endoglycosidase H kit (Endo Hf). Briefly, 1 µl of 10X 
glycoprotein denaturating buffer  (supplied with the kit) was added to 9 µl of purified 
HA1 then denatured at 100 °C / 10 min. 4 µl 10X GS reaction buffer (supplied with 
the kit) was added. Deglycosylation was done by incubation of the mixture with Endo 
Hf at a concentration of 1: 500. Deglycosylation was analysed after 0 min, 15 min, 30 
min, 1 hr, 2 hrs, 3 hrs and 4 hrs by SDS-PAGE, Western blot and blotting using 
concanavalin.  
3.2.1.21.3 Expression of rHA1 in the presence of tunicamycin 
rHA1 was expressed in YP 2 % MeOH (v/v) in the presence of tunicamycin (1 to 100 
mg / ml). In vitro characterization of protein expression was done by SDS-PAGE 
followed by Western blot. 
3.2.1.22 Protein precipitation 
3.2.1.22.1 TCA protein precipitation  
To concentrate proteins for analysis by Western blot, 10 % (v/v) of TCA 100 % was 
added to yeast culture supernatant and incubated on ice 1 hr at - 20 °C followed by 
centrifugation at 17900 xg / 5 min. The pellet was washed with cold acetone 100 % 
and centrifuged at 17900 xg / 5 min. The sample was dried under vacuum to 
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eliminate any acetone residue. For Western blot, 2X tricine sample buffer was added, 
sample and boiled 95 °C for 5 min before loading on to polyacrylamide gel. 
3.2.1.22.2 Acetone precipitation 
Four parts of 100 % acetone were added to protein sample and incubated 4 °C for 1 
hr followed by centrifugation at 4000 rpm / 45 min / 4 °C. The sample was dried 
under vacuum (speed-vac) to eliminate any acetone residue. For Western blot, after 
addition of 2X tricine sample buffer, the sample was boiled 95 °C for 5 min before 
loading onto polyacrylamide gel. 
3.2.1.22.3 Ultracentrifugation 
Yeast culture supernatant was concentrated using vivaspin ultrafilter. Different sizes 
of ultrafilters were used (5,000 – 60,000 Da) according to the protein size. 
3.2.1.22.4 Ammonium sulfate precipitation 
For purification, protein was precipitated using ammonium sulfate. Slowly, solid 
ammonium sulfate was added to a final concentration of 80 % (470 g / litre of 
solution) and stirred at 4 °C for 15 min. The sampl e was centrifuged by 
ultracentrifugation (Surespin Rotor, 11000 xg / 30 min / 4 °C). The pellet was 
resuspended in an appropriate volume of equilibration buffer that used in purification.  
3.2.1.23 Determination of protein concentration 
Protein quantitation was determined by colorimetric method, using BradfordTM assay 
kit. BSA with known concentration was used as a standard. Briefly, 25 µl of standard 
BSA or unknown sample was pipetted to 25 µl millipore H2O and serial dilution was 
done. 10 µl of each dilution was added to a 96 - micro-titre plate containing 200 µl of 
diluted dye with millipore water at a ratio of 1:4. Plates were incubated for 30 minutes 
at room temperature in dark place. The absorbance was measured at OD590 nm. The 
protein concentration was calculated by comparing with the protein standard curve. 
3.2.1.24 Cell passage 
Vero cells were grown in 25 or 75 cm2 plastic flasks in DMEM + GlutaMaxTM, 
supplemented with 5 % FCS at 37 °C in a 5 % CO 2 humidified incubator. When 
monolayer was confluent in the flask, the media was removed and the cells were 
washed with sterile 1X PBS  (PBS 10x - Ca2+, - Mg2+), then 3 ml of 0.05 % trypsin-
EDTA were added to the 25 cm2 flask and incubated 2 - 5 minutes at 37 °C to 
dislodge the cells from the flask. Trypsin was inhibited by addition of 7 ml DMEM + 
GlutaMaxTM containing 5 % FCS. The cells were passaged as before using a split 
ratio of 1: 10. 
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3.2.1.25 Virus propagation 
Influenza A subtype H5N1 (A / Thailand / 1 (Kan-1) / 2004) was propagated in Vero 
cells. When the Vero cells formed a monolayer, the medium was discarded and the 
cells were washed with sterile 1X PBS (3 ml / 25 cm2 flask and 6 ml / 75 cm2 flask). 
Aliquots of 50 - 150 µl of diluted influenza virus in 2-5 ml DMEM medium (DMEM + 
GlutaMaxTM) were inoculated onto monolayer cells. Cells were incubated for 60 - 90 
minutes at 37 °C in a 5 % CO 2 humidified incubator, followed by addition of 8 - 25 ml 
DMEM medium containing 5 % FCS. The cells were incubated at 37 °C in a 5 % CO 2 
humidified incubator for 5 days and observed daily for cytopathic effect (CPE). Virus 
growth was confirmed by virus haemagglutination.  
3.2.1.26 Virus titration 
Serial 10 fold dilutions of influenza A subtype H5N1 (A / Thailand /1 (Kan-1) / 2004) 
stock solution were made in DMEM + GlutaMaxTM medium. Titration was done in 96- 
well cell culture plate containing Vero cells monolayer. The medium was discarded 
and cells were washed with sterile 1X PBS (PBS without Ca2+ and Mg2+). 100 µl 
diluted virus was added to each well and incubated for 1 hr at 37 °C in a 5 % CO 2 
humidified incubator. 100 µl of DMEM + GlutaMaxTM containing 5 % FCS was added 
and incubated 37 °C in a 5 % CO 2 humidified incubator for 5 days. The medium was 
removed and cells were stained by 0.1 % crystal violet. The titre was expressed as 
50 % tissue culture infective dose / 0.1 ml (TCID50) and was calculated by the 
method of Reed-Muench (REED and MUENCH 1938) 
3.2.1.27 Virus inactivation and purification  
H5N1-virus was propagated on  Vero cells. After 5 days, supernatant was harvested, 
clarified (340 xg / 10 min.) and inactivated using ultraviolet irradiation (30 W / G30T8) 
for 1hr. The clarified supernatant was layered in 25 % sucrose cushion in TNE buffer 
and centrifuged by ultracentrifugation (Surespin Rotor, 11000 xg / 4 °C / 4 hrs). The 
pellet was resuspended in TNE buffer and the virus (100 TCID50 / 100 µl) was tested 
for its safety in Vero cells. Fractions were pooled and the virus was titrated by 
haemagglutination test using 1 % chicken red blood cells (RBCs). This preparation 
was used for chicken vaccination and as antigen in serological tests. 
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3.2.2 Immunogenicty of recombinant polypeptides in mice and chickens 
3.2.2.1 Immunogenicity of recombinant polypeptides in mice 
The immunogenicity of P1, P2 and rHA1 was evaluated in BALB/c Mice. Three 
groups of 2 mice were immunized subcutaneously with 50 µl Gerbu adjuvant. Two 
immunization protocols were used as shown in the following table. Another group of 2 
mice was injected with adjuvant in 1xPBS. Sera were obtained from euthanized mice 
one week after the 2nd and at the end of experiment from orbital sinus. Evaluation of 
the immune response was done by recombinant Elisa (using recombinant 
polypeptides), whole H5N1 Elisa and IFA.   
 
3.2.2.2 Immunogenicity of recombinant polypeptides in chickens 
The immunogenicity of P1, P2, P5 and rHA1 polypeptides was evaluated also in 
inbred commercial layer chickens in comparison with prepared inactivated H5N1 (A / 
Thailand / 1 (Kan-1) / 2004) antigen. Groups of 4 chickens were injected 
intramuscularly with 100 µg of recombinant polypeptide mixed with 100 µl Gerbu 
adjuvant. Two weeks post priming; chickens were boosted 3 times, at weekly 
intervals using the same amount of antigen and adjuvant that used for the initial 
immunization. Chickens immunized with inactivated vaccine were injected with a 
dose of 8 HA unit (HAU) mixed with 100 µl Gerbu adjuvant. Control chickens were 
injected with adjuvant only. Sera were obtained at day 0 as well as 4, 5, 6 and 8 
weeks post primary vaccination from wing vien and analyzed for specific antibodies 
with recombinant Elisa (using the same antigen used in vaccination), whole H5N1 
Elisa (using whole H5N1 antigen), AGID, IFA and µNT. Moreover, IgY was analysed 
in egg yolk collected at day 0 as well as 4, 5, 6 and 8 weeks post primary vaccination 
by recombinant Elisa, whole H5N1 Elisa and IFA. 
Immunization Immunization protocol  
                     (IP1) 
Immunization protocol  
                     (IP2) 
Priming 0 0 
1st booster 14 21 
2nd booster 21 28 
3rd booster 28 35 
4th booster 35 42 
5th booster 42 49 
Final Bleeding 45 52 
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Table (4): Experimental design for assessment of immunogenicity of 
recombinant polypeptides in chickens compared with inactivated H5N1  
Vaccination regime Group 
No 
Vaccine type Vaccine 
dose 
Frequency 
Assessment of immune 
response 
1 
2 
3 
4 
5 
6 
rHA1 
P1 
P2 
P5 
Inactivated H5 
Adjuvant 
vaccinated 
100 µg 
100 µg 
100 µg 
100 µg 
8 HAU 
- 
4X 
4X 
4X 
4X 
4X 
4X 
rElisaa 
whole H5 Elisab 
AGIDc 
Microneutralizationd 
IFAe 
 
 
aElisa plates were coated with homologous antigen used in vaccination (50 ng / well). 
bElisa plated were coated with inactivated  H5N1 (A / Thailand / 1 (Kan-1) / 2004) 
antigen (1 HAU / well). 
cAGID was done according to  (BEARD 1998) using H5N1 (A / Thailand / 1 (Kan-1) / 
2004) antigen.  
dMicroneutralization test was done according to (ROWE et al. 1999) using H5N1 (A / 
Thailand / 1 (Kan-1) / 2004) virus. 
eImmunofluorescence assay was done on Vero cells infected with H5N1 (A / Thailand 
/ 1 (Kan-1) / 2004) virus. 
3.2.2.3 Extraction of IgY from eggs 
Extraction and purification of IgY was done according to (POLSON et al. 1980). 
Briefly, individual yolk was separated from the egg white and washed with PBS. 400 
µl of egg yolk was obtained and mixed with 800 µl PBS. Polyethylene glycol (PEG), 
molecular weight 1500, was added to a final concentration of 3 % (w/v). After 
incubation for 20 min at room temperature the mixture was centrifuged at 14,000 xg 
for 10 min. The fatty layer was removed and the water soluble supernatants with the 
pellet were collected in another tube. PEG was added to a final concentration of 12 
% and the mixture was centrifuged at 14,000 xg for 10 min. The pellet was 
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resuspended in ethanol 50 % (v/v in dist. H2O). After centrifugation at 10,000 xg / 30 
min / 4 °C, the pellet was resuspended in 200 µl di st. water. Extracted IgY was 
analysed by SDS-PAGE. H5 specific antibodies were analyzed by recombinant Elisa, 
whole H5N1 Elisa and IFA. 
3.2.2.4 Elisa 
Recombinant peptide (50 ng / well) or inactivated whole H5N1 (1 HAU / well) was 
coated in duplicate onto 96–well microtiter plate (microlon high binding). The working 
dilution of HRP-conjugate rabbit anti-mouse IgG and HRP rabbit anti-chicken IgG  in 
PBS, pH 7.4  supplemented with 0.05 % (v/v) Tween20, 3 % (w/v) BSA) were 1:2,000 
and 1: 20,000, respectively. For Elisa, plates were coated with 50 µl antigen solution 
diluted in coating buffer (200 mM sodium bicarbonate, pH 9.6) and incubated 
overnight at 4 °C. Plates were washed (30 seconds) five times with washing buffer 
(PBS, 0.05 % Tween20) and blocked for 1 hrs at 37 °C with 300 µl / well blocking 
buffer (PBS, 0.05 % Tween20, 3 % BSA). Sera were diluted in blocking buffer and 50 
µl of the dilution was added to each well in duplicate. After 2 hrs incubation at 37 °C, 
and 5X washing, 100 µl HRP-labelled (anti-mouse or anti-chicken IgG) antibody was 
added and incubated 37 °C for 90 minutes. Plates we re then washed 5X and colour 
development was accomplished by adding 100 µl / well of 
3,3´,5,5´tetramethylbenzidin (TMB) in sodium acetate-citrate buffer with 2 µl 30 % 
hydrogen peroxide (H2O2). After 20 minutes incubation in the dark at room 
temperature, the reaction was stopped by addition of 50 µl Sulfuric acid (H2SO4, 0.5 
M). The optical density (OD) was read at 450. Antibody titres were expressed as the 
serum dilution at which half-maximal OD450 readings of serum (half-maximal OD450). 
3.2.2.5 Agar gel immunodiffusion test  
The test was performed as described by Beard  (BEARD 1998).  The test was carried 
out using 1 % (w/v) agarose and 8 % (w/v) NaCl in 1X PBS, PH, 7.2. The medium 
was poured to a thickness of 2- 3 ml in petri dishes. Six peripheral wells surrounding 
a central well in a hexagonal form were made in the agar medium, the well size was 
4 mm in diameter, and the distance between the central well and the evenly spaced 
peripheral wells was 4 mm. Thailand H5N1 virus was used as antigen. Sera to be 
tested for precipitating antibody were placed into the peripheral wells while the 
antigen was placed into the central well. Final readings were recorded as negative (-) 
or positive (+) after 48 hrs. 
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3.2.2.6 Micro neutralization test (µNT)  
µNT was carried out according to Rowe and coworkers (ROWE et al. 1999). Briefly, 
serum samples were diluted with cell culture medium in two fold steps. The dilutions 
were mixed at a ratio of 1:1 with H5N1 influenza virus (10 TCID50 per well), incubated 
for 1 hr at room temperature and transferred to a microtiter plate with a Vero cell 
monolayer. Plates were incubated 18 hrs at 37 °C. A fter removal of medium, plates 
were washed with PBS and fixed with 80 % acetone in sterile dist. H2O for 30 min.  
After blocking with PBS containing 1 % BSA and 0.1 % Tween20, 50 µl of influenza 
anti-nucleoprotein was added and incubated 1 hr at 37 °C. IgG HRP rabbit anti-
mouse antibody (1: 2,000) was added and plates were incubated 1 hr at 37 °C. 
Freshly prepared substrate was added and incubated 30 minutes at room 
temperature in the dark. Stop solution (H2SO4, 0.5 M) was added and the absorbance 
OD of the wells was read at 450 nm. The endpoint titre was expressed as the 
reciprocal of the highest dilution of serum with OD450 value above the mean + (3 x 
standard deviation) of the negative control. 
3.2.2.7 Immunofluorescence assay (IFA) 
For detection of influenza-H5 specific antibodies, Vero cells were propagated on 
cover slips in a 6-well plate and infected at 0.01 multiplicity of infection (m.o.i.) with A 
/ Thailand / 1(Kan-1) / 2004 isolate. After 24 hrs incubation at 37 °C, in a 5 % CO 2 
humidified incubator, cells were fixed for 30 minutes with ice cold 80 % acetone in 
sterile distilled water at -20 °C. Fixed cells were  blocked for 30 minutes with 5 % 
PBSA (PBS, pH 7.4 contains 5 % BSA) followed by incubation for 90 minutes with 
diluted chicken sera or mouse sera at 37 °C. After washing with 0.5 % PBSA, cells 
were incubated for 45 minutes with FITC labelled monoclonal anti-chicken IgY or 
anti-mouse IgG (at a dilution of 1: 100). After 5 times washing with 0.5 % PBSA, cells 
were rinsed again in dH2O. The cover slip was inverted, mounted onto a glass slide 
using mounting fluid (1x PBS, 10 % glycerine) and observed for fluorescent staining 
under fluorescence microscopy. 
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3.2.3. Development or recombinant Elisa for detection of influenza subtype A 
H5 antibodies 
3.2.3.1 Experimental design 
For this purpose 179 serum samples were obtained from commercial broiler chickens 
(see materials 3.1.7). The work design is shown in the following diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (3): Flow chart to study the validity of recombinant Elisa for detection of H5 
antibodies in chicken sera. 
aHI was done using homologous commercial H5N2 (A / chicken / Mexico / 232 / 94 / 
CPA) antigen.  
bHI was done using heterologous H5N1 (A / Thailand / 1 (Kan-1) / 2004) antigen 
cAGID test was done using heterologous H5N1 (A / Thailand / 1 (Kan-1) / 2004) 
antigen. 
 
 
179 serum samples from chickens 
vaccinated with commercial 
inactivated H5N1 and analysed by HI 
using homologous antigena 
 
rP1- Elisa 
rHA1- Elisa 
cAgar gel immunodiffusion test 
Single dilution rHA1-Elisa (serum dilution 1:100) 
Commercial Elisa 
Negative serum samples by the Elisa were 
confirmed by neutralization test. 
25 Serum samples from 
influenza non-vaccinated 
chickens (HI and Western 
blot negative) 
25 selected HI positive serum 
samples were tested with HI 
using heterologous antigenb 
and Western blot 
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3.2.3.2 Haemagglutination inhibition test  
Chicken sera were examined for haemagglutination inhibiting antibodies by HI test, 
according to OIE manual (OIE 2005), using commercial H5N2 antigen (A / chicken / 
Mexico / 232 / 94 / CPA) or H5N1 (A / Thailand / 1 (Kan-1) / 2004) antigen. 
Haemagglutination test 
HA test was used for the titration of commercial and H5N1 Thailand isolate antigen 
before the HI test. Lyophilized H5N2 (A / chicken / Mexico / 232 / 94 / CPA) antigen 
was dissolved by 1 ml sterile PBS (pH, 7.2).  For titration of influenza antigens, 25 µl 
of PBS were placed into each well of a plastic V-bottomed microtitre plate. 25 µl of 
virus suspension were placed in the first well and a two-fold dilution of virus 
suspension was done. A further 25 µl of PBS were dispensed to each well then 25 µl 
of 1 % (v/v) chicken RBCs were added to each well and the RBCs was left to settle at 
room temperature by which time control RBCs should be settled to a distinct button. 
The titration was read to the highest dilution giving complete HA, representing 1 HA 
unit (HAU). 
Haemagglutination inhibition test 
25 µl of PBS was dispensed into each well of a plastic V-bottomed microtitre plate. 
25 µl of serum was added to the first well of the plate and a two-fold dilution of the 
serum was done across the plate. 4 HAU of tirtrated influenza antigen in 25 µl was 
added to each well and plates were incubated for a minimum of 30 minutes at room 
temperature. 25 µl of 1 % (v/v) chicken RBCs was added to each well and after 
gentle mixing, RBCs was left to settle, by which time control RBCs should be settled 
to a distinct button. The HI titre is the highest dilution of serum causing complete 
inhibition of 4 HAU of antigen. The HI titres were determined as reciprocals of highest 
serum dilutions in which inhibition of haemagglutination was observed. 
3.2.3.3 Western blot for analysis of antibodies in serum 
For analysis of individual serum by Western blot, HA1 polypeptide was separated by 
SDS-PAGE and transferred on nitrocellulose membrane as mentioned before. After 
blocking, the membrane was cut into strips and incubated with 1:100 dilution of 
serum at 4 °C overnight. After washing with 1xPBS, the membrane was incubated 
with IgY HRP rabbit anti-chicken conjugate in a concentration of 1: 10000 at room 
temperature for 2 hrs. The membrane was washed with 1xPBS and developed as 
mentioned before. 
 
 71 
3.2.3.4 Recombinant Elisa 
Recombinant Elisa was done as described in 3.2.2.4 using 2 recombinant 
polypeptides (P1 and rHA1).  
3.2.3.5 Commercial Elisa  
The test was employed for detection of AI antibodies in chicken sera using 
commercial ELISA kits as described by manufacturer. For individual bird 
interpretation, titres ranging from 0 to 269 considered negative and ≥ 300 were 
considered positive. Valid AI-ELISA were obtained when the average optical density 
value of the normal control serum is less than 0.200 and corrected positive control 
value range is between 0.250 and 0.900. Samples testing with a sample / positive 
value (SP) value of less than or equal to 0,150 received a 0 titre value. Under optimal 
conditions (room temperature 21-24 C), the optical density values ranges from 0.060 
to 0.080 for AI normal control serum and 0.400 to 0.750 for AI positive control serum.  
3.2.3.6 Neutralization test 
Serum samples which are negative by both rHA1 and/or cElisa were analyzed by NT 
according to Rowe and co-worker (ROWE et al. 1999). After 3 days incubation at 37 
°C, plates were inspected as positive or negative a ccording to the presence or 
absence of cytopathic effect (CPE). Positive control sera were included as positive 
control. 
3.2.3.7 Validity of rHA1 Elisa for detection of H5 antibodies in duck serum 
Duck sera were tested using rHA1 in comparison with HI. rHA1-Elisa was performed 
as described before; however, goat anti-bird IgG HRP was used as a secondary 
antibody. 
3.2.3.8 Statistical analysis 
Relative sensitivity and specificity of rElisa in comparison with other performed 
serological tests were calculated according to Mohan and co-workers (MOHAN et al. 
2006). 
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Calculation of relative sensitivity and specificity 
Test B Test A 
 Positive Negative 
Total 
 
Positive a b a+b  
Negative c d c+d  
Total a+c b+d a+b+c+d 
 
Relative sensitivity = a / a + c  
Relative specificity = d / b + d  
Determination of agreement ratio 
The formula of JIN et al. (2004) was employed to compare differences among the 
Elisa (either commercial or recombinant) and HI test in evaluating sera obtained from 
experimentally vaccinated commercial broiler. The formula is given by the function: 
                   Agreement ratio =   
DC
xBA
+
+ %100
  
Where: A = the total number of positive sera examined by HI test subtracted from the 
total number of positive sera   examined by Elisa test. 
              B = the total number of negative sera examined by HI test subtracted from 
the total number of negative sera examined by Elisa test. 
              C = total positive number of sera examined by Elisa test. 
              D = total negative number of sera examined by Elisa test 
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4. RESULTS 
4.1 Expression of recombinant polypeptides in P. pastoris 
4.1.1 PCR 
The coding sequences of genes of interest were isolated and amplified from 
influenza A subtype H5N1 (A / Thailand / 1(Kan-1) / 2004) using primers designed 
with Xho1 and Not1 restriction sites (Figure 4).  The size of the H5-P1, H5-P2, H5-P5 
and H5-HA1 coding sequences were 159, 329, 128 and 1007 bp, respectively. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure (4): PCR amplification of truncated sequences of influenza A subtype H5N1 (A 
/ Thailand / 1(Kan-1) / 2004). Lanes (1 and 2): amplification of P1, lane (3): negative 
control. Lanes (4 and 5): amplification of P2. Lane (6): amplification of P5. Lane (7): 
amplification of HA1.  
4.1.2 Molecular cloning 
PCR products were digested using Xho1 and Not1, purified and ligated with pAOX. 
After transformation of pAOXH5-P1, pAOXH5-P2, pAOXH5-P5 and pAOXH5-HA1 to 
E-coli cells, many colonies arose on selecting plates. Single colonies were cultured in 
liquid medium (LS-LB) for plasmid isolation. Double digestion of pAOXH5-P1, 
pAOXH5-P2, pAOXH5-P5 and pAOXH5-HA1 resulted in large segments (2614, 
2400, 2454 and 2799 bp, respectively) and small segments (1224, 1206, 1183 and 
1716 bp, respectively) (Figure 5). Plasmids containing genes of interest were 
sequenced to confirm the presence of desired sequences. Linearized plasmids were 
analyzed on agarose gel electrophoresis (Figure 6). 
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Figure (5): Analysis of plasmids containing gene of interest. 
A) Double digest of pAOX-HA1 using Bgl II restriction enzyme resulting in a large 
segment (2799 bp) and a small segment (1716 bp). Lanes 1-4 different clones 
subjected to double digest. Lane 5: intact pAOX-HA1 plasmid. B) Double digest of 
pAOX-P5 using Bgl II and Xho1 restriction enzymes resulting in a large segment 
(2453 bp) and a small segment (1183 bp). Lanes 1-7 are different clones. 
 
 
 
 
 
 
 
 
 
 
Figure (6): Plasmids linearization. A) Linearized pAOX-P5 after restriction digest with 
BstX1 (size 3636 bp). B) Linearized pAOX-HA1 after restriction digest with BstX1 
(size 4515 bp). 
4.1.3 Pichia pastoris transformation  
Linearized plasmids were transformed successfully into P. pastoris either SMD1168H 
or GS115 strains. The colonies appear circular with a size of 1- 5 mm. The number of 
colonies ranged from 80 - 108 colonies in GS115 yeast cells and in case of 
SMD1168, the colonies number ranged from 10 – 20 colonies. Presence of the 
respective gene of interest was verified by colony PCR using gene specific primers 
and promoter specific primers (Figure 7). 
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Figure (7): Verifying the gene of interest in positive selected transformants by colony 
PCR using gene specific and promotor specific primers. 
A: Colony PCR of different P1 clones grown on SMD1168H (lanes 1-6) and GS115 
(lanes 8-13). Lanes (7 and 14) are untransformed SMD1168H and GS115, 
respectively. Positive P1 transformants result in a 160 bp fragment.  
B): Colony PCR of different P2 clones grown on SMD1168H (lanes 2-7) and GS115 
(lanes 9-14). Lanes 1 and 8 untransformed SMD1168H and GS115, respectively. 
Positive P2 transformants result in a 330 bp fragment.  
C): Colony PCR of different P5 clones grown on SMD1168H (lanes 1-5). Lanes (6 
and 7) untransformed SMD1168. Positive P2 transformants result in a 251 bp 
fragment.  
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4.1.4 Expression and analysis of recombinant polypeptides 
P1 and P2 polypeptides were expressed in YP 2 % methanol, pH 8 for 24 hrs / 29 °C 
/ 250 rpm. Purification was carried out using Ni-NTA chromatography under natural 
condition (Figure 8.A). For P1 polypeptide, washing and elution were achieved by 
increasing imidazole to 100 mM (wash buffer 1 and elution buffer 1). Washing of P2 
polypeptide was done by lowering pH to 6.5 and eluted at pH of 2-3 (Wash buffer 2 
and elution buffer 2). P5 polypeptide was demonstrated in cell lysate of both GS115 
and SMD1168H Pichia cells by SDS-PAGE and Western blot after induction in YP 2 
% methanol, pH 6. The expected band was detected in supernatant of SMD1168H 
after expression in YP 2 %, pH 8. For purification, P5 polypeptide could not bind to 
Ni-NTA, neither under natural nor under denaturing condition. It was purified by lectin 
affinity chromatography using wash buffer 3 and elution buffer 3 (Figure 8.A). P1, P2 
and P5 polypeptides were analyzed in culture supernatant 24 hrs after induction by 
Western blot using anti-His-tag antibodies (Figure 8.B). rHA1 polypeptide was 
demonstrated in cell lysate and supernatant of SMD1168H cells by SDS-PAGE and 
Western blot 24, 36 and 48 hrs after induction of expression, some protein 
degradation was observed as demonstrated by Western blot. Addition of 2 µg 
Pepstatin / ml prevented protein degradation. For purification, rHA1 polypeptide could 
not bind to Ni-NTA under natural condition; however, it binds under denaturing 
condition using 4 M urea. 1 mM PMSF was added to prevent the degradation during 
purification of rHA1 polypeptide. Washing was done using 10 mM imidazole (wash 
buffer 1).  However, the desired rHA1 polypeptide was eluted using 100 mM 
imidazole (elution buffer 1). Analysis of rHA1 polypeptide by SDS-PAGE and 
Western blot showed a broad smear above the expected size (above 39.6 kDa). 
Analysis of rHA1 polypeptide treated with Endo Hf by SDS-PAGE and Western blot 
showed a band which is in accordance with the expected size (Figures 8.C). It 
reacted with lectin from Con A which reveals the presence of glycosylation (Figure 
8.D). Expression of rHA1 in the presence of tunicamycin lead to partial 
deglycosylation but reduced the expression level. On the other hand, other 
glycosylated polypeptides (P2 and P5) could not react with Con A and could not 
deglycosylated with Endo Hf. MALDI-TOF analysis of P1 polypeptide showed a 
molecular weight of 7592.1 Da [M+ H]+ compared to the theoretical mass: 7591,52 
Da (Figure 9) 
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Figure (8): Analysis of recombinant polypeptides by SDS-PAGE and Western blot. 
A and B): SDS-PAGE and Western blot analysis of purified P1, P2 and P5 
polypeptides expressed in P. pastoris cells (strain SMD1168H) and secreted into 
supernatant, respectively. Lane 1): P1 polypeptide purified by nickel affinity 
chromatography, theoretical molecular mass 7.5 kDa. Lane 2): P2 polypeptide 
purified by nickel affinity chromatography, theoretical molecular mass is 13.9 kDa. 
Multiple bands are due to different glycosylation as P2 contains a glycosylation site. 
Lane 3) P5 polypeptide purified by lectin affinity chromatography, theoretical 
molecular mass is 6.5 kDa. The increase in size is attributed to presence of a 
glycosylation site.  
C): Western blot analysis of rHA1 polypeptide. Lane 1: purified rHA1, Lanes 2, 3, 4, 
5, 6 and 7 are purified rHA1 and treated with Endo Hf  for 15 min, 30 min, 1hr, 2 hrs 
3 hrs and 4 hrs, respectively.   
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D): Blot of rHA1 polypeptide using concanavalin. Lanes (1, 2 and 3):  purified rHA1 
polypeptide.  Lanes 4 and 5: rHA1 treated with Endo Hf for 15 min and 2 hrs, 
respectively, and blotted using concanavalin.
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (9): MALDI-TOF analysis of P1 polypeptide. The molecular mass of P1 
polypeptide is 7592.1 Da  [M + H]+ (theoretical mass: 7591,52 Da). 
 
4.1.5 Expression of rHA1 in pichia pastoris by high-density cell fermentation 
rHA1 was expressed in large scale using high-density cell fermentation. Analysis of 
rHA1 at 12, 24, 36 and 48 hrs after induction revealed that expression of rHA1 at 28 
°C for 36 hrs is the best cultural condition for ob taining better expression level. The 
expression level of rHA1 produced with optimized fermentation process reached 80 
mg / L, which is ten-fold higher than the one produced in regular shaking flask. The 
best method for concentration of rHA1 before purification was with ammonium sulfate 
80 % at 4 °C. Concentration of rHA1 with ammonium sulfate fac ilitates the purification 
of large volumes of rHA1. 
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4.2 Immunogenicity of recombinant polypeptides 
4.2.1 Immunogenicity of recombinant polypeptides in mice 
Vaccination of mice with recombinant polypeptides P1, P2 and rHA1 induced 
influenza H5 specific antibodies based on recombinant Elisa, whole H5N1 Elisa, as 
well as IFA. Elisa titres were calculated as half-maximal OD450. Elisa plates coated 
with the same antigen that was used in vaccination showed higher titres than plates 
coated with inactivated H5N1 (Figures 10, 11 and table 5). Sera of vaccinated mice 
were positive by IFA performed on Vero cells infected with H5N1 virus. 
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Figure (10): Optical densities (OD450) of mice sera vaccinated with rHA1 polypeptide. 
Sera dilutions were expressed as reciprocal log10. A: Mice were vaccinated with rHA1 
polypeptides using immunization protocols 1 (IP1) Elisa plates were coated with P1 
polypeptide (50 ng / well). Elisa titres calculated as half-maximal-OD450 were 57517 
and 98356 after 2 and 5 boosters, respectively. B: Mice were vaccinated with rHA1 
polypeptides using immunization protocols 2 (IP2) Elisa plates were coated with P1 
polypeptide (50 ng / well). Elisa titres were 18880 and 103898 after 2 and 5 boosters, 
respectively. C: Mice were vaccinated with rHA1 polypeptide using IP1 and IP2. Sera 
were analyzed after 5 boosters with Elisa plates coated with rHA1 polypeptide (50 ng 
/ well). Elisa titres were 140325 and 158622, respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure (11): Elisa titres of mice vaccinated with rHA1 polypeptide. Elisa plates were 
coated with different antigens (rHA1, P1 and whole H5N1). Elisa titres were 
expressed as reciprocal log10. 
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Table (5): Immunogenicity of recombinant polypeptides in mice using Elisa  
      Elisa titres  Antigen used in 
vaccination 
Immunization 
protocol 
Homologous Elisa 
antigen   
(50 ng / well) 
Whole H5N1 Elisa 
antigen 
(1 HAU / well) 
IP1           12,378 151 P1 polypeptide 
IP2 133,705 2,542 
IP1 71,619 2,237 P2 polypeptide 
IP2 >204,800 6,188 
IP1 140,325 13,935 rHA1 polypeptide 
IP2 158,622 12,346 
 
IP1 and IP2 are two different immunization protocols (see materials and methods). 
Elisa plates were coated with homologous antigen (the same antigen used in 
vaccination) or whole H5N1 antigen. Titres were calculated as half-maximal OD450. 
4.2.2 Immunogenicity of recombinant polypeptides in chickens 
Immunogenicity of P1, P2, P5 and rHA1 polypeptides was also evaluated in inbred 
commercial layer chickens in comparison with prepared inactivated H5N1 Thailand 
virus (3.2.127). Analysis of sera with Elisa showed H5 specific antibodies when Elisa 
plates coated with the same antigen used in vaccination or with whole inactivated 
H5N1 (Table 6). Serum samples obtained from chickens vaccinated with P1, P2 and 
rHA1 were positive by IFA performed on Vero cells infected with H5N1 Thailand 
isolate. Seroconversion of chickens immunized with P1 and rHA1 polypeptides was 
significant (p < 0.0001) at 4th week post primary vaccination, as analyzed by rElisa 
(Figure 12.A and B) and IFA (Figure 13). P2 polypeptide induced specific 
seroconversion at 5th week post primary vaccination. However, P5 polypeptide 
induced no significant seroconversion at any time of serum analysis. AGID was 
positive only in chickens vaccinated with inactivated H5N1. Moreover, µNT revealed 
presence of low neutralizing antibody titres in chickens vaccinated with P1, P2 and 
rHA1 polypeptides compared with inactivated H5N1 (Table 7). IgY could be detected 
in egg yolk of chickens immunized with rHA1 and P1 polypeptides at 4th and 5th week 
post primary vaccination, respectively, as assessed by recombinant Elisa using 
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homologous antigen that used in vaccination or whole H5N1. Analysis of IgY in egg 
yolk of chickens vaccinated with rHA1 revealed a lower titres than in serum based on 
whole H5N1 Elisa at 8 weeks post primary vaccination (Figure 12.C).  Egg yolk 
analysis of chickens vaccinated with P1 and rHA1 polypeptides tested positive by 
IFA. However, H5 specific antibodies could not be detected in egg yolk of chickens 
immunized with P2 and P5 polypeptides 
 
Table (6): Results of Elisa in commercial layer chickens vaccinated with 
recombinant polypeptides 
 
bMean Elisa titres (range) 
Homologous antigen H5N1 antigen  
Antigen aNo of 
chickens 
6- weeks cPV 8- weeks PV 8- weeks PV 
P1 4 205 (152 -319) 1924 (470- 2500) 907 (650- 1200) 
P2 4 130 (98- 378) 318 (218- 413) 133  (79 – 213) 
P5 4 89 (81- 93) 145 (87- 218) dn.d. 
rHA1 4 1059 (418-
1395) 
6157 (1220 – 
9173) 
1840 (1120-
3200) 
Inactivated H5N1 4 670 (340- 1212) 2415 (1870-2960) 
Control 4 72 (67 – 87) 84 (83- 89) 
 
aEach bird vaccinated with 100 µg of respective polypeptide mixed with 100 ug 
Gerbu adjuvant. Chickens vaccinated with inactivated H5 received a dose of 8 HAU. 
bElisa titres were calculated as half-maximal OD450 
cPV: Post primary vaccination 
dNot done. 
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Figure (12): Immunogenicity of recombinant polypeptides in commercial layer 
chickens. A and B): Mean log10 Elisa titres of chickens (sera and egg yolk) 
vaccinated with rHA1, and P1 polypeptides at intervals post primary vaccination, 
respectively. Elisa plates were coated with homologous antigen used in vaccination. 
Asterisks (*) indicate significant increase antibody levels compared with negative control. C): 
Analysis of IgY in serum and egg yolk of chickens immunized with rHA1 at 8 weeks 
post primary vaccination. Elisa plates were coated with whole H5N1 antigen.  
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Table (7): Summary results of humoral immune response of chickens vaccinated 
with recombinant polypeptides 
 
Vaccination 
aIFA 
(Positive No. / 
examined No.) 
bAGID  
(Positive No. / 
examined No.) 
cµNT 
P1  4/4  0/4 16-32 
P2  4/4  0/4 2-8 
P5   0/4 0/4 dn.d. 
rHA1  4/4 0/4 32-64 
Inactivated H5N1 4/4 4/4 132-264 
Control 0/4 0/4 n.d. 
 
aIFA was don on Vero cells infected with  H5N1 (A/Thailand/1/ Kan-1/2004) virus. 
 
bAgar gel immunodiffusion test performed using prepared H5N1 (A/Thailand/1/ Kan-
1/2004) antigen.  
cMicroneutralization test, the average OD450 was determined for triplicate wells of 
virus-infected and -uninfected control wells. The endpoint titre was expressed as the 
reciprocal of the highest dilution of serum with OD450 value above the mean + (3 x 
standard deviation) of the negative control.  
dNot detected. 
 
 
 
 
 
 
 
Figure (13): Analysis of chicken serum with IFA performed on Vero cells infected with 
H5N1 (A / Thailand / 1 / Kan-1 / 2004) virus. A): Sera were obtained from chickens 8 
weeks post primary vaccination with rHA1. B): Sera were obtained from chickens 8 
weeks post primary vaccination with P1 polypeptide. C: Negative control  
 
 
 
A B C 
 85 
4.3 Development of recombinant Elisa for detection of influenza A subtype H5 
antibodies 
4.3.1 Analysis of serum with HI test  
All serum samples (179) were analyzed by HI using commercial homologous (H5N2 
(A / chicken / Mexico / 232 / 94 / CPA) antigen. Out of 179 serum samples, 109 were 
positive by HI. Twenty five of these positive serum samples were retested by HI using 
heterologous (A / Thailand / 1/ Kan-1 / 2004) H5N1 antigen to be used for 
determination the validity of rElisa. Haemagglutination inhibiting titres ranged from 4 - 
8 log2 (geometric mean = 6.1) and 3 - 6 log2 (geometric mean = 4.7) using 
commercial homologous and hetrologous antigen, respectively (Table 8). All 25 sera 
obtained from influenza non-vaccinated chickens showed no Haemagglutination 
inhibiting titres using commercial homologous H5N2 or hetrologous H5N1 Thailand 
antigens.  
 
Table (8): Distribution of haemagglutination inhibiting antibodies in chickens 
vaccinated with commercial inactivated H5N2 vaccine using 2 different HA 
antigens  
 
AI-HI log2 Antigen Sera 
No 1 2 3 4 5 6 7 8 
Geometric 
Mean 
aHomologous    3 6 10 3 3 6.1 
bHeterologous 
25 
25   3 9 5 8   4.7 
 
aCommercial H5N2 (A / chicken / Mexico / 232 / 94 / CPA) 
bH5N1 (A / Thailand / 1 / Kan-1 / 2004) antigen 
4.3.2 Reactivity of rHA1 with chicken sera 
To study the reactivity of chicken serum samples with rHA1 antigens, twenty five 
serum samples that proved to be positive by HI using homologous and hetrologous 
antigen were analyzed by Western blot. Results showed that antibodies of chicken 
sera were reacted with rHA1 polypeptide. Sensitivity and specificity of Western blot 
were 100 %. All sera obtained from non vaccinated chicken sera were negative by 
Western blot (Table 9).  
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4.3.3 Recombinant Elisa 
Twenty five serum samples that proved to be positive by HI using homologous and 
heterologous antigen as well as by Western blot were analyzed by rHA1 and P1 
Elisa. At serum dilution of 1:100 and above, the optical densities of the negative sera 
plateaued whereas the positive sera continued to show a high optical densities value 
(Figure 14). Accordingly, serum dilution 1:100 was selected as an optimum dilution to 
be used in single dilution Elisa. To analyse the validity of recombinant Elisa, these 
serum samples were tested by single dilution Elisa (using P1, rHA1 and full H5N1 
antigens) and the results were compared with HI, Western blot and AGID. Summary 
results were shown in table (9). The specificities of rHA1-Elisa, rP1-Elisa and whole 
H5N1 Elisa were 100 %, 72 % and 100 %, respectively, and the sensitivities were 
100 %, 80 % and 100 %, respectively. AGID showed low sensitivity (52 %) but high 
specificity (100 %).  
Table (9): Overall sensitivity and specificity for recombinant Elisa compared 
with other serological tests  
aSensitivity: the probability of correctly identifying true positive (vaccinated). 
bSpecificity: the probability of correctly identifying true-negative (non vaccinated). 
cElisa plates were coated with rHA1 polypeptide (50 ng / well). 
dElisa plates were coated with P1- polypeptide (50 ng / well). 
eElisa plates were coated with whole inactivated H5N1 (A / Thailand / 1 / Kan-1 / 
2004) antigen (1HA U/ well). 
fHI was performed using commercial H5N2 (A / chicken / Mexico / 232 / 94 / CPA) 
and H5N1 (A / Thailand / 1 / Kan-1 / 2004) antigen. 
 
gWestern blot was performed using rHA1 polypeptide as antigen. 
hAgar gel immunodiffusion test was done using H5N1 (A / Thailand / 1 / Kan-1 / 
2004) antigen. 
Test Non vaccinated 
positive No / 
examined No. 
Vaccinated 
positive No / 
examined No. 
aSensitivity % bSpecificity % 
crHA1-Elisa 0/25 25/25 100 100 
drP1-ELisa 7/25 20/25 80 72 
eWhole H5N1-Elisa 0/25 25/25 100 100 
fHI 0/25 25/25 100 100 
gWb 0/25 25/25 100 100 
hAGID 0/25 13/25 52 100 
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Figure (14): Analysis of chicken sera with rHA1- Elisa. Plates were coated with rHA1 
(50 ng / well). Positive sera were obtained from commercial broiler chickens (n = 25) 
immunized once with commercial inactivated H5N2 vaccine at 7-day-old. Negative 
sera were obtained from influenza non- vaccinated chickens (n = 25). Serum dilutions 
were expressed as reciprocal log10. 
 
 
4.3.4 Agreement between rHA1-Elisa and commercial Elisa and HI 
To study the agreement between rHA1-Elisa and cElisa and HI, all serum samples 
(179) were analysed by rHA1-Elisa, cElisa and HI (using Thailand isolate antigen). 
Out of 179 serum samples, 109, 139 and 130 positives were obtained by HI test, 
cElisa and rHA1-Elisa, respectively, (Table 10). The relative sensitivity and specificity 
between rHA1-Elisa, and cElisa were 93.5 % and 100 %, respectively (table 11). 
Relative sensitivity and specificity between rHA1-Elisa, and HI was 100 % and 82.8 
%, respectively (Tables 12).The agreement ratio between rHA1-Elisa and HI was 
84.9 % whereas between cElisa and HI was 76.5 %. Negative serum samples by 
rHA1-Elisa were confirmed by neutralization test (NT) using H5N1 (A / Thailand / 1/ 
Kan-1 / 2004) virus. 
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Table (10): Agreement ratio between rElisa and cElisa and HI 
Test Sera No Positive Negative Positive 
ratio 
Negative 
ratio 
arHA1- Elisa 179 130 49 72.6 27.3 
cElisa 179 139 40 77.7 22.3 
HI 179 109 70 60.9 39.1 
 
aElisa plates were coated with rHA1 polypeptide 50 ng / well in coating buffer. 
bCommercial Elisa (Synbiotic Corporation 11011 VIA San Diego, CA 92127). 
cHaemagglutination inhibition test was done using hetrologous H5N1 (A / Thailand  / 
1 (Kan-1) / 2004) antigen. 
Table (11): Overall relative sensitivity and specificity between rHA1-Elisa, and 
commercial Flock check Elisa 
bc Elisa  arHA1 Elisa 
 Positive Negative 
Total 
 
Positive 130 a 0b 130 a+b  
Negative 9c 40d 49 c+d  
Total 139a+c 40b+d 179 a+b+c+d 
 
aElisa plates were coated with rHA1 polypeptide.  
bcElisa: Commercial flock check Elisa 
Relative sensitivity = a / a + c = 93.5 %. Relative specificity = d / b + d = 100 %. 
Table (12): Overall relative sensitivity and specificity between rHA1-Elisa, and 
HI 
bHI  arHA1- Elisa 
 Positive Negative 
Total 
 
Positive 109 a 12b 121 a+b  
Negative 0c 58d 58 c+d  
Total 109a+c 70b+d 179 a+b+c+d 
 
aElisa plates were coated with  50 ng / well rHA1 polypeptide  
bHI was done using homologous commercial H5N2 (A / chicken / Mexico / 232 / 94 / 
CPA) antigen. 
Relative sensitivity = a / a + c = 100 %. Relative specificity = d / b + d = 82.8 %. 
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4.5 Validity of rHA1 Elisa for analysis of duck sera 
HI analysis of duck sera showed that all samples obtained from ducks vaccinated 
with commercial inactivated H5N2 showed a Haemagglutination inhibiting titres 
ranged from 4 log2 – 8 log2 (geometric mean 5 log2) using H5N1 (A / Thailand / 1/ 
Kan-1 / 2004) antigen. Sera obtained from non- vaccinated ducks showed no 
Haemagglutination inhibiting antibodies. Analysis of duck sera with rHA1-Elisa 
showed that rHA1 could react with H5 antibodies in duck sera (Figure 15).   
Table (13): Distribution of Haemagglutination inhibiting antibodies in duck 
vaccinated with commercial inactivated H5N2  
AI- HI log2 Sera Sera 
No 0 1 2 3 3 4 5 6 7 8 
GM 
Vaccinated  5      3 1   1 5.0 
Non-vaccinated 3 3          0.0 
 
HI was performed using commercial H5N2 (A / chicken Mexico / 232 / 94 / CPA) 
antigen 
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Figure (15): Analysis of duck sera with rHA1-Elisa. Plates were coated with rHA1 (50 
ng / well). Positive sera were obtained from ducks (n = 5) immunized 3 times with 
commercial inactivated H5N2 vaccine. Negative sera were obtained from influenza 
non- vaccinated ducks (n = 3). Serum dilutions were expressed as reciprocal log10. 
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5. DISCUSSION 
Highly virulent H5 influenza viruses have been isolated from several recent outbreaks 
in poultry (BAHGAT et al. 2009; BEAN et al. 1985; CAPUA and ALEXANDER 2009; 
HORIMOTO et al. 1995; TANG et al. 2009). H5N1 influenza virus was transmitted 
from chickens to humans. Viruses isolated from humans and from birds were very 
similar in their genetic content and phenotypic features, including virulence for 
mammals (CLAAS et al. 1998; SUAREZ et al. 1998). Outbreaks of AI in poultry plays 
an important role in the generation of pandemic viruses for humans (CAPUA and 
ALEXANDER 2007; CAUTHEN et al. 2000; LAHARIYA et al. 2006). Emergency 
vaccination for AI has become an acceptable tool, in conjunction with other 
measures, for combating the spread of AI. Using emergency vaccination to reduce 
the transmission rate could provide an alternative to pre-emptive culling to reduce the 
susceptibility of healthy flocks at risk. The effectiveness of such program depends on 
variables such as the density of poultry flocks in the area, level of biosecurity and its 
integration into the industry, characteristics of the virus strain involved, and practical 
and logistical issues such as vaccine availability and adequate and speedy 
administration (CAPUA et al. 2009). The traditional egg-based vaccines have been 
successfully used for more than 50 years to prevent influenza. They are reliable, 
effective (if there is a good match), and affordable. However, the production cycle of 
the egg-based vaccines is lengthy and heavily dependent on egg supply and unable 
to be developed quickly in response to the urgent need in an influenza pandemic 
(COX 2005; OSTERHOLM 2005). To meet the challenge of a potential influenza 
pandemic, however, a reliable expression system and a quick, efficient downstream 
purification process are needed.  In the present study, truncated sequences were 
expressed in Pichia pastoris to be used in vaccination and diagnostic purposes. 
Immunogenic regions of H5 influenza 
HA, a homotrimeric class I membrane glycoprotein, is quantitatively the major surface 
protein of influenza virus and the major antigen against which neutralizing antibodies 
are elicited. Therefore, recombinant HA is favourable antigen as a candidate 
influenza vaccine. HA mediates the attachment of the virus to the target cell through 
specific binding with sialic acid-containing determinants and, following internalization, 
the release of the viral content into the attacked cell (WHITE et al. 1982; WILEY and 
SKEHEL 1987). HA-specific antibodies are protective as a result of their ability to 
prevent virus attachment and penetration of the host cell, and presumably by 
 91 
interfering with the low-pH-induced conformational change of the HA molecule 
needed for fusion (KIDA et al. 1982; KIDA et al. 1985). Because of the immune 
selection pressure, HA is the viral component which is most important in antigenic 
drift. The HA monomer is synthesized as a single polypeptide chain which undergoes 
post-translational cleavage at two sites: the N-terminal signal sequence is removed 
and, depending on the host cell and virus strain, the molecule is cleaved, with the 
removal of one or more intervening residues, resulting in two polypeptide chains 
called HA1 (36 kDa) and HA2 (27 kDa), linked via a disulfide bridge (SINGH et al. 
1990; SKEHEL et al. 1982). A c-terminal stretch of hydrophobic amino acids anchors 
HA to the viral membrane and, though not essential for secretion, this sequence 
plays a major role in the trimerization process (SINGH et al. 1990). The immunogenic 
potential of yeast derived HA may be appropriate for the development of an easily 
adaptable, safe and economic alternative to the currently used influenza vaccines. 
Furthermore being a recombinant expression system, it may be possible to improve 
its protective properties by genetic engineering. Recombinant protein vaccine was 
found to be a feasible approach to a variety of pathogens in poultry for improvement 
of new vaccines; i.e  IBD (OMAR et al. 2006), IB (YANG et al. 2009), Coccidiosis 
(DING et al. 2008; LILLEHOJ et al. 2000), ND (LEE et al. 2010), Runting Stunting 
Syndrome (SELLERS et al. 2010), Reo virus (WU et al. 2009), AI  (LIN et al. 2008; 
XIE et al. 2009). Peptide vaccination has many advantages and could be an 
alternative vaccine to commercially available vaccines. Subunit vaccines based on 
conserved antigens provide broader protection (TOMPKINS et al. 2007). The 
influenza HA glycoprotein is the primary target of neutralizing antibodies (Wiley et al., 
1981). The H3 structure was initially used to characterize the antigenic structure of 
H5 (PHILPOTT et al. 1990). In this study truncated HA polypeptides were expressed 
to analyze their potential use in vaccination and for diagnostic purposes. Five 
neutralizing epitopes were identified (designated A-E) and their location was mapped 
on the three-dimensional model of the H3 HA molecule (WILEY et al. 1981). The 
sequence and three-dimensional structure of the HA antigenic epitopes has been 
characterized in detail only in the H3 subtype of influenza A (WILEY et al. 1981). The 
H3 three dimensional model has since been used in studies of the H1 subtype 
(CATON et al. 1982), the H2 subtype (TSUCHIYA et al. 2001) and, to a limited 
extent, the H5 subtype (PHILPOTT et al. 1990). The region 136-141 corresponds to 
site A in the H3 structure (140±145 in H3 numbering) and to site Ca2 in H1 (CATON 
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et al. 1982), forming a loop at the side of the HA molecule. One amino acid change in 
this region (position 145, H3 numbering) was demonstrated in an H5 escape mutant 
by (PHILPOTT et al. 1990). The amino acid changes at positions 152 and 153 (156 
and 157 in H3 numbering) correspond to the area involved in the formation of site B 
in the H3 molecule (PHILPOTT et al. 1990) showed a change in the H5 molecule at 
position 156 (H3 numbering). The H5 area 124-129, which corresponds to 129-133 in 
the H3 sequence, is located outside any site in the H3 HA structure recognized by 
virus-neutralizing mAbs (WILSON et al. 1981b) but partially overlaps a region 
involved in the antigenic site Sa in H1 HA (CATON et al. 1982). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (16): Structural identification of the antibody- binding sites of influenza H3 and 
H5 according to WILSON et al. (1981b) and KAVERIN et al. (2002), respectively.  
A): HA contains 5 antigenic sites designated A (140-146), B (187-196 and 155-160), 
C (275- 278 and 53 - 54), D-(201-202), and E (60-83). 
 B): Structural identification of the antibody- binding sites of influenza H5. Site A is a 
conformational epitope but not conserved in H5 (136- 141) and 140- 145). Site B is 
described as a discontinuous epitope (152- 153) and 156-157 and 124-129 and 129-
133.  
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In this study, four regions were chosen for production of recombinant polypeptides 
and designated P1, P2, P5 and rHA1 (Table 1 and Figure 17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (17): Crystal structure of influenza A subtype H5 virus monomer 
(1JSM.pdb). The location of coding sequences used for expression within HA1 was 
coloured with WebLab ViewerLite program.  
 
P1 polypeptide, corresponds to the neutralizing epitope of Site E of H3 (WILEY et al. 
1981). Alignment of H5 revealed that this sequence is conserved in H5 viruses (40 
amino acids residues long). It is worthy to mention that H5 site that is equivalent to 
site B of H5 appears to be more complex in H5 than in H3. Site B in H5N2 (A / 
Mallard / Pennsylvania / 10218 / 84) contains not only the region present in H3 site B 
but also the region 124- 129 (KAVERIN et al. 2002), which partially overlaps site Sa 
of H1 (CATON et al. 1982). Accordingly, P2 epitope was chosen as it consists of the 
receptor binding site, site D and parts of site B, conserved in H5, 97 amino acid 
residues long, contains a glycosylation site.  P5 is a conformational epitope in H5 
(KAVERIN et al. 2002), not conserved, 30 amino acid residues long and contains a 
glycosylation site. Also, rHA1 which contains the majority of antigenic determinants 
P2 P5 
P1 
HA1 
HA2 
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are responsible for generation of virus-neutralizing antibodies, 320 amino acid 
residues long and contains 5 glycolsyation sites. 
P. pastoris expression 
Recombinant HA proteins can be produced in different ways such expression in 
insect cell system (JOHANSSON 1999; LAVER and WEBSTER 1976; POWERS et 
al. 1995; TREANOR et al. 2001; 2006) or in the recombinant baculovirus expression 
system in insect larvae (SUGIURA et al. 2001). Previous baculovirus / insect cell 
systems have been used to express HA genes isolated from AI subtypes. However, a 
protein band corresponding to rHA1 from baculovirus infected cells was not observed 
by SDS-PAGE of total cell protein. This could have been due to a low level of 
expression or alternatively incorrect glycosylation of the polypeptide in insect cells or 
toxicity of insect cells (POSSEE 1986). HA1 was expressed in monolayer or 
suspension culture insect cells by infection with the recombinant baculovirus (NWE et 
al. 2006). Although E. coli expression system is not complicated and high amount of 
recombinant protein could be produced when comparing to other production system, 
E. coli often leads to production of the expressed proteins in insoluble inclusion 
bodies (TSUMOTO et al. 2003). Accumulation of expressed foreign protein in E. coli 
in the discrete form of the inclusion bodies is the greatest drawback of bacterial 
expression system (MARSTON. 1986). P. pastoris has the potential of high-level 
expression and rapid growth to very high cell densities in inexpensive media 
(ROMANOS et al. 1992). In addition, P. pastoris is a highly successful system for the 
production of a variety of heterologous proteins. Choosing of this particular 
expression system can be attributed to several factors. P. pastoris has the ability to 
produce foreign proteins at high levels, either intracellular or extracellular. In addition 
P. pastoris has the capability of performing many eukaryotic post-translational 
modifications, such as glycosylation, disulfide bond formation and proteolytic 
processing. Moreover, P. pastoris system strong promoters are available to drive the 
expression of a foreign gene(s) of interest thus enabling production of large amounts 
of the target protein(s) with a relative lower cost than most other eukaryotic systems 
(CEREGHINO et al. 2002; DALY and HEARN 2005). Yeast is the favored alternative 
host for expression of foreign proteins in research, industrial or medical use 
(HITZEMAN et al. 1981; WEIDNER et al. 2010). As a food organism, it is highly 
acceptable for the production of pharmaceutical proteins. Additional advantages of P. 
pastoris are the availability of complete genome sequences, the stable high copy 
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numbers of nuclear plasmids and ability to secrete the target protein (HITZEMAN et 
al. 1990). Accordingly, P. pastoris was chosen as an expression system to be used in 
this study. Coding DNA fragments of full length or epitope-based truncated 
sequences of influenza A subtype H5N1 (A / Thailand / 1 (Kan-1) / 2004) were cloned 
in to pAOX vector for recombinant production using gene specific primers. 
Appropriate expression cassettes were used for transformation of P. pastoris cells 
(strains GS115, SMD1168H). E- coli provide a well defined simple system for stable 
storage of the construct as well as for isolation of large quantities for verification of 
the inserted sequence. Accordingly, before transformation to yeast genome, pAOX 
plasmids containing inserts were transformed into XL10®-Gold ultracompetent E-coli 
cells and plasmids were isolated for analysis. Plasmids were subjected to double 
digestion with restriction enzymes. For further analysis, the gene of interest was 
sequenced. Transformation is a crucial step in hetrologous protein expression barrier 
such as cell walls and cell membrane restrict effective uptake of foreign DNA. 
Moreover the expression cassette has to integrate by homologous recombination, 
resulting eventually in stable transfromants (CEREGHINO et al. 2002; ORR-
WEAVER et al. 1981). To study several clones for their protein production capacity, it 
is necessary to obtain sufficient large numbers of transformants. The pAOXα vector 
integrates at the AOX1 site of the Pichia genome. With the developed improved 
transformation protocol described in by Dr. Kathrin Rall (Virology institute, Leipzig 
University), coding DNA sequences of P1, P2, P5 and rHA1 were cloned in frame 
downstream of the alpha factor leader into pAOXα. The insert length varied from 159 
to 1007 bp. In our transformation protocol many colonies of transformed cells arose 
either GS115 or SMD1168H. Our own experience shows that not all transformed 
clones express the desired peptide or protein at high levels. Consistently, several 
clones completely failed in recombinant protein production and growth of such clones 
is not helpful. Selected clones were used for secretory expression of polypeptides 
fused to his-tag facilitating detection in culture supernatants using Western blot. The 
four developed polypeptides were identified by SDS-PAGE followed by Western blot 
in both cell lysate and culture supernatant. Secretion requires the presence of a 
signal sequence on the foreign protein to target it to the secretory pathway. While 
several different secretion signal sequences have been used including the native 
secretion signal present on some heterologous proteins, success has been variable. 
However the secretion sequences from S. cervisae factor PrePro peptide have been 
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used with the most success. S. cervisae factor prepro peptide consists of a 19 aa 
signal pre-sequence followed by a 66- residue pro sequence (KURJAN and 
HERSKOWITZ 1982). Signal processing starts with the removal of the pre signal by a 
signal peptidase in the endoplasmic reticulum followed by cleavage of the pro leader 
sequence between aa Arginine and Lysine by kex2 endopeptidase. Finally Glu-Ala 
repeats are cleaved by ste13 protein (BRAKE et al. 1983). The close proximity 
proline residues can influence cleavage efficiencies of Kex2 and Ste3 proteins and 
the tertiary structure formed by a foreign protein may protect cleavage sites from 
these proteases. 
Glycosylation analysis 
P. pastoris has the potential of performing post-translational modifications including 
N-glycosylation. It begins in the endoplasmic reticulum (ER) with the transfer of a 
lipid-linked oligosaccharide unit Glc3Man9GlcNAc2 (Glc: Glucose GlcNAc: N. 
acetylglucosamine) to Asparagine Asn-Xser / Thr. (CEREGHINO et al. 2002; DALY 
and HEARN 2005). Analysis of the N-linked carbohydrates showed the presence, 
predominantly, of (N-acetylglucosamine)2 Man8–10 residues (SAELENS et al. 1999). 
This result is in agreement with the reported average 8–14 mannose residues added 
post-translationally by P. pastoris residues (SAELENS et al. 1999) and is in striking 
contrast with the observation of the rather exceptional hyperglycosylated nature of 
soluble recombinant neuraminidase containing N-glycans with 30–40 mannose 
residues, from the same organism (MARTINET et al. 1997). Although the molecular 
mechanisms determining the outcome of the glycosylation pattern of a glycoprotein in 
a particular eukaryotic host organism remain enigmatic, one might speculate that the 
folding kinetics play a role. Glycoproteins that spend longer in the early exocytic 
vesicles might be more susceptible as a substrate for glycosyltransferase activity. 
Recognition of P. pastoris-secreted HA0s by a panel of mAbs implies that at least 
part of the molecule is correctly folded (SAELENS et al. 1999).  
In this study, rHA1 has a theoretical molecular mass of 39.67 kDa but when the 
protein was expressed in P. pastoris it gave a broad smear above the expected size 
as analyzed by SDS-PAGE and Western blot.  Endo Hf is a recombinant protein 
fusion of Endoglycosidase H and maltose binding protein. Endo Hf cleaves within 
chitobiose core of high mannose and some hybrid oligosaccharides from N-linked 
glycoprotein (ESHAGHI et al. 2005). It is used to get information about carbohydrate 
groups attached to glycoproteins and glycopeptides. After removal of mannose 
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residues, the proteins were analyzed using SDS-PAGE and Western blot. Treatment 
of purified rHA1 with Endo Hf revealed that its aberrant migration resulted from post-
translational glycosylation. Although the exact structure of the oligosaccharides did 
not analyzed, the most commonly observed N-linked glycans in P. pastoris secreted 
recombinant protein are short Man8GlcNAC and Man9 GLCNAc (MONTESINO et al. 
1998). The N-glycosylation appears to be important in correct protein folding, 
conformational stability and resistance to protease degradation during synthesis 
(ZHU et al. 1998). However, the site of glycosylation should be determined carefully; 
it should not interfere with the folding of the protein and should not cover the active 
site of the molecule (SAGT et al. 2000). N glycosylation containing only the first 
residue, GlcNAc, would be sufficient to maintain the conformational stability (ERBEL 
et al., 1999; ERBEL et al., 2000; WELLER et al. 1996; WILSON et al. 1981a). It is 
worthy to mention that lectins are extremely useful tools for the investigation of 
carbohydrates on cell surfaces as well as for the isolation and characterization of 
glycoproteins. Numerous lectins have been isolated from plants as well as 
microorganisms and animals (SHARON and LIS 2004). Lectins bind principally to 
oligosaccharides and cell surface glycoproteins and glycolipids that contain 
appropriately linked mannose residues (CHAN and REES 1975; GRODECKA et al. 
2010; SAINZ-PASTOR et al. 2006). rHA1 could be analyzed by blotting with 
concanavalin A. Analysis of P2 polypeptide by Western blot showed multiple bands 
due to different glycosylation pattern as it contains a glycosylation site. Analysis of 
culture supernatant of P5 by Western blot revealed that P5 polypeptide is secreted in 
a very low amount (detected only after concentration by ultraconcentration). Analysis 
of P5 polypeptide in cell lysate by SDS-PAGE and Western blot showed a size of 
about 21 kDa. This is attributed to the glycosylation of alpha factor. The pro 
sequence of alpha factor contains three N-linked- glycosylation sites and a dibasic- 
kex2–endopeptidase. P5 polypeptide could not bind with Ni-NTA affinity 
chromatography either under natural or denaturing condition. As optimal purification 
using Ni-NTA is dependent on the amount of 6x his-tagged protein, possibly, P5 
polypeptide hist-tag in the N-terminal might be removed by proteolysis. Eshaghi and 
others (ESHAGHI et al. 2005) mentioned that His-tag in N terminal of expressed 
proteins was suspected to proteolytic removal in sf-9 cells. P2 polypeptide contains 
one glycosylation site and its theoretical mass is ~14 Kda, however, analysis by 
SDS-PAGE and Western blot resulted two bands (about 10 and ~22 kDa). Presence 
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of multiple bands is attributed to not all the protein glycosylated. Endo Hf could not 
remove the glycosylation residues of P2 and P5 polypeptide. Furthermore, both P2 
and P5 polypeptides did not react with concanavalin A. Posttranslational 
modifications are also important in determining the efficacy of secretion of a protein, 
since the overall fold will affect the processing of the signal sequence. Expression of 
rHA1 in the presence of tunicamycin, was lead to partial deglycosylation but 
decrease in the amount rHA1 secreted in supernatant.  
Immunogenicity of recombinant polypeptides 
The need for vaccination of poultry is highly controversial. Anyway, speculation about 
potential problems of vaccine use must be balanced with the real problem of 
outbreaks in susceptible poultry. Vaccination of chickens against HPAI must be 
considered complement to other control measures. Vaccination of chickens with 
recombinant polypeptides P1, P2 and rHA1 showed H5 subtype specific antibodies 
as analyzed with Elisa, and IFA. Elisa titres were lower than that obtained in 
immunized mice which indicate that the vaccination regime in chickens should be 
optimized. The µNT revealed presence of neutralizing antibodies in chickens 
vaccinated with P1, P2 and rHA1 but with low titres as compared with inactivated 
vaccine. At present time we can not determine the reason for the low neutralizing 
activity of our polypeptides. Several reports (CHIU et al. 2009; PORTOCARRERO et 
al. 2008; SPITSIN et al. 2009; TREANOR et al. 2006; WEI et al. 2008) mentioned 
that selection of virus strain (s) and / or the epitope of HA polypeptides, expression 
system, choice of adjuvant, dosage, peptide folding may have an impact on the 
ability of HA to generate a protective antibody response. However, rHA1 polypeptide 
purification required denaturation which might be the reason for low neutralizing 
activity, hence, in a recent study (CHIU et al. 2009) it was found that the best method 
for generating HA1-specific neutralization determinant is on-column oxidative 
refolding procedures with Glutathione. On the other hand the effect of glycosylation 
of our developed polypeptides on the immune response should be studied in details. 
Glycolsyation may change the function and characteristics of the recombinant protein 
(KREIJTZ et al. 2007). It was mentioned that removal of structurally non essential 
glycans on viral surface glycoproteins may be a very effective approach for vaccine 
design against influenza and other human viruses (WEI et al. 2008). HA glycosylation 
affects the function of influenza HA (WAGNER et al. 2002). Interestingly, as the level 
of glycosylation on influenza H3N2 has increased since 1968, the morbidity, 
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mortality, and viral lung titres have decreased (VIGERUST et al. 2007). HA with a 
single GlcNAc attached to the glycosylation sites showed relaxed specificity but 
enhanced affinity to α 2,3 sialosides suggests that the N-glycans on HA may cause 
steric hindrance near the HA–receptor binding domain. The high specificity for 
receptor sialosides may prevent the virus from binding to some other specific glycans 
on the human lung epithelial cell surface. On the other hand, HA with truncated 
glycans can recognize α 2, 3 receptor sialosides with higher binding affinity and less 
specificity, suggesting that reducing the length of glycans on HA may increase the 
risk of avian flu infection. It is, however, unclear how the changes of HA–receptor 
interaction via glycosylation affect the infectivity of the virus and the NA activity in the 
viral life cycle. HA with a single GlcNAc is a promising candidate for influenza vaccine 
because such a construct retains the intact structure of HA and can be easily 
prepared (e.g., via yeast). It also can expose conserved epitope hidden by large 
glycans to elicit an immune response that recognizes HA variants in higher titre (SUI 
et al. 2009). This strategy opens a new direction for vaccine design and, together 
with other different vaccine strategies and recent discoveries of HA neutralizing 
antibodies should facilitate the development of vaccines against viruses such as 
influenza, hepatitis C virus, and HIV (EKIERT et al. 2009; HOFFMANN et al. 2005; 
HULEATT et al. 2008; KASHYAP et al. 2008; SCANLAN et al. 2007; SCHEID et al. 
2009; STEVENS et al. 2006; SUI et al. 2009; YANG et al. 2007). Glycans near 
antigenic peptide epitopes interfere with antibody recognition (OHUCHI et al. 1997) 
and glycans near the proteolytic activation site of HA modulate cleavage and 
influence the infectivity of influenza virus (DESHPANDE et al. 1987). Mutational 
deletion of HA glycosylation sites can affect viral receptor binding (GUNTHER et al. 
1993). However, little is known regarding how the structure and composition of its 
glycans affect HA activity, including structure, receptor binding, and immune 
response. The use of immunogenic peptides has been proposed as a means of 
developing defined vaccines. Once a potentially protective peptide has been 
identified, it must be delivered to the immune system in a form which elicits anti-
peptide antibodies that will recognize and neutralize the infectious agent. As a 
consequence of the small size of P1 (7.5 kDa), P2 (13.9 kDa) and P5 (6.5 kDa), it 
has been suggested that peptides require chemical coupling to a carrier as tetanus 
toxoid, to enhance their immunogenicity. But, chemically coupling short peptides to 
carrier proteins can result in poor immunogenicity. However, the immunogenicity 
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could be dramatically improved by synthesizing peptides consisting of tandem 
repeats of the epitope (BROEKHUIJSEN et al. 1987; DIMARCHI et al. 1986).  AGID 
was positive in chickens immunized with inactivated H5 and negative in chickens 
vaccinated with recombinant polypeptides indicating that the peptides could not elicit 
immune response towards precipitating antibodies, this in accord with (SNYDER et 
al. 1985; SUAREZ 2005) who mentioned that AGID test targets M protein and NP 
and subunit vaccines did not elicit immune response towards these proteins and this 
could help in DIVA. But the sensitivity of AGID should be considered as this test has 
high sensitivity but low specificity. Four DIVA strategies have been proposed for AI to 
overcome this limitation. All four DIVA strategies have advantages and 
disadvantages, and further testing is needed to identify the best strategy to make 
vaccination a more viable option for avian influenza. The most common is the use of 
unvaccinated sentinels. The main disadvantage is in the management of the sentinel 
birds, because they must either be marked or caged separately from the other birds 
in the house. There is also concern that these naıve birds may increase the risk of 
infection of the flock  (SUAREZ 2005). A second approach is the use of subunit 
vaccines targeted to the HA protein that allows serologic surveillance to the internal 
proteins. Because antibodies to the HA and neuraminidase proteins provide the 
primary protection against avian influenza virus challenge, it is possible to protect 
birds by having only these proteins in a vaccine. Antibodies to the HA protein in 
particular are critical for protection, and many experimental subunit vaccines have 
included only the HA protein. Many different types of subunit vaccines, including virus 
vectored vaccines and vaccines using protein expressed in different culture systems, 
have been shown to provide protection from HPAI challenge. However, only the fowl 
pox-vectored recombinant vaccine for the H5 subtype is available commercially (LEE 
et al. 2006). The subunit vaccines provide the most flexibility to work with existing 
type A serologic surveillance tests, specifically the AGID and commercial ELISA tests 
that target the M or NP structural proteins. Vaccinated birds will not develop 
antibodies to the internal proteins, providing a clear distinction between infected (has 
antibodies to HA, M and NP) and vaccinated birds (has antibodies to HA but no 
antibodies for M or NP). As previously mentioned, the only commercially available 
subunit vaccine for AIV is the fowl pox recombinant vaccine, and this vaccine is only 
available for the H5 subtype. This vaccine contains the A/Turkey/Ireland/83 H5 HA 
gene, and experimentally this vaccine has been shown to be protective for many 
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HPAI viruses (SWAYNE and SUAREZ 2000; TAYLOR et al. 1988). A third strategy is 
to vaccinate with a homologous HA to the circulating field strain, but a hetrologous 
neuraminidase subtype. Serologic surveillance can then be performed for the 
homologous NA subtype as evidence of natural infection (CAPUA et al. 2003). The 
fourth strategy is to measure the serologic response to the non-structural protein 1 
(NS1). This DIVA approach was demonstrated previously with equine influenza 
viruses in horses using an Elisa format (BIRCH-MACHIN et al. 1997). Experimentally, 
the approach also works with chickens with purified killed vaccines. However, 
commercial AI vaccines are made with allantoic fluid from infected embryonating 
chicken eggs and are only partially purified. Therefore, they contain small amounts of 
NS1 protein in the vaccine as a contaminant from the lysed cells in the allantoic fluid, 
and vaccinated chickens will develop some antibodies to the NS1 protein, particularly 
after repeated vaccinations. This small amount of NS1 antibody does make it more 
difficult to use the NS1 DIVA strategy, but infected birds appear to have higher levels 
of antibody as compared to vaccinated birds. By diluting the sera before testing, a 
clear distinction, at least experimentally, can be made between vaccinated and 
infected birds (TUMPEY et al. 2005). Our recombinant polypeptides could not elicit 
immune response towards precipitating antibodies. Accordingly, Elisa coated with 
internal proteins and AGID test could be used as DIVA tools. It is worthy to mention 
that the molecular mass of the antigen was an important factor in eliciting antibodies 
in hens as reflected in the titre of the antibodies in their yolk. Antigens with molecular 
mass equal to or higher than that of human IgG appear to produce a good responses 
in hens whereas antigens of lower molecular mass and less appear to be poor 
antigen (POLSON et al. 1980). The tendency of antigenic response of hens on 
molecular size of the antigen is not unique but is a well-known phenomenon which is 
frequently observed when mammalian species were hyperimmunized with antigens 
of low molecular weight. The only difference being that the responses of low 
molecular weight is poorer in hens (POLSON et al. 1980). In addition, there are 3 
classes of antibodies in chickens, namely IgY, IgA, and IgM. Chicken IgA and IgM 
are similar to mammalian IgA and IgM in terms of molecular weight, structure, and 
immunoelectrophoretic mobility (LILLEHOJ et al. 2000). Although structural 
differences exist between IgY and mammalian IgG, IgY is considered the avian 
equivalent to mammalian IgG. In eggs, IgY is present predominantly in the egg yolk 
(LILLEHOJ et al. 2000), whereas IgA and IgM are present in the egg white as a result 
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of mucosal secretion in the oviduct (ROSE et al. 1974). In chickens, the transfer of 
IgY from the dam to her offspring takes place in a 2-step process. In the first step, 
IgY is taken up into the egg yolk by the IgY receptors on the ovarian follicle from the 
dam’s blood (LOEKEN and ROTH 1983). In the second step, IgY is transferred from 
the egg yolk to the offspring via the embryonic circulation. Yolk IgY is transported at a 
low rate across the yolk sac into the embryonic circulation as early as embryonic day 
7 (KRAMER and CHO 1970). The rate of transfer started to increase by embryonic 
day 14 and by embryonic day 19 to 21, there was a steep rise in the rate of transfer 
of IgY from the egg yolk to the embryonic circulation  (KOWALCZYK et al. 1985). The 
amount of IgY transferred to the egg yolk has been reported to be proportional to 
maternal serum IgY concentrations (AL-NATOUR et al. 2004; LOEKEN and ROTH 
1983). As reported by Kaspers and coworkers (KASPERS et al. 1991), maternal 
antibodies to AI should be considered. IgY was analysed in egg yolk of chickens 
immunized with our recombinant polypeptides. In the present study, the amount of 
IgY of chicken, immunized with P1 and rHA1, transferred to the egg yolk has been 
reported to be proportional to maternal serum IgY concentrations which is in 
accordance with (Al-NATOUR et al. 2004; LOEKEN and ROTH. 1983). However, no 
detectable antibodies in egg yolk of chickens immunized with P2 and P5. This may 
attributed to their low immunogenicity.  
The Use of recombinant polypeptides to improve a diagnostic method for AI 
The use of live culture Elisa, and HI assay has biosafety implications (STEPHENSON 
et al. 2009)  and the solution to these problems is to use a standardized recombinant 
antigen created using recombinant technology (WANG et al. 2010). Conventional 
subtype-specific methods for serological investigations as HI, and NT have significant 
limitations (PRABAKARAN et al. 2009). Other assays, such as complement fixation, 
neuraminidase-inhibition test or microneutralization assay require special equipments 
and complex procedures. The indirect Elisa (I-Elisa) using crude or purified viral 
antigen on the solid-phase to detect viral specific antibodies has been developed for 
detection of chicken and turkey antibodies to AIV (ABRAHAM et al. 1988; ADAIR et 
al. 1989). The recombinant AI NP expressed in E- coli was purified, coupled with 
latex beads, and used as an antigen for the latex agglutination test (LAT) test. LAT 
test proved to be useful for monitoring AIV infection in the field (HORIE et al. 2009). 
Serologic testing of wild birds for AIV surveillance poses problems due to species 
differences and nonspecific inhibitors that may be present in sera of wild birds. Two 
 103 
commercial competitive Elisas detect AI antibodies in experimentally infected 
partridges, whereas HI was negative (ZHOU et al 1998). Both Elisas detected AIV-
antibody-positive samples were negative by specific HI against 9 of the 16 existing 
HA subtypes. Presumably this may reflects higher sensitivity of competitive ELISA 
when compared to HI. A competitive Elisa was developed as a serologic diagnostic 
tool to detect antibodies against NA subtype 3 of AIV. The NA antigen used in this 
ELISA was obtained by pronase treatment of allantoic fluid of specific-pathogen-free 
(SPF) eggs infected with AIV. The NA specific monoclonal antibodies were produced 
from purified NA. N3 c-ELISA could detect the antibodies from SPF chickens or 
commercial chickens vaccinated with H9N3 subtype of AIV. The sensitivity and 
specificity of the N3 c-ELISA were 83.7 % and 95.6 %, respectively (KIM et al. 2010). 
A recombinant HA of A / Vietnam / 1203 / 04 (H5N1) was expressed in mammalian 
cells, purified, and used for generation of H5-specific monoclonal antibodies (MAb). 
The purified H5-Bac was used to develop a competitive Elisa to detect H5 antibodies. 
Comparison of the results of the competitive Elisa with results obtained by HI showed 
a gradient of the sensitivity (turkeys > ducks > chicken). The described results 
showed that H5-specific antibodies in sera can be detected in a species-independent 
approach by using a recombinant protein (DLUGOLENSKI et al. 2010). An indirect 
ELISA was developed using baculovirus, purified, recombinant N1 protein from A / 
chicken / Indonesia / PA7 / 2003 (H5N1) virus. The N1-ELISA showed high selectivity 
for detection of N1 antibodies, with no cross-reactivity with other neuraminidase 
subtypes, and broad reactivity with sera to N1 subtype isolates from North American 
and Eurasian lineages. N1-ELISA can facilitate a vaccination strategy with 
differentiation of infected from vaccinated animals using a NA hetrologous approach 
(LIU et al. 2010). Because the NS1 is expressed in influenza virus-infected cells, and 
it is not packaged in the virion, it is an attractive candidate for a DIVA differential 
diagnostic test (AVELLANEDA et al. 2010). Active surveillance for AIV has expanded 
from chicken to various poultry species including duck. An alternative to serum, 
antibody monitoring of laying breeder duck using egg yolk with competitive ELISA is 
feasible and is recommended (JEONG et al. 2010). In addition, the results reflect the 
necessity of validation Elisa for individual species or at least families (PEREZ-
RAMIREZ et al. 2010). The use of chicken egg yolk antibody as an alternative to 
serum has shown a high degree of correlation among AGID, HI and ELISA 
approaches (BECK et al. 2003). Detection of NP, N3 and N7 antibodies to AI virus by 
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indirect ELISA using yeast-expressed antigens revealed that these indirect Elisas are 
rapid, sensitive, specific and can be used as promising tests during serological 
surveillance (UPADHYAY et al. 2009). Hence recombinant Elisa was superior to 
other serological assays because Elisa based on recombinant antigens are well 
known to offer higher reproducibility’s, lack of cross-reactivity,  easy to optimize, less 
labor intensive and do not require the cultivation of virus (MOHAN et al. 2006). In the 
present study, P1 and rHA1 polypeptides were used to study the possibility to use 
them in indirect rElisa for detection of antibodies towards H5. rHA1- Elisa proved to 
be highly sensitive and specific, as compared with HI, AGID and Western blot. 
Although Western blotting is sensitive (100 % in this study), blotting for large number 
of samples would be tedious, time consuming and precise quantification of antibody 
levels would not be feasible. In this study AGID test revealed to be less sensitive to 
detect H5 antibodies which in accordance with the results obtained by (MEULEMANS 
et al. 1987; SNYDER et al. 1985). Whole H5N1 antigen based Elisa showed high 
sensitivity to influenza A subtype H5 but it does not fulfil our purpose to produce safe 
antigen. Serial dilution Elisa was done to choose the best serum dilution for single 
dilution Elisa, hence, the use of single dilution Elisa reduces reagents, costs and time 
and the error inherent to serial dilution Elisa.  It is worthy to mention that, negative 
sera was obtained from chickens with a history of vaccination against ND, IBD, IB 
and MD and there were no cross reactivity with rHA1- Elisa (antibodies towards ND 
and IBD were analyzed with HI and Elisa respectively. Elisa based on recombinant 
polypeptides, especially if these polypeptides are conserved in H5 might offers a 
considerable a advantages for detection of viral antibodies.The low sensitivity of P1 
polypeptide (sensitivity 80 %)  may be attributable to its small size (only 40 amino 
acid). However, the immunogenicity of such small polypeptides could be improved by 
cloning with different copies of insert which called tandem peptide (BEACHEY et al. 
1987). The increase in the copy number of the coding sequence was important for 
antibody binding activity (WANG et al. 2010). 
Elisa test was adopted as a sensitive method for the detection of antibodies to AIV 
and the results of Elisa test should be interpreted on a flock and not on individual bird 
bases. In case of H5N1 HPAI outbreaks, chickens shows clinical signs very severely 
and then die which mean that Elisa might has no significant value in eradication 
program. However, vaccination of chickens against HPAI must be considered to be a 
complement to other control measures, as part of a science-based influenza control 
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strategy (CAPUA and MARANGON 2003). rHA1-Elisa could be used for the 
surveillance immune responses by detecting antibodies to AIV. On the other hand, 
HPAI viruses do not show high virulence for all species of birds, and the clinical 
severity seen in any host appears to vary with both bird species and virus strain 
(ALEXANDER et al. 1978; ALEXANDER et al. 1986). In particular, ducks rarely show 
clinical signs as a result of HPAI infections. Ostriches (Struthio camelus) also appear 
to show mild clinical response to HPAI infection. rElisa significantly improves the 
ability for quickly detection of the antibody levels of AIV during field outbreaks and 
providing key information for disease control decision making, thus it has great 
application potential in long-term prevention and control of AIV as recommended. 
rHA1- Elisa shows high OD with positive duck sera (positive also by HI) as compared 
with OD of negative duck serum which indicate the validity of rHA1-Elisa to detect H5 
antibodies in duck sera.  
In conclusion; our findings recommend the use of the rHA1-Elisa as a tool for 
improvement of serological diagnosis of influenza A subtype H5 in chickens and 
ducks. But it remains a question of value whether rHA1-Elisa is specific for influenza 
A subtype H5?  Additional studies are needed to further evaluate the rElisa in 
different avian species. The possibilities to use these recombinant polypeptides as a 
vaccine against H5 influenza should be further studied.  
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The highly pathogenic Avian Influenza subtype H5N1 can lead to 100 % mortality in 
chickens. The main issue in prevention of H5N1 is the development of efficient 
poultry vaccines. Influenza haemagglutinin (HA) derived recombinant polypeptides 
would not elicit an immune response against internal viral proteins. Thus HA 
polypeptide use facilitates differentiation between infected and vaccinated animals 
(DIVA). Serological tests using recombinant immune-dominant proteins devoid of 
non-specific moieties present in whole cell preparations might have higher sensitivity 
and specificity. In the present study, four non-overlapping sequences of different 
functional domains of influenza A virus subtype H5 virus (A / Thailand / 1 (Kan-1) / 
2004) designated P1, P2, P5 and rHA1 were cloned and expressed in Pichia 
pastoris for vaccination and diagnosis purposes.  
- The four polypeptides were expressed successfully in P. pastoris using peptone 
methanol (1 % (w/v) yeast extract, 2 % (w/v) peptone, 2 % (v/v) methanol). P1, P2 
and rHA1 polypeptides were purified using nickel affinity chromatography, whereas, 
P5 was purified using lectin affinity chromatography. Correct expression was 
analysed by SDS-PAGE and western blot, glycosylation analysis and MALDI-TOF. 
- The immune responses of P1, P2 and rHA1 polypeptides were assessed in 
BALB/C mice. To enhance antibody response, recombinant polypeptides were mixed 
with the Gerbu adjuvant and injected subcutaneously. Vaccination of mice induced 
high subtype specific antibody titres in mice as analysed by Elisa (using recombinant 
antigens or whole H5N1 antigen) and Immunofluorescence assay (IFA) performed 
on Vero cells infected with H5 (A / Thailand / 1 (Kan-1) / 2004). 
- The immunogenicity of P1, P2, P5 and rHA1 polypeptides was determined in 
commercial layer chickens. Results showed that P1, P2 and rHA1 polypeptides 
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induced high subtype specific antibody titres in chickens as analysed by Elisa (using 
recombinant antigens or whole H5N1 antigen), IFA (performed on Vero cells infected 
with H5N1 A / Thailand / 1 (Kan-1) / 2004) and microneutralization test (µNT). 
However, P5 polypeptide was not immunogenic in chickens. Neutralizing antibodies 
could be detected in chicken sera immunized with P1, P2 and rHA1 polypeptides as 
analyzed with microneutralization test. 
-IgY was analysed in egg yolk of chickens immunized with recombinant 
polypeptides. The IgY of chicken immunized with P1 and rHA1, transferred to the 
egg yolk was proportional to maternal serum IgY. However, IgY could not be 
detected in egg yolk of chickens immunized with P2 and P5 recombinant 
polypeptides 
- The more immunogenic polypeptides P1 and rHA1 were used in an recombinant 
Elisa (rElisa) for detection of influenza A subtype H5 in chickens and duck sera.The 
optimal antigen for the concentrations of rHA1, P1 was 50 ng / well, 50 ng / well. 
- Analysis of 25 positive sera and 25 negative sera to H5 antibodies revealed that, 
the sensitivity of Western blot, whole H5N1 Elisa, agar gel immunodiffusion test 
(AGID), P1-Elisa and rHA1-Elisa was 100 %, 100 %, 52 %, 80 % and 100 %, 
respectively, while the specificity was 100 %, 100 %, 100 %, 72 %, and 100 %, 
respectively. Moreover, duck sera, with haemagglutination inhibiting titer ranged from 
4 - 8 log2, were tested positive by rHA1 Elisa compared with negative duck sera. 
-Further analysis of 179 serum samples with rHA1-Elisa in comparison with  
haemagglutination inhibition (HI) and commercial Elisa  proved to be highly sensitive 
and specific. The agreement ratio between rElisa and HI was 84.9 % and between 
commercial Elisa (Flock check) and HI was 76.5 %.  
In conclusion, P. pastoris may allow development of an effective recombinant 
influenza vaccine based on truncated sequences of HA that might provide broader 
protection against H5 influenza viruses. The possibilities to use rHA1, P1 and P5 
recombinant polypeptides as a vaccine against H5 influenza should be further 
studied. Also our study demonstrates the potential utility of recombinant Elisa as a 
tool for improvement of serological diagnosis of influenza A subtype H5 in chickens 
and ducks. 
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Die hochpathogene aviäre Influenza des Subtyps H5N1 erreicht beim Ausbruch von 
Infektionen in Nutzgeflügelbeständen Mortalitätsraten von bis zu 100 %. Effektive 
und kostengünstige Impfstoffe werden benötigt, die möglichst auch eine 
Differenzierung zwischen geimpften Tieren und mit Wild-Virus infizierten Tieren 
zulassen. In diesem Zusammenhang könnten Peptid-Vakzine eine mögliche 
Alternative zu den herkömmlichen Impfstoffen darstellen, bei denen unter 
Verwendung des Vollvirus Antikörper gegen mehrere Virusproteine induziert werden. 
Außerdem, könnten rekombinante Antigene in serologischen Tests zur Diagnose von 
H5 Virus in Nutzgeflügel eingesetzt werden. Von dem Einsatz spezifischer 
rekombinanter Antigene ist eine Verbesserung der Serodiagnostik zu erwarten. In 
dieser Arbeit, wurden vier verkürzte Sequenzen des Hämagglutinins (P1, P2, P5 und 
rHA1) von Subtyp H5 (A / Thailand / 1 (Kan-1) / 2004) rekombinant in Pichia Pastoris 
exprimiert. 
- Dazu erfolgten zunächst eine Klonierung in der Expressionsvektor pAOX und die 
Transformation von Pichia Pastoris. Die Expression wurde durch Methanol induziert. 
Der Nachweis der rekombinanten Fusionspeptiden mit C-terminalen Histidin-Tag 
erfolgte durch SDS-PAGE, Western Blot, Glycolysierungsanalyse, und MALDI-TOF. 
Der Histidin-Tag ermöglichte die Reinigung von P1, P2 und rHA1 mit Metall-
Affinitätschromatographie. Polypeptid P5 hingegen wurde mittels Lectin-Affinitäts- 
chromatographie gereinigt. 
- Balb/c Mäuse wurden mit Polypeptid P1, P2 bzw. rHA1, versetzt mit Gerbu Adjuvans, 
immunisiert. Zur Untersuchung der Immunantwort wurden die murinen Seren mittels  
Elisa (unter Verwendung rekombinanter Antigene oder Voll-H5N1 Antigen) sowie IFA  
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(durchgeführt in Vero- Zellen infiziert mit A / Thailand / 1 (Kan-1) / 2004) analysiert. 
Dabei wurde die präferentielle Induktion von H5-spezifischen Antikörpern detektiert. 
- Die Immunogenität der P1, P2, P5 und rHA1-Polypeptide wurde in kommerziellen 
Legehennen bestimmt. Seren wurden mit ELISA, IFA, und Mikroneutralizationstest 
(µNT) analysiert. Die ELISA-Ergebnisse zeigten, dass die Polypeptide P1, P2 und 
rHA1 hohe Subtyp-spezifische Antikörpertiter in Hühnern induzierten. Im µNT konnte 
nur ein niedriger neutralisierender Antikörpertiter nachgewiesen werden. Das P5- 
Polypeptid ist bei Hühnern nicht immunogen.  
- Im Eigelb von Hühnern, die mit den rekombinanten Polypeptiden P1 und rHA1 
immunisiert wurden, konnten H5-spezifische IgY Antikörper detektiert werden.  
Hühner, die mit P2 und P5 immunisiert wurden, zeigten keine IgY im Eigelb. 
- Die rekombinanten Antigene P1 und rHA1 wurden im ELISA auf ihre potenzielle 
Eignung für die Serodiagnostik untersucht. Die optimale Antigenkonzentration war 
50 ng / well. Die serologische Analyse von 25 positiven und 25 negativen Seren auf 
Antikörper gegen H5 zeigte, dass Sensitivität und Spezifität von Western Blot, Voll-
H5N1 ELISA und rHA1-ELISA bei jeweils 100 % lagen. Bei Agargel- 
Immunodiffusiontest (AGID) lagen Sensitivität und Spezifität bei 52 % und 100 %, 
während im P1-Elisa lediglich eine Sensitivität von 80 % und eine Spezifität von 72 % 
erreicht wurden. Somit eignet sich rHA1 für die Anwendung in der Serodiagnostik. 
- Bei der serologischen Untersuchung von 175 Hühnerseren wurde eine 
Überbestimmung zwischen rHA1-ELISA und Hämagglutinationshemmungstest (HAI) 
84.9 % festgestellt, während diese zwischen dem kommerziellen ELISA (Flock Check) 
und HAI 76.5 % betrug.  
- Die Ergebnisse zeigten, dass das Expressionssystem P. pastoris als 
Produktionssystem rekombinanter Antigene für die Serodiagnostik von H5 Influenza  
geeignet ist. Challenge-Versuche sind nötig, um die Eignung von rekombinanten 
Antigenen als möglichen Impfstoff gegen H5 Influenza zu untersuchen. 
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
The coding sequence of P1 polypeptide cloned to pAOX vector. 
P1 – sequence including alpha factor, gene of interest and histag 
 
M R F P S I F T A V L F A A S S A L A A P V N T T T E D E T A Q I P A E A V I G Y 
S D L E G D F D V A V L P F S N S T N N G L L F I N T T I A S I A A K E E G V S L 
E K R E A E A D L D G V K P L I L R D C S V A G W L L G N P M C D E F I N V P 
E W S Y I V E K A A A S F L E Q K L I S E E D L N S A V D H H H H H H 
 
Alpha Factor: underlined 
P1 sequence: bold 
His tag and remains of MCS: Italic 
Theoretical pI / Mw: 4.40 / 16912.92 (Da) 
P1 polypeptide when it is completely processed 
D L D G V K P L I L R D C S V A G W L L G N P M C D E F I N V P E W S Y I V E K 
A A A S F L E Q K L I S E E D L N S A V D H H H H H H 
Theoretical pI / Mw: 4.88 / 7591.53 
 
 
 
 
 
 
 
 
pAOX-H5 Site E histag
3666 bp
H5 Site E
P(TEF1)
P(EM7)
P(AOX)pUC origin
AOX1 TT
CYC1 TT
Zeocin
alpha factor
myc epitope
6xHis
BstXI (707)
NotI (1330)
XhoI (1185)
pAOX-H5P1 histag 
3666 bp 
H5P1 
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pAOX-H5 RBS histag
3837 bp
H5 RBS
P(TEF1)
P(EM7)
P(AOX)pUC origin
AOX1 TT
CYC1 TT
Zeocin
alpha factor
myc epitope
6xHis
BstXI (707)
NotI (1501)
XhoI (1185)
X-H5P2 istag 
3837 bp 
H5 P2 
 
 
 
 
 
 
 
 
 
 
 
 
 
The coding sequence of P2 polypeptide cloned to pAOX vector. 
P2 – sequence including alpha factor, gene of interest and histag 
 
M R F P S I F T A V L F A A S S A L A A P V N T T T E D E T A Q I P A E A V I G Y 
S D L E G D F D V A V L P F S N S T N N G L L F I N T T I A S I A A K E E G V S L 
E K R E A E A N N T N Q E D L L V L W G I H H P N D A A E Q T K L Y Q N P T T 
Y I S V G T S T L N Q R L V P R I A T R S K V N G Q S G R M E F F W T I L K P N 
D A I N F E S N G N F I A P E Y A Y K I V K K G A A A S F L E Q K L I S E E D L N 
S A V D H H H H H H 
 
Alpha Factor: underlined 
P2 sequence: bold 
His tag and remains of MCS: Italic 
Theoretical pI / Mw: 5.09 / 23272.92 (Da) 
P2 polypeptide when it is completely processed 
 
N N T N Q E D L L V L W G I H H P N D A A E Q T K L Y Q N P T T Y I S V G T S T 
L N Q R L V P R I A T R S K V N G Q S G R M E F F W T I L K P N D A I N F E S N 
G N F I A P E Y A Y K I V K K G A A A S F L E Q K L I S E E D L N S A V D H H H 
H H H 
 
Theoretical pI / Mw: 6.46 / 13951.53 (Da) 
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The coding sequence of P5 polypeptide cloned to pAOX vector. 
P5- sequence including alpha-factor, gen of interest and his-tag 
 
M R F P S I F T A V L F A A S S A L A A P V N T T T E D E T A Q I P A E A V I G Y 
S D L E G D F D V A V L P F S N S T N N G L L F I N T T I A S I A A K E E G V S L 
E K R E A E A S L G V S S A C P Y Q R K S S F F R N V V W L I K K N S T Y A A 
A S F L E Q K L I S E E D L N S A V D H H H H H H 
 
Alpha Factor: underlined 
P5 sequence: bold 
His tag and remains of MCS: Italic 
Theoretical pI / Mw: 5.10 /15843.67 (Da)  
P5 polypeptide when it is completely processed 
 
S L G V S S A C P Y Q R K S S F F R N V V W L I K K N S T Y A A A S F L E Q K L 
I S E E D L N S A V D H H H H H H 
 
Theoretical pI / Mw: 7.98/ 6522.28 (Da) 
 
 
 
pAOX- H5P5 histag 
3636 bp 
H5P5
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The coding sequence of rHA1- polypeptide cloned to pAOX vector. 
 
HA1- sequence including alpha-factor, gen of interest and histag 
M R F P S I F T A V L F A A S S A L A A P V N T T T E D E T A Q I P A E A V I G Y 
S D L E G D F D V A V L P F S N S T N N G L L F I N T T I A S I A A K E E G V S L 
E K R E A E A D Q I C I G Y H A N N S T E Q V D T I M E K N V T V T H A Q D I L 
E K T H N G K L C D L D G V K P L I L R D C S V A G W L L G N P M C D E F I N 
V P E W S Y I V E K A N P V N D L C Y P G D F N D Y E E L K H L L S R I N H F E 
K I Q I I P K S S W S S H E A S L G V S S A C P Y Q R K S S F F R N V V W L I K 
K N S T Y P T I K R S Y N N T N Q E D L L V L W G I H H P N D A A E Q T K L Y 
Q N P T T Y I S V G T S T L N Q R L V P R I A T R S K V N G Q S G R M E F F W T 
I L K P N D A I N F E S N G N F I A P E Y A Y K I V K K G D S T I M K S E L E Y G 
N C N T K C Q T P M G A I N S S M P F H N I H P L T I G E C P K Y V K S N R L V 
L A T G L R N S P Q R A A A S F L E Q K L I S E E D L N S A V D H H H H H H 
  
Theoretical pI / Mw: 5.82 / 48996.22 
HA1- polypeptide when it is completely processed 
D Q I C I G Y H A N N S T E Q V D T I M E K N V T V T H A Q D I L E K T H N G K 
L C D L D G V K P L I L R D C S V A G W L L G N P M C D E F I N V P E W S Y I V 
E K A N P V N D L C Y P G D F N D Y E E L K H L L S R I N H F E K I Q I I P K S S 
W S S H E A S L G V S S A C P Y Q R K S S F F R N V V W L I K K N S T Y P T I 
K R S Y N N T N Q E D L L V L W G I H H P N D A A E Q T K L Y Q N P T T Y I S V 
G T S T L N Q R L V P R I A T R S K V N G Q S G R M E F F W T I L K P N D A I N 
F E S N G N F I A P E Y A Y K I V K K G D S T I M K S E L E Y G N C N T K C Q T 
P M G A I N S S M P F H N I H P L T I G E C P K Y V K S N R L V L A T G L R N S 
P Q R A A A S F L E Q K L I S E E D L N S A V D H H H H H H 
  
Theoretical p I/ Mw: 6.80 / 39674.8 
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